|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/7/26 ¤U¤È 02:22:07
|
2022.01-¤@´Á¼Æ¾Ú¤§Àu¤Æ²³ø(Y¥h¦~¤E¤ë®³³oª©À³¸Ó·|¦n¤@ÂI):ir.aslanpharma.com/static-files/2a7f1481-a0b3-47d1-87ef-e6ed30321475 2022.01-KOL²³ø:ir.aslanpharma.com/static-files/379e7107-c421-4401-b035-e43c4b682d19 2022.05.12- ir.aslanpharma.com/static-files/20941066-3bc3-418b-a970-9951565de0f2 2022.06²³ø-ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c 2022.09.15²³ø-ir.aslanpharma.com/static-files/1511fefc-ba34-4ee4-aac0-32f8bc4754a8 |
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2019/11/5 ¤W¤È 11:18:38²Ä 1424 ½g¦^À³
|
¨È·à±d·Pı¬Ý°_¨Ó§Ön¨S±Ï¤F ! 11¤ë¤¤¦¯¸Ñª¼ªº¼Æ¾Ú ¦¨¥\²v¥u¦³¦Ê¤À¤§¤@ 400¦h±i¤j³æÀ³¸Ó¬O¦³¤º¹õ ! ¤£·Qµ¥¤F ¬Q¤Ñ±¾¨ì¤µ¤Ñ ¨ÌÀ³¸Ó¬OÅK¤F¤ßn½æ ! ÁÙ¦n§Ú26¦´N½æ¥ú¥ú¤F ! ²{¦bµ¥¬ÝÀ¸ ~ ²{¦b¬Ý°_¨Ó n¦h§C¦³¦h§C |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2019/11/5 ¤W¤È 10:30:37²Ä 1423 ½g¦^À³
|
§Ú¤]¤£´q¦hÅý ¸}³Â ½Ð¦Ñ·à°õ¦æªø¤U£¸ÓÔ¿ïÃĪ« ¶}µo±Mªv¸}³Â À°§U·à¤Í«·s¯¸°_¨Ó ¥[ªo💪 |
|
|
·|û¡G³¯Ë¢¦w10144680 µoªí®É¶¡:2019/11/5 ¤W¤È 10:07:59²Ä 1422 ½g¦^À³
|
§Ú¤]¿é¨ì²æ¿Ç¤l¤F¡C³Q®a¤H¯º¡Cþ¦³¤H±q52¤¸©ñ¨ì²{¦b9.25¤¸©O¡H§Ú·QÀ³¸Ó¬O¤¤·ªº¤H¤F§a¡I«¢¡IW¯º |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/11/5 ¤W¤È 08:38:53²Ä 1421 ½g¦^À³
|
«ùªÑ¦Ê±i¥H¤WªÑªF¥e83.52%,¤jªÑªF³£¨S¥X³f,¥BÄ@·NÉ¿úµ¹¤½¥q,À³¸ÓÁÙ¬O¥¿¦V¬Ý«Ý.... |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2019/11/4 ¤U¤È 11:15:49²Ä 1420 ½g¦^À³
|
¨º±¾³æ«Ü°² ¦Ó¥B¥¦¥Øªº¤]¹F¨ì¤F §Ú¬O°¾¥¿¦V¬Ý«Ý ¤@¤Á´N¬Ý¸Ñª¼µ²ªG §Æ±æ¤j®a¥i¥H§â¿Ç¤l¬ï¦^¨Ó |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/11/4 ¤U¤È 08:37:23²Ä 1419 ½g¦^À³
|
§ÚÓ¤H¬Ýªk¤]¬O¥¿¦Vªº¡A¤½¥q»Ýn¦¨ªG¨Ó¥l¶}ªk»¡·|¡A¤§«e²{ª÷¬y¤½¥q¹w¦ô²{¼W»ù¬O12¤¸¡A¥Nªí¤½¥q¹ïªÑ»ù¤]¬O¥¿¦V¬Ý«Ýªº¡A¦pªG³oӪѪF¥L¯uªº¤£¬Ý¦n¡A¥H²{¦bªº¦¨¥æ¶q·Qn¤@¦¸½æ¥X¤]«Ü§xÃø¡An¤]¬O§äì¦]¦¬Áʪº¤j¤á¦Y¤U¡A¨S¥²n±¾¦b¨ºÃäµ¥¦¨¥æ¡A©ú¤Ñ¥i¥H¦AÆ[¹î¬Ý¬Ý¡A·d¤£¦n¥u¬O´ú¸Õ¤]»¡¤£©w¡C |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2019/11/4 ¤U¤È 08:11:33²Ä 1418 ½g¦^À³
|
§Ú¤ñ¸û¥¿¦V ½Ö¦³433±i·|±¾¦b¨ºÃä´½µÛ ¤]½æ¤£¥X¥h§a¡H ¤Ï¦V¦¬³f ¥uÄ@§C±µ¤£·Q°ª¶RÀ~À~«ùªÑ¤H¡]¦ýÄ@¡^ ¦b¸Ñª¼«e³£·|¦p¦¹³o¯ë§a Ó¤HÆ[ÂI ¦Ñ·à¥[ªo·à¤Í¥[ªo ¡]§Ú¿é¨ì²æ¿Ç¤l¤F¡^ |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2019/11/4 ¤U¤È 07:56:19²Ä 1417 ½g¦^À³
|
§Ú¤ñ¸û¥¿¦V ½Ö¦³433±i·|±¾¦b¨ºÃä´½µÛ ¤]½æ¤£¥X¥h§a¡H ¤Ï¦V¦¬³f ¥un§C±µ¤£·Q°ª¶R Ó¤HÆ[ÂI |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/11/4 ¤U¤È 06:30:00²Ä 1416 ½g¦^À³
|
¨º½Ð°ÝªÅÄ_§A¦³¦ó¨£¸Ñ©O¡H ¦³¤j³æ±¾¦b9.3¨ºÃä¡A¥i¥H¥ý»¡»¡§Aªº¬Ýªk¡A¤j®a¦A¨Ó°Q½×¤@¤U§a¡I |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2019/11/4 ¤U¤È 05:51:05²Ä 1415 ½g¦^À³
|
433±i©e½æ9.3 ¦U¦ì·à¤Í¤j¤j¦³¦ó¨£¸Ñ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/11/1 ¤W¤È 09:29:08²Ä 1414 ½g¦^À³
|
·s»D½Z---2019¦~1¤ë2¤é ¨È·à±d-KY¥þ²y©Ê¼Ï¯ÃÁ{§É¸ÕÅçTREETOPP§¹¦¨¨ü¸ÕªÌ¦¬®×¡A¶W«e¹w©w¶i«× ³Ì¤j«¬¤§¥þ²y¤G½uÁx¹DÀù¦w¼¢¾¯¹ï·ÓÁ{§É¸ÕÅçTreeTopp¤§ªì¨BÁ{§É¼Æ¾Ú¹wp©ó2019¦~¤U¥b¦~¥XÄl ¡A·s¥[©Y ¡V ±Mª`©ó¶}µo¨È¬w²±¦æ»P¼Ú¬ü©t¨à¯e¯fÀù¯g¡B¦ì©óÁ{§É¶¥¬q¤§¥Íª«»sÃĤ½¥q¨È·à±d-KY (NASDAQ: ASLN, 6497. TT) ¤µ¤é«Å¥¬§¹¦¨varlitinib¤G½uÁx¹DÀù¥þ²y©Ê¼Ï¯Ã¸ÕÅçTreeTopp (TREatmEnT OPPortunity)¨ü¸ÕªÌ¦¬®×¡Aªì¨BÁ{§É¼Æ¾Ú¹wp±N©ó 2019¦~ ¤U¥b¦~¥XÄl¡C TreeTopp¸ÕÅç¬O¤@¶µÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Óªº¤G½uÁx¹DÀùÁ{§É¸ÕÅç¡A¦®¦b¤ñ¸ûvarlitinib»P¦w¼¢¾¯¤À§O¦X¨Öcapecitabine¨Ï¥ÎªºÀø®Ä ¡CTreeTopp«Y¥Ø«e¬°¤î°w¹ïÁx¹DÀù©Ò°õ¦æ¹L³Ì¤j«¬ªº¥þ²y¡B¦w¼¢¾¯¹ï·Ó¤§Á{§É¸ÕÅç¡CÁx¹DÀù¦b¨È¬w¨C¦~¼vÅT¹O20¸U¤H¡A¥Ø«e©|¥¼¦³®Ö㪺¼Ð¹vÀøªk¥i¥HªvÀø¦¹¯e¯f¡C ¸Ó¶µ¸ÕÅç¦Û¥þ²y56³BÁ{§É¸ÕÅ礤¤ß©Û¦¬127¦ì±µ¨ü¹L²Ä¤@½uªvÀø¦ý¯e¯f¤´´c¤Æªº¯f±w¡A¸ÕÅç¦aÂI¥]¬A¬ü°ê¡B¼Ú¬w¡B¿D¬w¡B¤é¥»¡B Áú°ê»P¨ä¥L¨È¤Ó¦a°Ï¡C ³o¶µ¸ÕÅ窺¦@¦P¥Dnµû¦ô«ü¼Ð¬°«ÈÆ[¤ÏÀ³²v»PµL´c¤Æ¦s¬¡´Á¡C Y¨ä¤¤¤@¶µ¸ÕÅç«ü¼Ð¦b³æ§ÀÀË©w5%ªºÅãµÛ¤ô·Ç¤U¹F²ÎpÅãµÛ¡A©Î¨â¶µ¸ÕÅç«ü¼Ð¬Ò¦b³æ§ÀÀË©w10%ªºÅãµÛ¤ô·Ç¤U¹F²ÎpÅãµÛ¡A¦¹¸ÕÅç§Y¹F¥DnÀø®Äµû¦ô«ü¼Ð¡C Y¥»¸ÕÅçµ²ªG¬°¥¿±¡A¨È·à±d-KYÀÀ¦V¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA) ¥Ó½Ð¥H¥[³t®Öã¤è¦¡¶i¦ævarlitinib©ó¤G½uÁx¹DÀù¤§ÃÄÃҥӽСC ¨È·à±dÀç¹BªøMark McHale³Õ¤hªí¥Ü¡G¡u°ê»Ú¸~½F¾Ç¬É¹ïTreeTopp¸ÕÅ窺°ª«×Ãöª`¡A¨Ï§Ú̱o¥H¶W¶V¹wq¶i«×¡A´£«e§¹¦¨¨ü¸ÕªÌ¦¬®×¡A³o¤]²M·¡¦a®i²{¤F°w¹ïÁx¹DÀù·sÀøªkªº»Ý¨D¡CÁx¹DÀù¤§ªvÀø¿ï¾Üµ}¤Ö¥B¦s¬¡²v§C¡A¦h¼Æ¯f±w¦b¶EÂ_®É¤w¶i¤J±ß´Á¡C¡v Varlitinib ¬°¤@±j®Ä¤p¤À¤l¥i°f©Êªx HER §í¨î¾¯¡A¥Ø«e°w¹ïÁx¹DÀù¡BGÀù¡BÂಾ©Ê¨ÅÀù»PÂಾ©Ê¤j¸zª½¸zÀùµ¥¦h¶µ¾AÀ³¯g¶i¦æ¬ãµo¡CVarlitinib¦b1b´Á¸ÕÅç§Y¹ïÁx¹DÀù¯f±w®i²{¸~½FÁY¤p¤Î«ùÄòéw¯e¯f¤§¦¨®Ä¡A¨Ã¤w¨ú±o¬ü°êFDA»PÁú°ê¹«~ÃĪ«¦w¥þ³¡(MFDS) ±Â¤©¤§Áx¹DÀù©t¨àÃĸê®æ»{©w¡C |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/10/31 ¤U¤È 10:15:47²Ä 1413 ½g¦^À³
|
²{¦bªº¦¨¥æ¶q¸ò¦¨¥æµ§¼Æ¡A¸ò¦³¤À½L¨S¤À½L¤]¨S¦h¤j¤À§O¡A«ÂI´N¦b11¤ë¤¤¦¯ªº¤G½uÁx¹DÀù¸Ñª¼¤F¡A¨È·à±d¥¼¨Óªº¨«¦V´N¬Ý³o¤@§Ð¤F¡A¦nºò±i¸Ñª¼¤é´Á§Ö¨ì¤F¡I |
|
|
·|û¡Gjones10146258 µoªí®É¶¡:2019/10/31 ¤U¤È 09:38:08²Ä 1412 ½g¦^À³
|
©Ò¥H²bȶ^¯}¤T¶ô¤F......·Ç³Æ30¤ÀÄÁ¤À½L¥æ©ö |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/10/31 ¤U¤È 03:43:05²Ä 1411 ½g¦^À³
|
·s»D½Z ¨È·à±d-KY¤½¥¬2019¦~²Ä¤T©u°]°È·~ÁZ¤Î§ó·s¬ãµo¶i«× 2019¦~10¤ë31¤é¡A·s¥[©Y ¡V »EµJ©óÁ{§É¶¥¬q¸~½F¤Î§K¬Ì¾Ç¤§Á{§É¶¥¬q¥Íª«»sÃĤ½¥q¨È·à±d-KY (NASDAQ:ASLN, TPEx:6497)¤µ¤é¤½¥¬ºI¦Ü2019¦~9¤ë30¤é¤§©u«×°]°È³ø§i¥H¤Î³Ì·sÁ{§É¬ãµo¶i«×¡C ¨È·à±d-KY°õ¦æªø³Å«i³Õ¤hªí¥Ü:¡u¨È·à±d-KY¦b²Ä¤T©u¨ú±o¤F«¤j¶i®i¡A¥]¬A©ó¼Ú¬w¸~½FÂå¾Ç·|(ESMO)¦~·|µoªívarlitinib¤§·s¼Æ¾Ú¡AÀH«á¥H¤fÀY¤è¦¡µoªí©ó¤¤°êÁ{§É¸~½F¾Ç·|(CSCO) ¦~·|¡A¥H¤Î§Ú̦b10¤ë¥÷¨ú±o¤½¥q¸³¨Æªø¡B¸³¨Æ·|¦¨û©M´X¦ì¥Dn§ë¸êªÌ´£¨Ñ¦@p¤T¦Ê¸U¬ü¤¸¿Ä¸ê¶U´ÚÃB«×¡A¦¹¿Ä¸ê¶U´Ú±N¥i¬°¤½¥q´£¨ÑÃB¥~¥B¼u©Ê¹B¥Î¤§Àç¹B¸êª÷¡A¥H¥þ¤O¤ä«ù¥¿¦b¶i¦æªº¬ãµop¹º©MÁ{§É¬ã¨s¡A§Ṳ́]»PBukwang Pharmaceuticalñq¦X¬ù¡A¦@¦P¦¨¤F¤@¶¡¦X¸ê¤½¥qJAGUAHR Therapeutics¡A±N±Mª`©ó¶}µoÁ{§É«e´ÁAhR (aryl hydrocarbon receptor)«ú§Ü¾¯¡C®i±æ¥¼¨Ó¡A§Ú̹wp©ó11¤ë¤¤¦¯«Å¥¬varlitinib©óÁx¹DÀù¤G½u¼Ï¯Ã©Ê¸ÕÅç(TreeTopp)¤§ªì¨B¼Æ¾Ú¡A¥¼¨Ó§ó·Ç³Æ©ó2020¦~¤½§G¹ïASLAN004¦b²§¦ì©Ê¥Ö½§ª¢¤¤ªº¬ã¨s±o¥Xªº¼Æ¾Ú¡C¡v 2019¦~²Ä¤T©u©Mªñ´Á·~°È«GÂI Á{§É¬ã¨sµo®i Varlitinib • ©ó¤¤°êÁ{§É¸~½F¾Ç·|(CSCO) ¦~·|µoªí³Ì·s¬ð¯}©Ê²Îp¼Æ¾Ú¡A¤½¥¬¥Hvarlitinib¦X¨ÖcapecitabineªvÀø¤G½uÁx¹DÀù¯f±w¤§¤¤°ê¤G´ÁÁ{§É¹êÅç´ú¸Õ¦¨ªG¡C±wªÌ¤ÏÀ³²v¡]response rate¡^¹F¨ì11%¥B¨ä¤¤¨â¨Ò§¹¥þ½w¸Ñ¡]complete response¡^¡AµL´c¤Æ¦s¬¡´Áªº¤¤¦ì¼Æ¡]median PFS¡^¬°2.7Ó¤ë¡A¾ãÅé¦s¬¡´Á¡]OS¡^¬°5.8Ó¤ë¡A¥B«ùÄò¦¨¼ô¤¤¡C¥Ñ©ó¬ã¨s¹ï¶H¯f¯g´c¤Æµ{«×¸û°ª¡A¥[¤J¥»¬ã¨s«e¶È10%¹ï©ó¥Hgemcitabine¬°¥D¤§¤@½uªvÀø¦³©Ò¤ÏÀ³¡A¬Gvarlitinib¦X¨ÖcapecitabineªºªvÀø¥i¯à¬°¤G½uÁx¹DÀù¯f±w´£¨Ñ¥þ·sªºªvÀø¿ï¶µ¡C • ©ó2019 ¼Ú¬w¸~½FÂå¾Ç·|(ESMO)¦~·|¤Wµoªívarlitinib¦b1b ´Á¶}©ñ©Ê¾¯¶q»¼¼W¬ã¨sªº·s¼Æ¾Ú¡A¦¹¶µ¸ÕÅç«Y±´°Qvarlitinib ¦X¨Ömodified irinotecan »Pinfusional 5-fluorouracil (mFOLFIRI)¡C³o¶µ¬ã¨s¸ÕÅç©Û¦¬16 ¦W¨ü¸ÕªÌ¡A¥ý«e±µ¨ü¹L¤§¤Æ¾ÇÀøªk¼Æ¶q¤¤¦ì¼Æ¬°3¡Cµû¦ô±ß´Á¹êÅé½F¤§¦w¥þ©Ê¡B@¨ü©Ê»P¨ä³Ì¤j@¨ü¾¯¶q(MTD, maximum tolerated dose)¡C¾ãÅé¤ÏÀ³²v¬°13¢H¡AµL´c¤Æ¦s¬¡´Áªº¤¤¦ì¼Æ(median PFS)¬°4.2 Ó¤ë¡C ASLAN004 • ¨È·à±d-KY¦b10¤ë¥÷«Å¥¬©Û¶ÒASLAN004²§¦ì©Ê¥Ö½§ª¢¸ÕÅç¦h¾¯¶q»¼¼WÃĪ«´ú¸Õ¡]MAD¡^º¦ì±wªÌ¡C¦¹¸ÕÅç°w¹ï¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢¯f±w¶i¦æ¦P¯Åº¨£ªvÀø©Ê§ÜÅéASLAN004¤§¦h¾¯¶q»¼¼WÃĪ«´ú¸Õ¡]MAD¡^¡C¦¹¦¸¸ÕÅç¬OASLAN004¤@´ÁÁ{§É¸ÕÅ窺²Ä¤G¶¥¬q¡A¨ü¸ÕªÌ¤£¶W¹L50¦ì²§¦ì©Ê¥Ö½§ª¢¯f±w¡C¦¹¦¸ªºMAD¸ÕÅç±N¥H¥Ö¤Uª`®g¤è¦¡¡Aµ¹¤©¤TºØ¤£¦P¾¯¶qªºASLAN004¡A¨Ã±N³Ì¦³®Ä¾¯¶q¥Î©óÀø®ÄÂX¼W±Ú¸s(Expansion cohort)¡Aªì¨B¼Æ¾Ú¹wp·|¦b2020¦~¤W¥b¦~±oª¾µ²ªG¡C ¤½¥qÀç¹Bªv²z§ó·s • ¨È·à±d»P±Mª`©ó¬ãµoªºÁú°ê»sÃĤj¼tBukwang Pharmaceutical¦@¦P¦¨¤F¤@¶¡¦X¸ê¤½¥qJAGUAHR Therapeutics¡A®Ú¾Ú¨óij¡A¨È·à±d±N´£¨ÑAhR§Þ³N»P¬ÛÃö¸ê²£¤§¥þ²y©Ò¦³Åvµ¹JAGUAHR¡C¦ÓJAGUAHRÁ`³¡±N·|³]¥ß¦b·s¥[©Y¡A¨Ã±N±Mª`©ó¬°¥þ²y¥«³õ¶}µo°w¹ïAhR¶Ç»¼¸ô®|ªº¥þ·s¸~½F§K¬ÌÀøªk¡CBukwang±N¤À¨â¦¸¦VJAGUAHR§ë¸êÁ`ÃB¦@5¦Ê¸U¬ü¤¸¨Ñ¬ÛÃö¬ã¨sµo®i§@·~¡C ¹wp¹F¦¨¤§¨½µ{¸O • Yvarlitinib¤G½uÁx¹DÀù¥þ²y©Ê¼Ï¯Ã¸ÕÅç(TREETOPP)ªì¨BÁ{§É¸ÕÅç¼Æ¾Ú¹F¥DnÀø®Äµû¦ô«ü¼Ð¡A¨È·à±d-KY¹wp¦V¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)´£¥æ·sÃÄ¥Ó½Ð(NDA)¡A¨ú±o¤G½uÁx¹DÀù·sÃÄÃÄÃÒ¤§®Öã¡C • ©ó2020¦~¨ú±oASLAN004©ó¤¤««×²§¦ì©Ê¥Ö½§ª¢±wªÌ¤§¦h¾¯¶q»¼¼W¸ÕÅ礧¤¤«×¦w¥þ©Ê©M¦³®Ä©Ê¼Æ¾Ú¡C 2019¦~²Ä¤T©u°]°È«GÂI • 2019¦~²Ä¤T©u¡AÀç¹B¬¡°Ê©Ò¥Î²{ª÷¬°700¸U¬ü¤¸¡A2018¦~¦P´Á¬°990¸U¬ü¤¸¡C • 2019¦~²Ä¤T©u¬ãµo¶O¥Î¬°410¸U¬ü¤¸¡AºÞ²z¶O¥Î¬°110¸U¬ü¤¸¡A2018¦~¦P´Á¤À§O¬°870¸U¬ü¤¸»P240¸U¬ü¤¸¡C¬ãµo¶O¥Î¤U°¤§ì¦]¬°³¡¤ÀÁ{§É¸ÕÅ秹¦¨¥H¤Î»s³y¶O¥Î°§C¡C • 2019¦~²Ä¤T©u²b·l¬°520¸U¬ü¤¸¡A2018¦~¦P´Á²b·l¬°1,120¸U¬ü¤¸¡C • ºI¦Ü2019¦~9¤ë30¤é¡A²{ª÷¡B¬ù·í²{ª÷©Mµu´Á§ë¸êÁ`ÃB¬°800¸U¬ü¤¸ ¡A¥h¦~ºI¦Ü2018¦~12¤ë31¤é¬°2,890¸U¬ü¤¸¡C2019¦~²Ä¤T©u¥[Åv¥§¡流³q¦b¥~ªÑ¼Æ¬°1.6»õªÑ¡A¬ù¦P2018¦~¦P´Á¡C¨C³æ¦ì¬ü°ê¦s°U¾ÌÃÒªí¹ü¨È·à±d-KY´¶³qªÑ5ªÑ¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/10/31 ¤U¤È 03:28:32²Ä 1410 ½g¦^À³
|
®É§Ç¶i¤J11¤ë,§Æ±æ¤G½uÁx¹DÀù»°§Ö¸Ñª¼,ORR¹LÃö¾÷²v°ª,PFS«h¬ÝHER®a±Ú°ò¦]Åܲ§¦¬®×ªº¦h¹è,¥[ªo~~~ ¥H¤W¨Ñ°Ñ¦Ò |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/10/31 ¤W¤È 11:01:26²Ä 1409 ½g¦^À³
|
It is estimated that about one in 10 adults in Singapore suffer from atopic dermatitis. In up to a quarter of the cases, the adults have a moderate-to-severe form of the condition, which severely impacts their quality of life. Read more at www.todayonline.com/singapore/living-severe-eczema-lost-sleep-blood-clothes-mental-health-struggles ¾Ú¦ôp¡A·s¥[©Y¬ù¦³¤Q¤À¤§¤@ªº¦¨¦~¤H±w¦³¯SÀ³©Ê¥Ö½§ª¢¡C ¦b¦h¹F¥|¤À¤§¤@ªº¯f¨Ò¤¤¡A¦¨¦~¤H±w¦³¤¤«×¦Ü««×¯e¯f¡AÄY«¼vÅT¤F¥L̪º¥Í¬¡½è¶q¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/10/30 ¤U¤È 10:25:58²Ä 1408 ½g¦^À³
|
1 ¤£«æµÛ«ì´_Åܦ¨´¶³q¥æ©ö (´Nºâ²Ä¤T©u²bȤ£¯à¦^¨ì5¤¸¡A²Ä¥|©u²bȨ̤½¥q10¤ë18¤é¤½§iªº¥¼¨Ó¤TÓ¤ë²{ª÷¬y¶q¹w´ú¤Î¬ÛÃö»¡©ú , Ó¤H¨Ì¾Ú16»õªÑ¥»²Ê¦ô¤j¬ù¯à¦^¨ì7.5¤¸, ¦p¥[¤W¨ú±o¤½¥q¸³¨Æªø¡B¸³¨Æ·|¦¨û©M´X¦ì¥Dn§ë¸êªÌ´£¨Ñ¦@p¤T¦Ê¸U¬ü¤¸¿Ä¸ê¶U´ÚÃB«×»PÁú°êBUKWANG PHARMACEUTICAL¦X¸ê¦¨¥ßªº¤l¤½¥q500¸U¬ü¤¸²Ä¥|©u²bȦ^¨ì8.5¤¸¤]¬O¥i¯àªº 2 ²{¦b³QÁY¥æ©ö,¦b¦¨¥æ¶q¤Öªº±¡ªp¤U¤@¦³¬ðµo©Ê§Q¦h·|§Î¦¨¤@ªÑÃø¨Dªº±¤°â²{¶H, ¦b¥i¹w´Á¨CªÑ²bÈ·|¦^¨ì5¤¸¥H¤Wªº ±¡ªp¤U²Ä¤T©u¨CªÑ²bȦ³¨S¦³¦^¨ì5¤¸¥H¤W¤w¸g¤£¬O«ÂI 3 §ë¸êÀò§Q»P§_ ¹B®ðªº¦¨¤À»·¤j©ó¤@¤Á ¥H¤W¬OÓ¤H¬Ýªk¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/10/23 ¤U¤È 03:12:23²Ä 1407 ½g¦^À³
|
ªÑ»ùn¦³¶q¤~·|¦³»ù¡AÅܦ¨¥þÃB¥æ³ÎªÑ¤§«á¡A¦]¬°½æ½æ³Â·Ð¡An¥ý§â¿ú¦s¨ì«ü©w¤áÀY¡A¦A³qª¾Àç·~û¡A¸ò¥H«e¥unÂIÂI·Æ¹«©Î«ö«ö¤â¾÷ªº°Ê§@¨Ó¤ñ¡A½ÆÂø«Ü¦h¡A©Ò¥H´Nºâ¦³¦n®ø®§n¤ÏÀ³¤]§xÃø¡A²{¦b´N¬ÝQ3°]³ø¬Ý²bȪºÅܤơAQ3·|¼W¥[ªº¦³¤§«eÅܧ󪺨ϥΥتº²{ª÷¤j¬ù2»õ8¤d¦h¸U¡AÁÙ¦³¤§«e»PÁú°êBUKWANG PHARMACEUTICAL¦X¸ê¦¨¥ßªº¤l¤½¥q¡A³o¨â¶µ³£·|¦C¤Jpºâ¡A©Ò¥H¤£ª¾¹D³o¼Ë¤½¥q²bȯण¯à¦^¨ì5¤¸¡A§_«h´Nnµ¥¨ìQ4¶Ò¸ê§¹¦¨¤~·|«ì´_Åܦ¨´¶³q¥æ©ö¤F¡A§Æ±æQ3°]³ø¥X¨Ó¯à¦³¦n®ø®§¡C |
|
|
·|û¡G³¯¹Å¥Í10148680 µoªí®É¶¡:2019/10/23 ¤W¤È 10:07:58²Ä 1406 ½g¦^À³
|
¬ÝªÑ»ù¦ü¥G§Q¦h¤£º¦¡H¬Ý¨Ó²{¦b³ÌÃö¤ßªº¬O11¤ë¬O§_¸Ñª¼¦¨¥\¡I§ë¸ê¤H¤£´±§ë¸ê¥þÃB¥æ³ÎªÑ¡A·ÀI¤Ó¤j¤F¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/10/22 ¤U¤È 06:43:24²Ä 1405 ½g¦^À³
|
¶W¥G·Q¹³ªº§Ö³t¡A²{¦b¶i¦æ¤¤·Ó¶ÒªºÁ{§É¸ÕÅç¥i¤£¥i¥H§â·§©À©ÊÅçÃÒ·Q¦¨¤G´ÁÁ{§É¡H ¨È·à±d-KY(6497)«Å§GASLAN004²§¦ì©Ê¥Ö½§ª¢·§©À©ÊÅçÃÒ¸ÕÅç¡A©Û¶Òº¦ì±wªÌttps://mops.twse.com.tw/mops/web/t05sr01_1 |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2019/10/22 ¤U¤È 04:15:59²Ä 1404 ½g¦^À³
|
04¦³¶i«× ¦³·ÓµÛpµe¦b¨« «ö¨B´N¯ZÁö¬Oº©ªø ȱo¹Å³\ ¦Ñ·à¥[ªo¡C·à¤Í¥[ªo |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/10/22 ¤W¤È 09:52:51²Ä 1403 ½g¦^À³
|
«e¸³¨ÆªøCarl Firth±M¤ß·í°õ¦æªø¡A¦A§ä¤@¦ì¦³±M·~ªº¤H¨Ó·í¸³¨Æªø¡A³¡¥÷¥DºÞ½Õ¾ã³o¬O«Ü¥¿±`ªº¡AAndrew Howden¸³¨Æªø´¿¥ô¿D¬wiNova»sÃÄ°õ¦æªø¡AiNova¬°¤@¾î¸ó¦hºØªvÀø»â°ì¤§¥þ²y©ÊÃĪ«¶}µo¤Î°Ó«~¤Æªº»sÃĤ½¥qIMS Health¡¦s ¨È¤Ó°ÏÁ`µô¡BAstraZeneca¨È¤Ó°Ï°ÆÁ`µô¡A¨Ã¦b©ø®õ (Quintiles)¾á¥ô¸ê²`ºÞ²z¾°È |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/10/21 ¤U¤È 08:27:19²Ä 1402 ½g¦^À³
|
To ¥¬âB¡A §Ú¸ò§A¤@¼Ë³£¥u¬OªÑªF¦Ó¤w¡A§Ú¤]¤£²M·¡ÅU°Ýn°µ¤°»ò¨Æ±¡¡A¥LÂàÅU°Ý¥u¬O§Ú¤§«e¥´¥h¤½¥q¿Ô¸ß¡A¤½¥q¨ºÃä§i¶D§Úªº¡A²{¦bÀ³¸Ó¤]¨S¦³¤°»ò«nªº¨Æ±¡¸òÁÂÂå®v¦³Ãö§a¡A«ÂIÀ³¸ÓÁÙ¬O©ñ¦b¸Ñª¼¤W±§a¡I ÁÂÁ |
|
|
·|û¡G¥¬½\10148647 µoªí®É¶¡:2019/10/21 ¤U¤È 04:54:07²Ä 1401 ½g¦^À³
|
¨º½Ð°Ý¸¤H¥d¯S,§Aª¾¹DÁÂÅU°ÝÂå®vªºÂ¾°È³£¦b°µ¤°»ò¤º®e¶Ü,¥L³£«Ý¦b·s¥[©Y¶Ü?¥Lªº¨È·à±d³sµ¸«H½c¤]¨S¦b¥Î¤F,¥L¹ï¨È·à±d¶·n°µ¤°»ò«n¨ÑÄm?°Ý¥x¥_¤½¥q,¥LÌ»¡¤£¤Ó¸òÅU°Ý©¹¨Ó,©Ò¥H¬O¸ò·s¥[©Yª½±µ±µ¬¢¶Ü,.¦]¬°¥xÆW¥u¦³³o¦ì¬O«n¤Hª«,¨ä¥L³£¬O°ê¥~ªº¤H©Ò¥H¤ñ¸û¦n©_¥L³£¦b¥xÆW°µ¨Ç¤°»ò¾°È¤º®e?¥L¤£¬O«Ý¦b¥xÆW¤½¥q,¨º¥L«Ý¦b·s¥[©Y¤½¥q¶Ü? |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2019/10/18 ¤U¤È 07:32:21²Ä 1400 ½g¦^À³
|
¤£¿ù¡A¤jªÑªF¤@°_¦@±wÃø ¼W±j§Ú¤£¤Ö«H¤ß éw·à¥[ªo¡A¦¤éÅܶ¯·à |
|
|
·|û¡G³¯¹Å¥Í10148680 µoªí®É¶¡:2019/10/18 ¤U¤È 05:34:40²Ä 1399 ½g¦^À³
|
³o¯u¬O«¤j¦n®ø®§¡A¹wp¤U¶g¤@ªÑ»ùÀ³¦³ªí²{¡I11¤ë§Ö¨ì¤F¡A¦ýÄ@¸Ñª¼¦¨¥\¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/10/18 ¤U¤È 04:16:59²Ä 1398 ½g¦^À³
|
(1)11¤ëASLAN001¸Ñª¼. (2)©ú¦~ªìASLAN004´N¥iª¾1b AD±wªÌªvÀøµ²ªG. (ªvÀø´Á¶È8¶g/¤H) --------------------------- [¤½§i] ¨È·à±d-KY:¨ÌÃÒÂdºÊ¦r²Ä10802014802¸¹¨Ó¨ç¿ì²z¤½§i¥¼¨Ó¤TÓ¤ë²{ª÷¬y¶q¹w´ú¤Î¬ÛÃö»¡©ú ¤½¶}¸ê°TÆ[´ú¯¸ (2019-10-18 14:49:30) ²Ä53´Ú 1.¨Æ¹êµo¥Í¤é:108/10/18 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¥»¤½¥q©ó¥Á°ê108¦~10¤ë4¤é¸g¸³¨Æ·|³q¹L²{ª÷¼W¸êµo¦æ´¶³qªÑ³Ì°ªªÑ¼Æ100,000,000ªÑ °Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ¡A©ó¥Á°ê108¦~10¤ë7¤é¨ú±o¤¤¥¡»È¦æ®Ö³Æ¦b®×¡A¥B¹wp©ó 108¦~10¤ë18¤é¦Vª÷ºÞ·|ÃÒ´Á§½´£¥æ¬ü°ê¦s°U¾ÌÃÒ¤§µo¦æ¥Ó½Ð¡C ¬°¿í´`»OÆW¤WÂd¤½¥q¬ÛÃöªk¥O³W½dº[«OÅ@§ë¸ê¤HÅv¯q¡A¥»¤½¥q¨Ì¨Ó¨ç«ü¥Ü¡B©ó»¼¥æ ª÷ºÞ·|ÃÒ´Á§½¥»¦~«×²{ª÷¼W¸êµo¦æ·sªÑ°Ñ»P¬ü°ê¦s°U¾ÌÃҥӽЮ׫e¡A¤½§iªñ¤TÓ¤ë ²{ª÷¬y¶q¹w´ú¡C ¥Ñ©ó¥Í§Þ²£·~¯S®í©ÊP¥¼¨Ó²{ª÷¬y¶q¹w´ú¨ã¤£½T©w¦]¯À¡A¥]¬A¥»¤½¥q¥Ø«e¿n·¥Äwµe¤§ Äw¸ê¬¡°Ê¤Î±ÂÅv¥æ©ö¡C°ò©ó¹w´ú©Ê»¡©ú°ò¦¡A¥»¤½¥q«Y¥H¤Uz°²³]¦ôp¥¼¨Ó¥i¯à¤§ ²{ª÷¬y¶q: °²¨Ï¥»¤½¥q©ó¥Á°ê108¦~12¤ë¥H¨CªÑ¼È©w»ù®æ·s¥x¹ô12¤¸µo¦æ¦Ü100,000,000´¶³qªÑ°Ñ»P µo¦æ¬ü°ê¦s°U¾ÌÃÒ¡A¥»¤½¥q¥¼¨Ó¤TÓ¤ë²{ª÷¬y¶q¹w´ú¦p¤U¡G ³æ¦ì¡G¬üª÷¦Ê¸U¤¸ ¶µ¥Ø 108¦~10¤ë 108¦~11¤ë 108¦~12¤ë ´Áªì²{ª÷¾lÃB 8.0 8.6 6.2 Àç·~¬¡°Ê¤§²{ª÷¬y¥X -2.4 -2.4 -2.4 Äw¸ê¤Î¿Ä¸ê¬¡°Ê¤§²{ª÷¬y¤J 3.0 - 36.4 ´Á¥½²{ª÷¾lÃB 8.6 6.2 40.2 °²³]»¡©ú¦p¤U: -²{ª÷¬y¶q¹w´ú¶È¥Î©ó¥»¤½§i»¡©ú¤§¥Î³~¡C¤Wz¦U¤ë´Á¥½²{ª÷¾lÃB¥¼¸g·|p®v ¬d®Ö/®Ö¾\¡C -¥»¤½¥q«Y¨Ì°²³]°ò¦¨Ó¹w¦ôÀç·~¬¡°Ê¥i¯à¤§²{ª÷¬y¥X¡A¥]¬A¦ý¤£©ó¥H¤U¨Æ¶µ¡G ¥Ø«e¥¿¦b¶i¦æªºÁ{§É¸ÕÅ礧³¡¤À¨½µ{¸O¥i¯à¦b¥¼¨Ó¤TӤ뤺¹F¦¨¡C ¥t¥Ñ©ó¥»¤½¥q©e¥Ñ²Ä¤T¤èCROs¤ÎCMOs¼t°Ó¶i¦æ¦U¶µ¸ÕÅç¡AµLªk½T¤Á´x´¤©Ò¦³¥i¯à µo¥Í¤§ÅÜ°Ê¡C -Äw¸ê¬¡°Ê¤§²{ª÷¬y¤J«Y°ò©ó¥»¤½¥q¨ú±oª÷ºÞ·|ÃÒ´Á§½¤§®Öã¨ç«á¨Ã¨¬¥Hµo¦æ¥þ³¡¥Ó½Ð ¼ÆÃB100,000,000ªÑ¥B¥H¨CªÑ¼È©wµo¦æ»ù®æ·s¥x¹ô12¤¸¤§°²³]°ò¦¤U¡B¦©°£¦ôp¤§µo¦æ ¦¨¥»¦Ó±o¡C -¤Wz²{ª÷¬y¤J¤£¥]¬A¥»¤½¥q¥i¯àij©w¤§±ÂÅv¥æ©ö©Î¥»¤½¥q¥i¯à¶i¦æ¤§¨ä¥L¿Ä¸ê¤è¦¡¡C ¥»¤½¥q¥Ø«e»P²Ä¤T¤è«Y³B©ó¨Ì¥¿±`°Ó·~ºD¨Ò¨ó°Ó¶¥¬q¡C -¤Wz²{ª÷¬y¶q¹w´ú«Y°w¹ïºI¦Ü¥Ø«eªº¸ê®Æµo¥¬¡A¤£½T©w©Ê¤§°²³]°ò¦¥i¯à·|ÀH¨Æ¥ó©Î ±¡ªp¤£¦P¦Ó¼vÅT³Ì²×²{ª÷¬y¶q¤§µ²ªG¡C°ò©óÀç¹B±¡B¸gÀÙ±¤ÎÄvª§±¤W¦U¶µ·ÀI¦]¯À¡A ¹w´ú©Ê¸ê°T±N¨ü¨ì¹ê½è¤W©Î¼Æ¾Ú¤W¤§¼vÅT¡A¨ã¦³¥i¯à¤£°÷ºë½T©Î»P³Ì²×¹ê»Úµ²ªG¦³«¤j ®t²§¤§·ÀI¡C 6.¦]À³±¹¬I:¸Ô¤W»¡©ú¡C 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: ¥»¤½¥q¨¬°¥~°êµo¦æ¤H¤w«ùÄò¥BºÉ¤O¦^À³¥DºÞ¾÷Ãö¦U¶µn¨D¡C¥Á°ê108¦~9¤ë25¤é¡A ¥»¤½¥q¥ý¥H¨È¶}¦r²Ä201909006¸¹¨çÂÐ¥DºÞ¾÷Ãön¨D¤§¤»Ó¤ëµLÀ禬»¡©ú¡A¨Ã¤w¸ÔºÉ¦V Âd¶R¤¤¤ß³ø§i¥»¤½¥q§Y±N¨ì¨Ó¤§Äw¸êpµe¥H¤ÎÀÀij¤§®Éµ{¡F¸Ó¶Ò¸êpµe·~¤w©ó ¥Á°ê108¦~10¤ë4¤é¸g¸³¨Æ·|¼f¬d¨Mij³q¹L¡A¥B¨ÌÂd¶R¤¤¤ß¦A«×¨Ó¨çn¨D¡A¥»¤½¥q§ó¤w ¨çÂл¡©úTreetop¸ÕÅç¸Ñª¼µ{§Ç¡A¨Ã³ø§iÃB¥~ªº¥i¯à¿Ä¸êpµe§@¬°¥¼¯à¹F¦¨¶Ò¸ê¤§¨ä¤@ ¦]À³±¹¬I¡C ¥Á°ê108¦~10¤ë8¤é¡A¥»¤½¥q¦A¦¸¨Ì¥¿¦¡¨ç¤å¨È¶}¦r²Ä201910004¸¹¨ç¦^ÂСA»¡©ú¥»¤½¥q °ò©ó²{ª÷¬y¶q¤§¸·¤§©Ò¦³¦]À³±¹¬I¡A¨Ã©ú½T±j½Õ¥»¤½¥q¨¬°¥xÆW¤Î¬ü°êÂù±¾µP¤§¬ã¨s µo®i¶¥¬q¥Í§Þ¤½¥q¥²¶·©ó¤£¦P¸ê¥»¥«³õ±¹ï¤§ªk¿í½ÆÂø©Ê¡CºI¦Ü¥Ø«e¬°¤î¡A¥»¤½¥q¤wºÉ ¤@¤Á³Ì¤j§V¤O¥H´Á²Å¦X¥DºÞ¾÷Ãö¤§n¨D¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/10/18 ¤U¤È 04:01:52²Ä 1397 ½g¦^À³
|
¨ÌÃÒÂdºÊ¦r²Ä10802014802¸¹¨Ó¨ç¿ì²z¤½§i¥¼¨Ó¤TÓ¤ë ²{ª÷¬y¶q¹w´ú¤Î¬ÛÃö»¡©ú mops.twse.com.tw/mops/web/t05sr01_1 ¨ì12¤ë©³¹w¦ô²{ª÷40.2¦Ê¸U¬ü¤¸ ( ¬ù12.3»õ¤¸¥x¹ô ) ¤£¥]¬A±ÂÅv¥æ©ö ²Ä4©u²bÈ´N·|¤j´T´£¤É «ÂI¦b³o¤@¬q ¨È·à±d-KY °õ¦æªø³Å«i³Õ¤h¡]Dr Carl Firth¡^ªí¥Ü¡G¡u³oµ§¿Ä¸ê¶U´Ú¥i´£¨Ñ¨È·à±d-KY §ó¥R¨¬ªº²{ª÷³¡¦ì¬°²Ä ¥|©u¨ú±o«nÁ{§É¼Æ¾Ú°µ·Ç³Æ¡A¨ä¤¤¥]§t 11 ¤ë¨ú±o¼Ï¯Ã TreeTopp ¸ÕÅ礤 varlitinib ¹ï¤G½uÁx¹DÀùªºÁ{§É¸ÕÅç ¦¨ªG¡A¥H¤Î©ó 2020 ¦~ªì¨ú±o ASLAN004 º¦¸¥Î©ó¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢ªºÀø®Ä¼Æ¾Ú¡C§ÚÌ«D±`·PÁ¤Wz ¦¨û¦b¨È·à±d-KY §Y±N¹F¨ì³o¼Ë«nªºÁ{§É¨½µ{¸O®É¡A¹ï§Ú̬ãµopµe«O«ù«H¤ß¨Ã´£¨Ñ°]°È¤Wªº¤ä«ù¡C Ó¤H²q´ú2020¦~¤TÓ¥Dn¬ãµo²£«~¤¤·|¦³¨âÓ±ÂÅv®× ¥H¤W¤À¨É¡AÂԨѰѦҡC |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/10/18 ¤U¤È 04:00:58²Ä 1396 ½g¦^À³
|
·s»D½Z ¨È·à±d-KY«Å¥¬¨ú±o300¸U¬ü¤¸¿Ä¸ê¶U´Ú 2019¦~10¤ë18¤é¡A·s¥[©Y ¡V »EµJ©óÁ{§É¶¥¬q¸~½F¤Î§K¬Ì¾Ç¤§Á{§É¶¥¬q¥Íª«»sÃĤ½¥q¨È·à±d-KY (NASDAQ:ASLN, TPEx:6497)¤µ¤é«Å¥¬¤w¨ú±o¤½¥q¸³¨Æªø¡B¸³¨Æ·|¦¨û©M´X¦ì¥Dn§ë¸êªÌ´£¨Ñ¦@p¤T¦Ê¸U¬ü¤¸¿Ä¸ê¶U´ÚÃB«×¡A¦¹¿Ä¸ê¶U´Ú±N¥i¬°¤½¥q´£¨ÑÃB¥~¥B¼u©Ê¹B¥Î¤§Àç¹B¸êª÷¡A¥H¥þ¤O¤ä«ù¥¿¦b¶i¦æªº¬ãµop¹º©MÁ{§É¬ã¨s¡C ¨È·à±d-KY °õ¦æªø³Å«i³Õ¤h¡]Dr Carl Firth¡^ªí¥Ü¡G¡u³oµ§¿Ä¸ê¶U´Ú¥i´£¨Ñ¨È·à±d-KY§ó¥R¨¬ªº²{ª÷³¡¦ì¬°²Ä¥|©u¨ú±o«nÁ{§É¼Æ¾Ú°µ·Ç³Æ¡A¨ä¤¤¥]§t11¤ë¨ú±o¼Ï¯ÃTreeTopp¸ÕÅ礤varlitinib¹ï¤G½uÁx¹DÀùªºÁ{§É¸ÕÅ禨ªG¡A¥H¤Î©ó2020¦~ªì¨ú±oASLAN004º¦¸¥Î©ó¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢ªºÀø®Ä¼Æ¾Ú¡C§ÚÌ«D±`·PÁ¤Wz¦¨û¦b¨È·à±d-KY§Y±N¹F¨ì³o¼Ë«nªºÁ{§É¨½µ{¸O®É¡A¹ï§Ú̬ãµopµe«O«ù«H¤ß¨Ã´£¨Ñ°]°È¤Wªº¤ä«ù¡C¡v ¥»¤åµ²§ô ´CÅéÁpµ¸¤H Emma Thompson Spurwing Communications Tel: +65 6340 7287 Email: ASLAN@spurwingcomms.com Robert Uhl Westwicke Partners Tel: +1 858 356 5932 Email: robert.uhl@westwicke.com ¤ýµq¼w Peter ¸g´ï¤½Ãö Tel: +886 2 2766 1500 E-mail:peter@clavis.com.tw |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/10/18 ¤U¤È 03:19:38²Ä 1395 ½g¦^À³
|
¨È·à±dµo¤F¨â«h«°T¡A¨ä¤¤¤@«h¬O¦V¥DnªÑªF¿Ä¸ê¥R¹êÀç¹B¸êª÷³Æ¦Ó¤£¥Î¡A¥t¥~¤@«h¬O»¡©ú¥¼¨Ó³o¤TӤ몺²{ª÷¬y¶q¡A¬Ý¨Ó³Ì§Ö12¤ë´N·|¶Ò¸ê§¹¦¨¡A¥Ø«e¤]ÁÙ¦³¨ä¥L¶Ò¸êºÞ¹D¦b¶i¦æ¡Aê©ó°Ó·~ì«h¤£¯à¤½¶}¡A¥i¯à¬O±ÂÅv©Î¬O¨ä¥L¶Ò¸êºÞ¹D¡A¥H²{ª÷¬y¨Ó¬Ý¡A³Ì§ÖQ4²bÈ´N·|¤j´T´£¤É¡A¤]¦³¦V¤½¥q°]°È½T»{¡A¤§«e9¤ë¦¨¥ßªº·s¤½¥q¡A¬O·|¯Ç¤J°]³øpºâªº¡A©Ò¥H²bÈÀ³¸Ó¤]¦³´£¤Éªº¥i¯à¡C |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2019/10/17 ¤U¤È 07:48:17²Ä 1394 ½g¦^À³
|
éw·à¤£n¤@ª½¦A·d¯º ¤½¥q³£¨S¿ú¤FÁÙ³Q»@ »°§Ö¸Ñª¼¦¨¥\§a¡Aµ¥¨ìÀY¾v¥Õ¤F |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/10/17 ¤U¤È 04:19:47²Ä 1393 ½g¦^À³
|
¡i®É³ø°OªÌ±iº~ºö¥x¥_³ø¾É¡jÂdÂi¶R½æ¤¤¤ß°w¹ï¨È·à±d-KY (6497) ¹H¤Ï«¤j°T®§³W©w¡A³B¥H¹H¬ùª÷3¸U¤¸¡C ¡@¨È·à±d-KY¤½¥q²{ª÷¬y¶q°T®§¹ïªÑªFÅv¯q¦³«¤j¼vÅT¡A¸g³qª¾¸Ó¤½¥q´N¥¼¨Ó¤TÓ¤ë(108¦~10¤ë¦Ü12¤ë)¤§²{ª÷¦¬¤ä¹w¦ô¥H¤Î¤½¥q¥¼¨Ó¶Ò¸ê¤è¦¡¡B®Éµ{³Wµeº[¥¼¯à¹F¦¨¶Ò¸ê¤§¦]À³±¹¬I¿ì²z«¤j°T®§¤½§i¡A¸Ó¤½¥q¤´¥¼¨Ì³W¿ì²z¡AÂd¶R¤¤¤ß¬¸³B¥H·s»O¹ô3¸U¤¸¤§¹H¬ùª÷¡C ³o¤½§iÀ³¸Ó¬O»¡¤½¥q¨S¦³«ö®É¤½§i³o¨Ç°T®§§a¡A¤£¹L¤WÓ¤ë¤w¸g¦³Åܧ󤧫e¶Ò¸êªº¨Ï¥Î¤è¦¡¡A©Ò¥H²{ª÷¬yÀ³¸Ó¥Î¨ì©ú¦~¤W¥b¦~À³¸Ó³£¨S°ÝÃD¡A¥u¬O¶Ò¸ê¥¼§¹¦¨ªº¦]À³±¹¬I¤½¥q¨S¦³»¡©ú¡AÁÙ¦³´N¬O¹w¦ô³o¤TӤ몺²{ª÷¸ê¥X¥¼¹w¦ô©Ò¥H³Q¶}»@¤F¡A¤µ¤Ñ¦³¥´¥hID¨ºÃä¸ß°Ý¡An¨ì¤U§«ô¤~·|¦³§ó·sªº®ø®§¡A¬Ý¤½¥qn«ç¼Ë¹ï¥~»¡©ú! |
|
|
·|û¡G³¯¹Å¥Í10148680 µoªí®É¶¡:2019/10/17 ¤U¤È 03:06:38²Ä 1392 ½g¦^À³
|
¤µ¤Ñ¬Ý¨ì¡m¥ÍÂåªÑ¡n¨È·à±d-KY¹H¤Ï«°T³W©w¡A³B¥H¹H¬ùª÷3¸U¤¸¡I»¡¹ê¦b¡A¤j®a³£«Ü©È¦Ñ·à¦b¥xÆW¤U¥«¡A©Ò¥H¨S¦³¤H´±¸I³oÀɪѲ¼¡A©È¦å¥»µLÂk¡IY²Ä¥|©u¸Ñª¼¦A¥¢±Ñ¡A¨º¤j·§ª±§¹¤F¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/10/17 ¤W¤È 11:21:58²Ä 1391 ½g¦^À³
|
9¤ë¨È·à±d¦bCSCO¤¤°êªº¤G½uÁx¹DÀù¥i¥HºÙ§@¬ð¯}©Êì¦]¬O¦]¬°¤¤°ê¯f±w¹ï¤@½uªvÀø¤ñ¥@¬É¨ä¥L°ê®a¦a°Ï¤ÏÀ³²v®t«Ü¤j¡A¥u¦³¦Ê¤À¤§¤Q¡A¨È·à±d¬O¤G½u¤ÏÀ³²v¬O¦Ê¤À¤§¤Q¤@¡A¤ñ¤@½uÁÙ¦n¡Hºâ¬O¶W¹L¹w´Á¡A·à±dºô¯¸¤E¤ë¤½§i¤w»¡©ú«Ü²M·¡¡A²Ä¥|©u¸Ñª¼²{¦b¤~¤Q¤ë¤¤¦¯¡A²Å¦X®Éµ{³W¹º |
|
|
·|û¡G¥[¯Z¤H¥Í10148422 µoªí®É¶¡:2019/10/16 ¤U¤È 09:33:24²Ä 1390 ½g¦^À³
|
½Ð°Ý¤@¤U¦U¦ì¡A¬°¦ó9¤ëCSCO¤¤°êªº¤G½uÁx¹DÀù¥i¥HºÙ§@¬ð¯}©Ê¡Hµ²ªGÀ³¸Óºâ¬O¤£²Å¦X¹w´Á§a¡IÁÙ¬O³o¡§real world¡¨ data ¦b¤¤°ê¯uªººâ¦nªº¡C ÁÙ¦³Ãö©óTreeToppÁÙ¿ð¿ð¥¼¸Ñª¼¡A¨ä¹ê¤ß¸Ì¬O¦³¤@ÂIª¸½D¡A·|¤£·|¦]¬°¥DnÃöÁä¼Æ¦rÁÙ¨S±µªñ¤Q¦ì¼Æ°Ú¡HmPFS,mOSºâºâ®É¶¡À³¸Ó³£®t¤£¦h¦¨¼ô¤F¡CÁÙ¬O¯uªºnµ¥¨ì½T©w¤F¤~·|¸Ñª¼¡H ·PÁ¡C |
|
|
·|û¡G±áÄf10141758 µoªí®É¶¡:2019/10/16 ¤U¤È 07:25:06²Ä 1389 ½g¦^À³
|
éw·à³Q»@3¸U. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/10/11 ¤U¤È 11:52:43²Ä 1388 ½g¦^À³
|
ASLAN004²§¦ì©Ê¥Ö½§ª¢1b´ÁÁ{§É©Û¶Ò50¦ì¨ü¸Õ¥ÎÃÄ«á¬ÛÃöµû¦ô8¶g¡A°lÂÜ12¶g¡Aªº½T¤ñDepulimabµû¦ô®É¶¡¬[ºc16¶g¨Óªºµu¡C ·j´M¡GÁ{§É¸ÕÅç¤À´Á¤¶²Ð ·|µo²{Á{§É¸ÕÅçªk³W»P¤@¯ë¤Hªº·Qªk®t«Ü¤j |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/10/10 ¤U¤È 05:30:21²Ä 1387 ½g¦^À³
|
aslan004 ³]p , 8¶g¥´8°w¡A2Ӥ먣ªvÀø®ÄªG¤§¦³µL. ¤ñ²{¦³¤W¥«¼Ð¹vÃĪ« ¥|Ó¤ë§MÀø¤Ö2Ó¤ë¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/10/10 ¤W¤È 10:09:55²Ä 1386 ½g¦^À³
|
1±qÁ{§É¹êÅç³]p¨Ó¬Ý©Û¶Ò¨ü¸Õªº±ø¥ó¦³¤KÓ¡A±Æ°£ªº±ø¥ó¦³27Ó¡A¦¬®×±ø¥ó·¥¬°ÄY®æ 2 ¤@B´Á´N¶i¦æ¦h¤¤¤ß¡AÂùª¼¡A¦w¼¢¾¯¹ï·Ó¡AÀH¾÷¡A¦h¦¸¤W¤É¾¯¶q¡]MAD¡^Á{§É¬ã¨s ¨Ãµû¦ôÀø®Ä¡A¸õ¯ÅÁ{§Éªº¥ø¹Ï¤ß±j¯P¡C 3µo¦æADR¹w´Á¨È·à±d·|²æÂ÷²bȧC©ó¤¤¸ªº§x¹Ò¡Cªº ¥H¤W¬OÓ¤H¬Ýªk¡A¶È¨Ñ°Ñ¦Ò¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/10/9 ¤W¤È 11:26:36²Ä 1385 ½g¦^À³
|
A Phase 1B, multi-center, double-blind, placebo-controlled, randomized, multiple ascending dose (MAD) clinical study is designed to evaluate ASLAN004 versus placebo in patients who have moderate-severe AD. The treatment period duration will be 8 weeks with a 12-week follow-up period after the end of treatment. clinicaltrials.gov/ct2/show/NCT04090229?term=aslan&rank=1 ¤@¶µ1B´Á¡A¦h¤¤¤ß¡AÂùª¼¡A¦w¼¢¾¯¹ï·Ó¡AÀH¾÷¡A¦h¦¸¤W¤É¾¯¶q¡]MAD¡^Á{§É¬ã¨s¦®¦bµû¦ô¤¤««×AD±wªÌªºASLAN004»P¦w¼¢¾¯ªº¤ñ¸û¡C ªvÀø´Á¬°8¶g¡AªvÀøµ²§ô«á¬°´Á12¶g¡C Study Design Go to sections Study Type : Interventional (Clinical Trial) Estimated Enrollment : 50 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Double Blind, Placebo-controlled, Randomized Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis Estimated Study Start Date : September 30, 2019 Estimated Primary Completion Date : October 31, 2020 Estimated Study Completion Date : October 31, 2020 |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/10/6 ¤U¤È 05:36:13²Ä 1384 ½g¦^À³
|
§ó¥¿¤@¤U¡APeter wang ¤£¬O¤½¥qµo¨¥¤H¡A¥L¬O¨È·à±d©e°Uªº§ë¸ê¤HÃö«Yªºµ¡¤f¡A¦b¦¹»¡©ú¤@¤U¡C |
|
|
·|û¡G¥¬½\10148647 µoªí®É¶¡:2019/10/6 ¤U¤È 03:17:09²Ä 1383 ½g¦^À³
|
OK,«D±`·PÁ§A,¥´ÂZ§A¤F^^ |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/10/6 ¤U¤È 01:51:28²Ä 1382 ½g¦^À³
|
To ¥¬âB §A¤W¯Z®É¶¡¥´²Ä¤TÓ¸¹½X´N¥i¥H§äªº¨ì¨È·à±dªº§ë¸êªÌÃö«Y Peter Wang¡A¥i¥H¸ò¥L»¡¤¤¤å¡C ÁÂÁ |
|
|
·|û¡G¥¬½\10148647 µoªí®É¶¡:2019/10/6 ¤W¤È 11:34:31²Ä 1381 ½g¦^À³
|
§Ú¦b¤½¥qºô¶¤W¥u¬Ý¨ì³o¨Ç¹q¸Ü ¹q¸Ü: +886 2 3725 7770 ¶Ç¯u: +886 2 3725 7999 IR: +886 2 2766 1500 §ä¤£¨ì¦³µo¨¥¤H¹q¸Ü:§A¥i¥HÀ°§Ú§ä¶Ü?µo¨¥¤HPeter Wang¬O¥xÆW¤H¶Ü? |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/10/5 ¤U¤È 11:33:57²Ä 1380 ½g¦^À³
|
To ¥¬âB §Ú¤£²M·¡¬ã¨s«Çªº¨Æ±¡¡A§Ú¤£¬O¤½¥q¤º³¡ªº¤H·íµM¤£ª¾¹D¤½¥q±µ¤U¨Óªºpµe¡A°T®§¨Ó·½¤]³£¬O¤w¸g¤½§iªº¡A¦pªG§A·Qnª¾¹D¤°»ò®ø®§¥i¥H¥´¹q¸Ü¥h¸ß°Ý¡Aµo¨¥¤H¹q¸Ü¦b¤½¥qºô¶¤W¡AÀ³¸Ó«Ü®e©ö§ä¨ì§a¡A¦³°ÝÃD«Øij§A¥i¥H¿Ë¦Û¥´¹q¸Ü¸ß°Ý¡I ÁÂÁ |
|
|
·|û¡G¥¬½\10148647 µoªí®É¶¡:2019/10/5 ¤U¤È 08:23:16²Ä 1379 ½g¦^À³
|
¨º¥LÌþ¸Ì¦³¬ã¨s«Ç§A¤]¤£ª¾¹D¶Ü,ÁÙ¦³³Ìªñ¦³¤°»ò·|ij,§A³£¬On°Ýµo¨¥¤H¤~ª¾¶Ü,¨º¦³µo¨¥¤H¹q¸Ü¶Ü |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/10/5 ¤U¤È 06:53:37²Ä 1378 ½g¦^À³
|
To ¥¬âB §Ú¬O¥´¹q¸Ü¸ß°Ý·sªºµo¨¥¤Hªº¡A¦Ü©óÁÂÂå®vÂàÅU°Ý§Ú¤]¤£²M·¡ì¦]¡AÀ³¸Ó´NÓ¤H¦]¯À§a¡A§Ú¬O¥´µ¹·sªºµo¨¥¤HPeter Wang¡A²{¦bªº·s»D½Z¤]³£¬O¥Ñ¥Lt³d¼Ú¡I ÁÂÁ |
|
|
·|û¡G¥¬½\10148647 µoªí®É¶¡:2019/10/5 ¤U¤È 03:46:56²Ä 1377 ½g¦^À³
|
¦A½Ð°Ý¤@¤U¸¤H¥d¯S,¨È·à±d°£¤F2019/9/18ªº¤¤°ê·|ij,¦A¨Ó¬O9/27ªº¼Ú¬w¦~·|,¦A¨Ó³ÌªñÁÙ¦³¤°»ò·|ij¶Ü,©Î°ê¤º¦ó®É·|¦³¤°»òºtÁ¿¶Ü?§Aªº«Ü¦h¸ê°T³£¬O¦bþ±oª¾ªº,¬O°Ý¨È·à±d¥N¨¥¤H¶Ü |
|
|
·|û¡G¥¬½\10148647 µoªí®É¶¡:2019/10/5 ¤U¤È 03:34:25²Ä 1376 ½g¦^À³
|
½Ð°Ý¸¤H¥d¯S,¨È·à±d¦b¥x¥_þ¸Ì¦³¬ã¨s«Ç?Å¥»¡¸ò¥x¥_Âå¾Ç¤j¾Ç¦³¦X§@,¥i¬O¥´¥h«ç»ò¤@°Ý¤T¤£ª¾,¦]¬°¤£ª¾n§ä¤°»ò¬ì§O,§Aª¾¹D¶Ü? ÁÙ¦³¦A½Ð°Ý¬°¦óÁÂÂå¾Çªø¤£°µ¤F,nÂà¦^·íÅU°Ý©O? |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/10/4 ¤U¤È 03:41:05²Ä 1375 ½g¦^À³
|
¤½§i¥»¤½¥q¸³¨Æ·|¨Mij¿ì²z²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»P µo¦æ®ü¥~¦s°U¾ÌÃÒ 1.¸³¨Æ·|¨Mij¤é´Á:108/10/04 2.¼W¸ê¸êª÷¨Ó·½:¿ì²z²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ 3.µo¦æªÑ¼Æ(¦pÄݬվlÂà¼W¸ê¡A«h¤£§t°tµoµ¹û¤u³¡¥÷): ÀÀ¥H²{ª÷¼W¸êµo¦æ´¶³qªÑ15,000,000ªÑ¦Ü100,000,000ªÑ½d³ò¤º °Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ¡C 4.¨CªÑ±ÃB:·s¥x¹ô10¤¸ 5.µo¦æÁ`ª÷ÃB:¨Ì¬ü°ê¦s°U¾ÌÃÒ¹ê»Úµo¦æ»ù®æ¤Îµo¦æ³æ¦ì¼Æ¨M©w¤§¡C 6.µo¦æ»ù®æ: ¹ê»Úµo¦æ»ù®æ¨Ì¤¤µØ¥Á°êÃÒ¨é°Ó·~¦P·~¤½·|©Ó¾P°Ó·|û»²¾Éµo¦æ¤½¥q¶Ò¶°»Pµo¦æ¦³»ù ÃÒ¨é¦Û«ß³W«h¡]¤UºÙ¡u¦Û«ß³W«h¡v¡^³W©w¡A¤£±o§C©óq»ù¤é´¶³qªÑ¦¬½L»ù¡A©Îq»ù¤é «e¤@¡B¤T¡B¤ÓÀç·~¤é¾Ü¤@pºâ¤§´¶³qªÑ¦¬½L»ù²³æºâ¼Æ¥§¡¼Æ¦©°£µLÀv°tªÑ°£Åv ¡]©Î´î¸ê°£Åv¡^¤Î°£®§«á¥§¡ªÑ»ù¤§¤E¦¨¡C±©¹ê»Úµo¦æ»ù®æ±ÂÅv¥»¤½¥q°õ¦æªø¤Î°]°È °ÆÁ`µô©ó«ez½d³ò¤º¡A¨Ì°ê»ÚºD¨Ò¨Ã°Ñ¦Ò¸ê¥»¥«³õ¤Î·JÁ`°éÁʱ¡§Îµ¥¡A¬¢ÃÒ¨é©Ó¾P°Ó ¦@¦Pij©w¤§¡C 7.û¤u»{ÁʪѼƩΰtµoª÷ÃB: ¥»¤½¥q«O¯dµo¦æ·sªÑÁ`¼Æ10%¥Ñ¥»¤½¥qû¤u»{ÁÊ¡Cû¤u©ñ±ó»{Áʩλ{Áʤ£¨¬³¡¤À¡A ÀÀ±ÂÅv¥Ñ¥»¤½¥q°õ¦æªø¤Î°]°È°ÆÁ`µô¬¢¯S©w¤H»{Áʩεø¥«³õ»Ý¨D¦C¤J°Ñ»Pµo¦æ¬ü°ê¦s°U ¾ÌÃÒ¤§ì¦³»ùÃÒ¨é¡C 8.¤½¶}¾P°âªÑ¼Æ: ¨Ì¥»¤½¥q107¦~ªÑªFÁ{·|¨Mij¡A¦¹¦¸µo¦æ·sªÑ°£10%«O¯dû¤u»{ÁÊ¥~,¨ä¾l90%¤§·sªÑ¥þ¼Æ ¥R§@µo¦æ¬ü°ê¦s°U¾ÌÃÒ¤§ì¦³»ùÃÒ¨é¡C 9.ìªÑªF»{ÁʩεLÀv°tµo¤ñ¨Ò(½Ðµù©ú¼È©w¨C¥aªÑ»{ÁʩΰtµoªÑ¼Æ): ¨Ì107¦~²Ä¤@¦¸ªÑªFÁ{®É·|¤§¨Mij¡AìªÑªF¥þ¼Æ©ñ±óÀu¥ý»{ÁÊÅv§Q¡A¥þ¼Æ¥R§@µo¦æ¬ü°ê ¦s°U¾ÌÃÒ¤§ì¦³»ùÃÒ¨é¡C 10.·î¹sªÑ¤Î¹O´Á¥¼»{Áʪѥ÷¤§³B²z¤è¦¡: û¤u©ñ±ó»{Áʩλ{Áʤ£¨¬©Î·î¹sªÑ³¡¤À¡A¥Ñ¥»¤½¥q°õ¦æªø¤Î°]°È°ÆÁ`µô¬¢¯S©w¤H»{ÁÊ©Î ¦C¤J°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ¤§ì¦³»ùÃÒ¨é¡C 11.¥»¦¸µo¦æ·sªÑ¤§Åv§Q¸q°È:»P¤wµo¦æ¤§´¶³qªÑ¬Û¦P¡C 12.¥»¦¸¼W¸ê¸êª÷¥Î³~: ¥Î¥H¤äÀ³Varlitinib(ASLAN001)¡BASLAN003¡BASLAN004µ¥¤T¶µ¬ãµopµe©Ò»Ý¤§¬ãµo¤ä¥X ©M¥R¹êÀç¹B¸êª÷¡A¦]À³Á{§É¬ã¨sªø´Áµo®i»Ý¨D¡B¶Ò¶°¸êª÷¥H¹F¦¨Á{§É¶}µo¨½µ{¸O¡B¼W¥[ ¥»¤½¥q¶Ò¸ê³~®|º[´£¤É¥»¤½¥qÄvª§¤O¦]À³Á{§É¬ã¨sªø´Áµo®i»Ý¨D¡B¶Ò¶°¸êª÷¥H¹F¦¨Á{§É ¶}µo¨½µ{¸O¡B¼W¥[¥»¤½¥q¶Ò¸ê³~®|º[´£¤É¥»¤½¥qÄvª§¤O¡C 13.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1)¥»¦¸¿ì²z²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ®ü¥~¦s°U¾ÌÃҮסA«Y¸g108¦~10¤ë04¤é¸³¨Æ·| ¤Î107¦~10¤ë30¤éªÑªFÁ{®É·|¨Mij³q¹L¡C (2)¥»¦¸²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ¤§pµe¤º®e¡A¥¼¨Ó¦p¦³¨Ì¥DºÞ¾÷Ãö n¨D×¥¿©ÎÅܧó©Î¨Ì¹ê»Úª¬ªp»Ýn¦Ó½Õ¾ã®É¡A±ÂÅv¥»¤½¥q°õ¦æªø¤Î°]°È°ÆÁ`µô¥þÅv ³B²z¤§¨Ã³ø§i³Ìªñ´Á¸³¨Æ·|¡C (3)¥»¦¸²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ¬ÛÃö¨Æ©y¡A¦p¦³¥¼ºÉ¤§³B¡A¥]¬A¦ý¤£ ©óµo¦æªÑ¼Æ¡Bµo¦æª÷ÃB¡Bµo¦æ»ù®æ¡Bµo¦æ±ø¥ó¡B©Ó¾P¤è¦¡¡Bµo¦æpµe¡Bpµe¶µ¥Ø¡B ¹w¦ô®Éµ{¤Î¹w´Á®Ä¯q©Î¨ä¥L¥¼ºÉ¨Æ©yµ¥¡A±ÂÅv¥»¤½¥q°õ¦æªø¤Î°]°È°ÆÁ`µô¨Ì¥»¤½¥q ¸êª÷»Ý¨D¤Î¥«³õ¹ê»Ú±¡ªp¡A¥þÅv¨M©w¤§¡C ¨È·à±d°e¼fADR¼W¸ê®×¤F¡AÁÙ¬O§Æ±æ»°§Ö¯àºÝ¥X©Ô©ïªÑ»ùªº§Q¦h¥X¨Ó¡A§_«h¥i¥H¶Ò¸êªºª÷ÃB·|¤Ö«Ü¦h! |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/10/3 ¤W¤È 10:01:22²Ä 1374 ½g¦^À³
|
To:«Ó°¶¤j ¨ä¹ê¦Ñ·àªºORR(¸~½FÁY¤p²v)µ²ªG¦¤w¥XÄl,¦ý³Q«Ê¦sÁÙ¤£¸Ñª¼(Ó¤Hı±o¹LÃö¾÷²v°ª)....¦Ó¦Ñ·àªº¨Mµ¦ªÌÁÙ¦bµ¥PFSªº³Ì«áÁ{§Éµ²ªG,¨Ó©Ô°ª¨âÓ«ü¼Ð(ORR¤ÎPFS)³£¹LÃöªº³Ì«á¾÷·|,³o¼Ë¥¼¨Ó±ÂÅvªº¸ô¤~·|¨«±o§ó¼e°Ú~~~¤£¹Lªº½T¦p§A©Ò»¡,¤G½uÁx¹DÀùªº¼Ï¯Ãªº¸Ñª¼½T¬O¨M©w¥Í¦ºªº¤@§Ð~~~~ ¥H¤W¨Ñ°Ñ¦Ò,¤Å·í¶i¥XªÑ²¼¨Ì¾Ú |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2019/10/2 ¤U¤È 09:33:29²Ä 1373 ½g¦^À³
|
³Ì¦h´N¦Aµ¥¨â¤TÓ¤ë¤F ÅuµP¦b§Y¡A·à¤l¤@½¨âÀü²´ ¤ñ°_¨º¨Ç¤£ª¾¹D¥Á°ê´X¦~¤~¦³µ²ªGªº·sÃĪѦn¦h¤F |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/10/2 ¤U¤È 04:51:42²Ä 1372 ½g¦^À³
|
¤@´Á¼Æ¾Ú,¶È¯à°Ñ¦Ò,ªº½T«æ»Ý¤G½uÁx¹DÀù¼Æ¾Úªº¸Ñª¼,¥[ªo~~¦Ñ·à |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/10/2 ¤U¤È 03:01:04²Ä 1371 ½g¦^À³
|
¨È·à±d-KY ©ó 2019 ¼Ú¬w¸~½FÂå¾Ç·|¦~·|µoªí VARLITINIB ³Ì·s¬ã¨s¼Æ¾Ú 2019 ¦~ 10 ¤ë 02 ¤é,·s¥[©Y ¡V »EµJ©óÁ{§É¶¥¬q¸~½F¤Î§K¬Ì¾Ç¤§Á{§É¶¥¬q¥Íª«»sÃĤ½¥q¨È·à±d-KY (NASDAQ:ASLN, TPEx:6497)¤µ¤é«Å¥¬µoªí varlitinib ¦b 1b ´Á¶}©ñ©Ê¾¯¶q»¼¼W¬ã¨sªº·s¼Æ¾Ú,¦¹¶µ¸ÕÅç«Y±´ °Q varlitinib ¦X¨Ö modified irinotecan »P infusional 5-fluorouracil (mFOLFIRI)©ó±ß´Á¹êÅé½F¤§¦w¥þ©Ê¡B@¨ü©Ê »P¨ä³Ì¤j@¨ü¾¯¶q(MTD, maximum tolerated dose)¡C¸Ó¬ã¨s¦¨ªG¥H¾À³ø§Î¦¡©ó 2019 ¼Ú¬w¸~½FÂå¾Ç·|(ESMO) ¦~·|¤Wµoªí¡C ³o¶µ¬ã¨sªÌµo°_ªº¸ÕÅç¥Ñ·s¥[©Y«O°·¶°¹Î(SingHealth)¸ÕÅç¥Î·sÃij¡ªù°Æ¥D¥ô¶À¶W½å³Õ¤h(Dr Matthew Chau Hsien Ng)¥D«ù,¥Ñ¨È·à±d-KY ©M·s¥[©Y°ê®aÂåÀø¬ã¨s©eû·|¨ó§U°õ¦æ¡C¸Ó¸ÕÅç©Û¦¬ 16 ¦W¨ü¸ÕªÌ,¥ý«e±µ¨ü ¹L¤§¤Æ¾ÇÀøªk¼Æ¶q¤¤¦ì¼Æ¬° 3¡C¨ü¸ÕªÌ±µ¨ü¨C¤é¨â¦¸ varlitinib (200mg ©Î 300mg)¥[¤W mFOLFIRI ¤§ªvÀø ; ªv Àø¤£¶W¹L¤EÓ¶g´Á(14 ¤Ñ¬°¤@¶g´Á),¨Ã±q²Ä¤QÓ¶g´Á¶}©l¥H varlitinib ³æ¤@ÃĪ«ªvÀø¡C Varlitinib ¦X¨Ö mFOLFIRI ªº³Ì¤j@¨ü¾¯¶q(MTD)¬° 300mg ¨C¤é¤fªA¨â¦¸¡C¾ãÅé¤ÏÀ³²v¬° 13%,µL´c¤Æ¦s¬¡ ´Áªº¤¤¦ì¼Æ(median PFS)¬° 4.2 Ó¤ë¡C¨ä¤¤,Æ[¹î¨ì¤@¦WÁx¹DÀù¯f±w(¥ý«e±µ¨ü¤@¦¸¤ÆÀø)»P¤@¦W HER2 ¶§ ©Ê³z©ú²ÓM§Z±_Àù¯f±w(¥ý«e±µ¨ü¤¦¸¤ÆÀø)¹ï¦¹ªvÀø¤è¦¡¦³«ù¤[ªº¤ÏÀ³,¤À§Oºû«ù 7.5 Ó¤ë©M 6.1 Ó¤ë¡C¦Ó ³Ì±`µo¥Íªº¤£¨}¤ÏÀ³¬°¯h³Ò¡B¤fµÄÂH½¤ª¢¡B¹½¹©M 1¡B2 ¯Å¸¡Âm,¦Ó¦³ 0%ªº±wªÌµo¥Í 3¡B4 ¯Å¸¡Âm¡CºI¦Ü 2019 ¦~ 2 ¤ë 15 ¤é(¾À³ø¼Æ¾Ú³Ì«á§ó·s¤é´Á),¦³ 4 ¦W¨ü¸ÕªÌ¤´¦b¸ÕÅ礤¡C ºKn¥þ¤å½Ð±q¦¹³sµ²¦Ü¨È·à±d-KY ©xºô¬d¬Ý¡C ¤S¦³¼Æ¾Ú§ó·s¤F! |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/10/2 ¤U¤È 01:25:22²Ä 1370 ½g¦^À³
|
ÆZ©_©Çªº¡Aµo¤F¨âÓ¦n®ø®§¡AªÑ»ù«o¤£º¦¤Ï¶^¡A¹ê¦b¬O¬Ý¤£À´¨È·à±d³o´X¤Ñªº¨«¶Õ? |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/9/30 ¤U¤È 08:58:30²Ä 1369 ½g¦^À³
|
¨È·à±d¤µ¤Ñ¤@¤f®ðµo¤F¤Ó«°T¡A¦³¤H¨Æ²§°Ê¡B¦³¥R¹êÀç¹B¸êª÷¡B¦³¦¨¥ß·s¤½¥q¶}µo·s²£«~¡A¤@¤Ñµo¥¬¤F¤£¤Ö¦n®ø®§¡A§Æ±æ¤½¥q¦A±µ¦A¼FÄ~Äò¥[ªo¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/9/30 ¤U¤È 08:55:28²Ä 1368 ½g¦^À³
|
è褽¥q¤S¦b¤½¶}¸ê°TÆ[´ú¯¸¤½§i·s¸ê°T¡A·PÁ¤½¥q¹ï§ïµ½°]°È¯à¤O¡AÅܧ󤧫eªº¸êª÷¹B¥Î¥H´£°ª¨CªÑ²bÈ©Ò°µªº§V¤O¡C |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/9/30 ¤U¤È 08:51:12²Ä 1367 ½g¦^À³
|
¤½¥qÅܧ󤧫eªº¸êª÷¹B¥Î¤F ¨Æ¹êµo¥Í¤é 108/09/30 »¡©ú 1.¸³¨Æ·|¨MijÅܧó¤é´Á:108/09/30 2.ìpµe¥Ó³ø¥Í®Ä¤§¤é´Á:107/01/22 3.ÅÜ°Êì¦]: ¥»¤½¥q©ó2019¦~1¤ë29¤é¸g¸³¨Æ·|¨Mij«Å¥¬½Õ¾ãÁ{§É¸ÕÅç¶}µoµ¦²¤»P«¾ã¤½¥q²Õ´¬[ºc¡A ¦]«ez½Õ¾ãÁ{§É¸ÕÅç¶}µoµ¦²¤©Mµ¥«ÝVarlitinib ¤G½uÁx¹DÀù¼Ï¯Ã¸ÕÅçTreeToppÁ{§É¹êÅç µ²ªG¤§®Éµ{¡A¾ÉPìpµe¶i«×¸¨«á¡A¦Ò¶q¸êª÷¨Ï¥Î®Ä²v¡AÀÀ±N«e¦¸¶Ò¸êª÷ÃB½Õ¾ã¹B¥Î¡A ¬GÅܧópµe¡C 4.¾ú¦¸Åܧó«e«á¶Ò¶°¸êª÷pµe: ¥»¤½¥q2017¦~²{ª÷¼W¸êÅÜ°Ê«e«á¤§pµe¤º®e¦C¥Ü¦p¤U¡G ³æ¦ì¡G¥a¤¸ pµe¶µ¥Ø Åܧóp¹º«e Åܰʪ÷ÃB Åܧóp¹º«á »PVarlitinib (ASLAN001)¤§¤Þ¤J NT$ 990,000 NT$ (300,000) NT$ 690,000 ±ÂÅv¹Ù¦ñArray«·sñ©w¦X¬ù US$ 33,000 US$ ( 10,000) US$ 23,000 Varlitinib¹w³Æ¦b¤¤°ê¤j³° NT$ 540,000 NT$ (252,000) NT$ 288,000 °Ó«~¤Æ¤§«e¸m§@·~ US$ 18,000 US$ ( 8,400) US$ 9,600 Varlitinib·sÃĬdÅçµn°O¥Ó½Ð NT$ 150,000 NT$ (150,000) NT$ 0 US$ 5,000 US$ ( 5,000) US$ 0 ¥R¹êÀç¹B¸êª÷ - NT$ 287,400 NT$ 287,400 US$ 9,580 US$ 9,580 5.¹wp°õ¦æ¶i«×:¹wp108¦~²Ä¥|©u§¹¦¨ 6.¹wp§¹¦¨¤é´Á:¹wp108¦~²Ä¥|©u§¹¦¨ 7.¹wp¥i¯à²£¥Í®Ä¯q: (1)³z¹LVarlitinib (ASLAN001) ¥»¤½¥q¹w´ÁVarlitinib ¤G½uÁx¹DÀù¼Ï¯Ã¸ÕÅçTreeTopp©ó2019¦~²Ä¥|©u¤½¥¬Á{§É¹êÅç ¦p¬°¥¿¦Vµ²ªG«á¡A¸Ó¼Æ¾Úµ²ªG±N¥Î©ó¬ü°ê¡B¤¤°ê¤j³°©M¨ä¥L¥Dn°Ï°ìªº·sÃÄÃÄÃҥӽР(NDA)¤§®Öã¨Ã²£¥Í¸Ó¦a°Ï¤§®Ä¯q¦¬¤J¡C (2)¥R¹êÀç¹B¸êª÷ ¥»¤½¥qÀÀ±N«e¦¸©Ò¶Ò¸êª÷287,400¥a¤¸¡A¥Î©ó¥»¤½¥q¬ãµo¬¡°Ê¤§Àç¹B¸êª÷¥R¹ê¡A°£¥i ¼W¥[ªø´Á¸êª÷¨Ó·½Ã©w«×¡A¤äÀ³¤é±`¤ä©Ò»Ý¥~¡A¥ç¥i´î¤Ö¦]¦Vª÷¿Ä¾÷ºcÉ´Ú©Ò³y¦¨¤§§Q ®§t¾á¡A¶i¦Ó±j¤Æ¤½¥qªø´ÁÄvª§¤O¡A¨Ã´£¤É¸êª÷ÆF¬¡½Õ«×¤§¼u©Ê¡C 8.»Pì¹wp®Ä¯q²£¥Í¤§®t²§: ¥»¦¸pµeÅܧó¹wp±Nìpµe¶µ¥Ø¥Î©óVarlitinib¹w³Æ¦b¤¤°ê¤j³°°Ó«~¤Æ¤§«e¸m§@·~¡B ·sÃĬdÅçµn°O¥Ó½Ð¡A¦]½Õ¾ãÁ{§É¸ÕÅç¶}µoµ¦²¤©Mµ¥«ÝÁx¹DÀùTreeToppÁ{§É¸ÕÅçµ²ªG¡A ¦]¦Ó©µ«áìpµe¶µ¥Ø¤§¤ä¥X¡A¸g¼f·Vµû¦ô«á¡AÀÀ½Õ¾ã¬ÛÃö¸êª÷¹B¥Î¡A±Nìpµe¤¤¥¼¤ä¥Î ³¡¤À¥Î©ó¥R¹êÀç¹B¸êª÷¡A¶Ò±o¸êª÷¥i¨ú¥N»È¦æ¿Ä¸ê¡A¼W¥[ªø´Á¸êª÷éw©Ê¡B±j¤Æ¸êª÷ÆF ¬¡½Õ«×¯à¤O¤Î°·¥þ°]°Èµ²ºc¥~¡A¨Ã¥i¸`¬Ù§Q®§¤ä¥X¡A´£°ª¤½¥qÀç¹B¯à¤O¡C 9.¥»¦¸Åܧó¹ïªÑªFÅv¯q¤§¼vÅT: ¥»¦¸¸êª÷¹B¥Î½Õ¾ã¡A¦]½Õ¾ãÁ{§É¸ÕÅç¶}µoµ¦²¤»P«¾ã¤½¥q¬[ºc¡AP¨Ï¨ä¹wp°õ¦æ¶i«×¤Î ®Ä¯q®Éµ{¦³©Ò»¼©µ¡A±©´N¤½¥qªø´Áµo®i¦Ó¨¥¡A¹ïªÑªFÅv¯q¤§¼vÅT©|Äݦ³¡C 10.ì¥D¿ì©Ó¾P°Óµû¦ô·N¨£ºKn: ¸Ó¤½¥q¥»¦¸pµeÅܧó¥Dn«Y¸Ó¤½¥q©ó2019¦~1¤ë29¤é«Å¥¬½Õ¾ãÁ{§É¸ÕÅç¶}µoµ¦²¤»P«¾ã ¤½¥q¬[ºc¡AVarlitinib ¤G½uÁx¹DÀù¼Ï¯Ã¸ÕÅçTreeTopp¤w©ó2018¦~12¤ë´£«e§¹¦¨¨ü¸ÕªÌ ¦¬®×¡AVarlitinib ¤G½uÁx¹DÀù¼Ï¯Ã¸ÕÅç TreeTopp¹wp©ó2019¦~²Ä¥|©u¦~¨ú±oªì¨BÁ{§É ¸ÕÅç¼Æ¾Ú¡A¦¹¥~¡A¸Ó¤½¥q¤w²×¤î¥Ø«e¥¿©ó¤¤°ê¶i¦æªº³æÁu¤G½uÁx¹DÀùÁ{§É¸ÕÅç¡A¦]¥Ø«e ¸Ó¶µ¸ÕÅç¼Æ¾Ú¹wp¤§¥XÄl®É¶¡±N±ß©óTreeTopp¸ÕÅç¡A¦pTreeTopp¼Æ¾Úµ²ªG¬°¥¿±¡A¸Ó¤½ ¥q±N¸Ó¼Æ¾Ú±N¥Î©ó¬ü°ê¡B¤¤°ê¤j³°©M¨ä¥L¥Dn°Ï°ìªº·sÃÄÃÄÃÒ¥Ó½Ð(NDA)¡C¦]«ez½Õ¾ãÁ{ §É¸ÕÅç¶}µoµ¦²¤¡A¾ÉPpµe¶i«×¸¨«á¡A¸Ó¤½¥q¦Ò¶q¸êª÷¨Ï¥Î®Ä²v¡AÀÀ±N¶Ò¸êpµe¤¤¶i¦æ¡@ pµeÅܧó©|ÄݦX²z¡C 11.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2019/9/30 ¤U¤È 07:10:09²Ä 1366 ½g¦^À³
|
¦pªGÁú¤è¬O500¸U¬ü¤¸ ¨È·à±d·í«¬AhR¸ê²£»ùȤ]µ¥¦P500¸U¬ü¤¸ ¸ê²£§@»ù½×¤§ À³¸Ó´N¬O500¸U¬ü¤¸ ¦ý¤À2¦¸§ë¸ê ®É¶¡ÂIªº»{¦C ¹ï²Ä¤T©uªº²bÈ´£¤É ¦³«ÝÆ[¹î Ó¤HÆ[ÂI ¥[ªo·à¤Í |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/30 ¤U¤È 06:52:51²Ä 1365 ½g¦^À³
|
®Ú¾Ú¨óij¡A¨È·à±d-KY±N´£¨Ñ»PMark Graham³Õ¤h¦@¦Pµo²{¤Î¶}µoªºAhR§Þ³N»P¬ÛÃö¸ê²£¤§¥þ²y©Ò¦³Åvµ¹JAGUAHR AhR§Þ³N»P¬ÛÃö¸ê²£¤§¥þ²y©Ò¦³Åv §@»ù¦h¤Ö? Y500¸U¬ü¤¸ ,²bȼW¥[500¸U¬ü¤¸? Y1000¸U¬ü¤¸,²bȼW¥[1000¸U¬ü¤¸? Y1500¸U¬ü¤¸,²bȼW¥[1500¸U¬ü¤¸? µ¥°]³ø¤~ª¾¹D. |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2019/9/30 ¤U¤È 06:21:10²Ä 1364 ½g¦^À³
|
¬Û¹ï©ó¥xÆW§ë¸êªÌ Áú°ê¹ï©ó¨È·à±d¸û¦³«H¤ß ÁöµMÁÙ¦³¤@¬q¸ôn¨« ¥[ªo¦Ñ·à ¥[ªo¤F·à¤Í |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/30 ¤U¤È 02:52:39²Ä 1363 ½g¦^À³
|
·s»D½Z ¨È·à±d-KY »PÁú°êBUKWANG PHARMACEUTICAL ¦@¦P¦X¸ê¦¨¥ßJAGUAHR THERAPEUTICS ¶}µo·s«¬¸~½F§K¬ÌÀøªk µo½Z¤é´Á¡G2019¦~09¤ë30¤é -¬°¤F¦@¦P¦X¸ê¦¨¥ßJAGUAHR THERAPEUTICS¡A¨È·à±d-KY¤À©îÁ{§É«e´Á¬ã¨s¸ê²£¡BBukwang§ë¸ê¤¦Ê¸U¬ü¤¸ -¨È·à±d-KY©MBukwang±N¦@¦P¦¨¥ß·s¤½¥q¡A¦@¦P¶}µo·s«¬ªºÁ{§É«e´ÁAhR«ú§Ü¾¯ 2019¦~09¤ë30¤é¡A·s¥[©Y¡B«nÁú ¡V»EµJ©óÁ{§É¶¥¬q¸~½F¤Î§K¬Ì¾Ç¤§Á{§É¶¥¬q¥Íª«»sÃĤ½¥q¨È·à±d-KY (NASDAQ:ASLN, TPEx:6497) »P±Mª`©ó¬ãµoªºÁú°ê»sÃĤj¼tBukwang Pharmaceutical(KRX:003000)¡A¤µ¤Ñ«Å¥¬¦@¦P¦¨¤F¤@¶¡¦X¸ê¤½¥q¡A¨Ã¥H¨È·à±d-KY¦´ÁÃÄ«~¬ãµopµe¬°°ò¦¡A¶}µoÁ{§É«e´ÁAhR (aryl hydrocarbon receptor)«ú§Ü¾¯¡C¿W¥ß¤½¥qJAGUAHR TherapeuticsÁ`³¡±N·|³]¥ß¦b·s¥[©Y¡A¨Ã±N±Mª`©ó¬°¥þ²y¥«³õ¶}µo°w¹ïAhR¶Ç»¼¸ô®|ªº¥þ·s¸~½F§K¬ÌÀøªk¡C ®Ú¾Ú¨óij¡A¨È·à±d-KY±N´£¨Ñ»PMark Graham³Õ¤h¦@¦Pµo²{¤Î¶}µoªºAhR§Þ³N»P¬ÛÃö¸ê²£¤§¥þ²y©Ò¦³Åvµ¹JAGUAHR¡C¦ÓBukwang±N¤À¨â¦¸¦VJAGUAHR§ë¸êÁ`ÃB¦@5¦Ê¸U¬ü¤¸¨Ñ¬ÛÃö¸ê²£¬ãµo¡B½T»{¼ç¦bªº¶}µo¤Æ¦Xª«©M´£¥æ·sÃÄÁ{§É¸ÕÅç¡]IND¡^¥Ó½Ð¡C ¨È·à±d-KY°õ¦æªø³Å«i³Õ¤h¡]Dr Carl Firth¡^ªí¥Ü¡G¡uAhR«ú§Ü¾¯¤w³Qµø¬°¸~½F§K¬ÌÀøªkªº¼öªù·s»â°ì¡A¦]¦¹¦¨¥ßJAGUAHR¬O¨È·à±d-KY¹ê²{¦´Á¬ã¨s§Þ³N»P¸ê²£»ùÈ·¥¬°«nªº¤@¨B¡A¨Ã¦³§U©ó±À¶i¤F§Ú̦bAhR«ú§Ü¾¯§Þ³Nªºµo®i¡CBukwang¦b»sÃÄ·~°È¤è±¦¨ÁZ´´µM¡AÂù¤è¹ï©ó³o¦¸¦X§@¥i¥H§Ö³t±À®i¬ÛÃö¤Æ¦Xª«ªº¬ã¨s·P¨ì«D±`®¶¾Ä¡A¬Æ¦Ü¥i¯à´£¨Ñ·s«¬Á{§É¬ã¨s¸ê²£¡AÂ×´I¨È·à±d-KYªºÃÄ«~¶}µopµe¡C§ÚÌ´Á¬ß»PBukwang¹Î¶¤¦X§@¡A¨Ã»EµJ§ä¥XJAGUAHRªº²Ä¤@´ÚÔ¿ïÃĪ«¡C¡v Bukwang°õ¦æªø柳憙´D³Õ¤h¡]Dr Hee-Won Yoo¡^«ü¥X¡G¡u§ÚÌ«Ü°ª¿³¯à©M¨È·à±d-KY¦X§@¦¨¥ßJANUAHR¡CBukwang¾Ö¦³±j¤jªº¬ãµo¸gÅç»P¸ê²£¡A³o¦¸¨óij¤]²Å¦X§Ṳ́@³eªºµ¦²¤: ±j¤Æ³Ð·sÃÄ«~¶}µopµe¨ÃÂX¤j´£«e¨ú±o¨ã¼ç¤Oªº·s§Þ³N¡A¨Óº¡¨¬¥Ø«e¤´µLªk¸Ñ¨MªºÂåÀø»Ý¨D¡CAhR«ú§Ü¾¯pµeÃÒ©úBukwang¤w¸g¶}©l¥¿¦¡¸ó¨¬§K¬Ì¸~½FÀøªk»â°ì¡A§ÚÌÂù¤è¹ï¦¹±H¤©«p±æ¡A¤]«D±`´Á«Ý¯à»P¨È·à±d-KY¦@¦P¦X§@±N·s«¬ªº¸~½F§K¬Ì¤Æ¦Xª«±À¶i¦Ü¸~½F¾ÇÁ{§É¶}µo¶¥¬q¡C¡v AhR¬O¤@ºØÂà¿ý¦]¤l¡A¦P®É¬°§K¬Ì¨t²Îªº¥D±±¦]¤l¤§¤@¡CIDO1¡BIDO2©MTDO³o¤TºØ»Ã¯À¡A¦b«Ü¦hÃþ«¬ªº¸~½F¤¤±`¥X²{¹L«×ªí¹Fªºª¬ªp¡A¨Ã±N¸~½F·LÀô¹Ò¤¤ªº¦âÓi»ÄÂà´«¬°¤ü§¿Ói»Ä¡]kynurenine¡^¡C±µµÛ¤ü§¿Ói»Ä·|³Q¥D°Ê¿é°e¨ì¥i°»´ú¨Ã±þ¦º¸~½F²ÓMªº¾ð¬ðª¬²ÓM©M§@¥Î©ÊT²ÓM¡C¤ü§¿Ói»Ä³z¹L³o¨Ç²ÓM¸Ì ªº AhRµo¥X°T¸¹¡A±N¥¦ÌÂà´«¬°½Õ¸`T²ÓM¡A§í¨î§K¬Ì¨t²Î¨Ãªýꥦ§ðÀ»¸~½F²ÓM¡C¬ã¨sÅã¥Ü¡AAhR«ú§Ü¾¯ªº¿W¯SÀu¶Õ¡A¥]¬A¥i¥H¼sªx§í¨î¥Ñ¥ô¦ó¥i¥NÁ¦âÓi»Ä¤§»Ã¯À©Ò²£¥ÍªºAhR°tÅé1¡AÁÙ¥i±j¯P¬¡¤Æ§K¬Ì¤ÏÀ³¡A¥Î¨Ó±þ¦ºÀù¯g²ÓM¡A¤w³Qµø¬°¸~½F§K¬ÌÀøªkªº¼öªù·s»â°ì¡C ¥»¤åµ²§ô ´CÅé»PIRÁpµ¸¤H ¨È·à±d-KY Emma Thompson Spurwing Communications Tel: +65 6571 2021 Email: ASLAN@spurwingcomms.com Robert Uhl Westwicke Partners Tel: +1 858 356 5932 Email: robert.uhl@westwicke.com ¤ýµq¼w Peter ¸g´ï¤½Ãö Tel: +886 2 2766 1500 Email: peter@clavis.com.tw Bukwang Pharmaceutical Co., Ltd. Riswanto Global Business Development Tel: +82-2-828-8072 Email: riswanto@bukwang.co.kr Ãö©ó¨È·à±d-KY ¨È·à±d-KY(6497)¬°±Mª`©óÁ{§É¶¥¬q¸~½F©M§K¬Ì¾ÇÃĪ«¡A¨Ã¶}µo¨ã¦³¥þ²y¥«³õ¤§·s¿oÀøªkªº¥Íª«»sÃĤ½¥q¡C¨È·à±d-KYÂê©w¦b¨È¬w²±¦æ¥B¦b¼Ú¬ü¬°©t¨à¯e¯f¤§Àù¯g¥ÎÃÄ¡C¨È·à±d-KY¥Ñ¸gÅçÂ×´IªººÞ²z¹Î¶¤¤Î¥þ²y»sÃıM®a±a»â¡AÁ`³¡³]©ó·s¥[©Y¡A¦b¥xÆW¤Î¤¤°ê³]¦³¾ÚÂI¡C¨È·à±d-KY¾Ö¦³¤T¶µÂê©w¦³®Ä¥Íªø¸ô®|¤§Ô¿ïÃĪ«¡A¥Ø¼Ð¬OÀ³¥Î©ó·s±wªÌ¸sÅé¡B·s«¬§K¬ÌÀˬdÂI¤Î·s«¬Àù¯g¥NÁ¸ô®|¡C¨È·à±dªº¦X§@¹Ù¦ñ¥]¬AArray BioPharma¡BBristol-Myers Squibb(BMS)¡BAlmirall¤ÎCSL¡C±ýÀò±o§ó¦h¸ê°T¡A½Ð°Ñ¦Òwww.aslanpharma.com Ãö©óBukwang Pharmaceutical Co., Ltd. Bukwang Pharmaceutical Company Ltd.¦¨¥ß©ó1960¦~10¤ë17¤é¡A55¦~¨ÓP¤O©ó¥Í²£¥H§ïµ½¥þ²y°·±d¬°¥Ø¼ÐªºÀu¨}ÃÄ«~¡C¦Û1988¦~BukwangªÑ²¼©óÁú°êÃÒ¨é¥æ©ö©Ò¤W¥«(KRX:003000)¥H¨Ó¡ABukwang¤@ª½«O«ù¨}¦n°]°Èª¬ªp©M𷪺·~ÁZªí²{¡A²`Àòû¤u©MªÑªFÌ«H¥ô¡CBukwang¾Ö¦³ªº·~°È²[»\¦UºØ¾AÀ³¯g¡A¥]¬A¨xŦ¡B·s³¯¥NÁ¡B©I§l¹D¡B¤¤¼Ï¯«¸g¨t²Î¯e¯f©M¸~½F¬ÛÃö¯e¯f¡ABukwangªº¥»·~¸gÀçªí²{¡A»P¨ä°í±jªº°]°È¹ê¤O¡A¨Ï¨ä¯à«ùÄò±À°Ê·sÃĬãµo¡Cwww.bukwangpharm.com/ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/30 ¤U¤È 02:48:28²Ä 1362 ½g¦^À³
|
¹Î¶¤¦X§@¡A¨Ã»EµJ§ä¥XJAGUAHRªº²Ä¤@´ÚÔ¿ïÃĪ«¡C¡v Bukwang°õ¦æªø柳憙´D³Õ¤h¡]Dr Hee-Won Yoo¡^«ü¥X¡G¡u§ÚÌ«Ü°ª¿³¯à©M¨È·à±d-KY¦X§@¦¨¥ßJANUAHR¡CBukwang¾Ö¦³±j¤jªº¬ãµo¸gÅç»P¸ê²£¡A³o¦¸¨óij¤]²Å¦X§Ṳ́@³eªºµ¦²¤: ±j¤Æ³Ð·sÃÄ«~¶}µopµe¨ÃÂX¤j´£«e¨ú±o¨ã¼ç¤Oªº·s§Þ³N¡A¨Óº¡¨¬¥Ø«e¤´µLªk¸Ñ¨MªºÂåÀø»Ý¨D¡CAhR«ú§Ü¾¯pµeÃÒ©úBukwang¤w¸g¶}©l¥¿¦¡¸ó¨¬§K¬Ì¸~½FÀøªk»â°ì¡A§ÚÌÂù¤è¹ï¦¹±H¤©«p±æ¡A¤]«D±`´Á«Ý¯à»P¨È·à±d-KY¦@¦P¦X§@±N·s«¬ªº¸~½F§K¬Ì¤Æ¦Xª«±À¶i¦Ü¸~½F¾ÇÁ{§É¶}µo¶¥¬q¡C¡v AhR¬O¤@ºØÂà¿ý¦]¤l¡A¦P®É¬°§K¬Ì¨t²Îªº¥D±±¦]¤l¤§¤@¡CIDO1¡BIDO2©MTDO³o¤TºØ»Ã¯À¡A¦b«Ü¦hÃþ«¬ªº¸~½F¤¤±`¥X²{¹L«×ªí¹Fªºª¬ªp¡A¨Ã±N¸~½F·LÀô¹Ò¤¤ªº¦âÓi»ÄÂà´«¬°¤ü§¿Ói»Ä¡]kynurenine¡^¡C±µµÛ¤ü§¿Ói»Ä·|³Q¥D°Ê¿é°e¨ì¥i°»´ú¨Ã±þ¦º¸~½F²ÓMªº¾ð¬ðª¬²ÓM©M§@¥Î©ÊT²ÓM¡C¤ü§¿Ói»Ä³z¹L³o¨Ç²ÓM¸Ì ªº AhRµo¥X°T¸¹¡A±N¥¦ÌÂà´«¬°½Õ¸`T²ÓM¡A§í¨î§K¬Ì¨t²Î¨Ãªýꥦ§ðÀ»¸~½F²ÓM¡C¬ã¨sÅã¥Ü¡AAhR«ú§Ü¾¯ªº¿W¯SÀu¶Õ¡A¥]¬A¥i¥H¼sªx§í¨î¥Ñ¥ô¦ó¥i¥NÁ¦âÓi»Ä¤§»Ã¯À©Ò²£¥ÍªºAhR°tÅé1¡AÁÙ¥i±j¯P¬¡¤Æ§K¬Ì¤ÏÀ³¡A¥Î¨Ó±þ¦ºÀù¯g²ÓM¡A¤w³Qµø¬°¸~½F§K¬ÌÀøªkªº¼öªù·s»â°ì¡C ¥»¤åµ²§ô ´CÅé»PIRÁpµ¸¤H ¨È·à±d-KY Emma Thompson Spurwing Communications Tel: +65 6571 2021 Email: ASLAN@spurwingcomms.com Robert Uhl Westwicke Partners Tel: +1 858 356 5932 Email: robert.uhl@westwicke.com ¤ýµq¼w Peter ¸g´ï¤½Ãö Tel: +886 2 2766 1500 Email: peter@clavis.com.tw Bukwang Pharmaceutical Co., Ltd. Riswanto Global Business Development Tel: +82-2-828-8072 Email: riswanto@bukwang.co.kr Ãö©ó¨È·à±d-KY ¨È·à±d-KY(6497)¬°±Mª`©óÁ{§É¶¥¬q¸~½F©M§K¬Ì¾ÇÃĪ«¡A¨Ã¶}µo¨ã¦³¥þ²y¥«³õ¤§·s¿oÀøªkªº¥Íª«»sÃĤ½¥q¡C¨È·à±d-KYÂê©w¦b¨È¬w²±¦æ¥B¦b¼Ú¬ü¬°©t¨à¯e¯f¤§Àù¯g¥ÎÃÄ¡C¨È·à±d-KY¥Ñ¸gÅçÂ×´IªººÞ²z¹Î¶¤¤Î¥þ²y»sÃıM®a±a»â¡AÁ`³¡³]©ó·s¥[©Y¡A¦b¥xÆW¤Î¤¤°ê³]¦³¾ÚÂI¡C¨È·à±d-KY¾Ö¦³¤T¶µÂê©w¦³®Ä¥Íªø¸ô®|¤§Ô¿ïÃĪ«¡A¥Ø¼Ð¬OÀ³¥Î©ó·s±wªÌ¸sÅé¡B·s«¬§K¬ÌÀˬdÂI¤Î·s«¬Àù¯g¥NÁ¸ô®|¡C¨È·à±dªº¦X§@¹Ù¦ñ¥]¬AArray BioPharma¡BBristol-Myers Squibb(BMS)¡BAlmirall¤ÎCSL¡C±ýÀò±o§ó¦h¸ê°T¡A½Ð°Ñ¦Òwww.aslanpharma.com Ãö©óBukwang Pharmaceutical Co., Ltd. Bukwang Pharmaceutical Company Ltd.¦¨¥ß©ó1960¦~10¤ë17¤é¡A55¦~¨ÓP¤O©ó¥Í²£¥H§ïµ½¥þ²y°·±d¬°¥Ø¼ÐªºÀu¨}ÃÄ«~¡C¦Û1988¦~BukwangªÑ²¼©óÁú°êÃÒ¨é¥æ©ö©Ò¤W¥«(KRX:003000)¥H¨Ó¡ABukwang¤@ª½«O«ù¨}¦n°]°Èª¬ªp©M𷪺·~ÁZªí²{¡A²`Àòû¤u©MªÑªFÌ«H¥ô¡CBukwang¾Ö¦³ªº·~°È²[»\¦UºØ¾AÀ³¯g¡A¥]¬A¨xŦ¡B·s³¯¥NÁ¡B©I§l¹D¡B¤¤¼Ï¯«¸g¨t²Î¯e¯f©M¸~½F¬ÛÃö¯e¯f¡ABukwangªº¥»·~¸gÀçªí²{¡A»P¨ä°í±jªº°]°È¹ê¤O¡A¨Ï¨ä¯à«ùÄò±À°Ê·sÃĬãµo¡Cwww.bukwangpharm.com/ |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/9/30 ¤W¤È 10:38:24²Ä 1361 ½g¦^À³
|
¾Ú¤½¥q¤º³¡Âàz¡A«¸µo¨¥¤H¬OÂ÷¾±N¥ÑPeter Wang±µ¥ôµo¨¥¤H¤ÎIR¡A¦ÓÁÂÂå®v¬OÂàÅU°Ý¡A¥Ø«eÁÙ¥¼¦³±µ¥ôÂå¾Çªø¤H¿ï¡C |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2019/9/29 ¤U¤È 09:51:16²Ä 1360 ½g¦^À³
|
¨È·à±dªº©xºô¤w¸g¤£¨£ÁÂÂå¾Çªø©M«¸µo¨¥¤H ¬OÂ÷¾¤F¶Ü? |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/29 ¤W¤È 08:17:48²Ä 1359 ½g¦^À³
|
www.slideshare.net/mobile/jtcancercenter/grothey-gi-malignancies-11111 p.78 ToGA Efficacy : OS by HER2 status (¹ï·Ó²Õ VS.¶PÀù¥ ¡X-©ó¤@½uGÀùÁ{§ÉMOSªº·ÀI¤ñ) ¨ä¤¤ N¦Xp584 (1)IHC¡Ï3/FISH+ , 12.3¤ëVS17.9¤ë , ·ÀI¤ñ0.58 ³Ì¨Î ,N=256( 256/584=43.8%) (2)IHC+ 2/FISH+ , 10.8¤ë VS12.3¤ë,·ÀI¤ñ0.75 ¦¸¤§,N=159 (3)IHC+ 1/FISH+, 10.2¤ë VS 8.7 ¤ë, ·ÀI¤ñ1.24 ³Ì®t,N=70 (4)IHC+ 0/FISH+, 7.2¤ë VS 10.6 ¤ë, ·ÀI¤ñ0.92 ³Ì®t,N=69 (5)IHC+ 3/FISH-, 17.7¤ë VS 17.5 ¤ë, ·ÀI¤ñ0.83 ³Ì®t,N=15 (6)IHC+2&3 , /FISH+ ,11.8¤ë VS. 16.0¤ë ,·ÀI¤ñ0.65 ORR=34.5%VS 47.5% ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¶PÀù¥²ÕORR =47.5% , (P.80) (IHC+3 ¦ûÁ`¤H¼Æ256/584=43.8 %) ORR 47.5% ±µªñ©óIHC+3/FISH+ ªº¤ñ²v43.8% ¥Dn«ü¼ÐOS ¤§KM¹Ï¦p P.76 ¥Dn«ü¼ÐOS(IHC+2&¡Ï3)¤§KM¹Ï¦p,P.79 ¡X¡X¡X¡X¡X¡X¡X¡X- ASLAN001 ,©M¶PÀù¥¹ï©óHER2¡Ï¦P¤@¾÷Âà¡A. ASLAN001 VS ¹ï·Ó²Õ IHC+3/FISH+ , ( HER1/HER2/HER3/HER4 ) À³¦³¹w«áÀu©ó§CIHC+2/IHC+1/IHC+0¤§®t§O. §Ü·½ªí±ªí²{«×IHC+·U°ª¹w«áOS/PFS/ORR ·U¨Î¡C |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2019/9/27 ¤U¤È 03:15:50²Ä 1358 ½g¦^À³
|
¦Ñ¥~¦A¶i50±i ¥[ªo |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/9/27 ¤U¤È 02:37:57²Ä 1357 ½g¦^À³
|
¥Dn³Ìªñ¤TÓ¥Dn²£«~³£¨SÔ£¶i«×§ó·s¡A¥[¤WADR¨S¦³Ä~Äò©¹¤W§ðÀ»¡A©Ò¥HªÑ»ù´N¦b³oÃäì¦a¥´Âà¤F¡A¤£ª¾Ô£®É¤~·|¦³¼W¸êªº®ø®§¶Ç¥X©O? ADR¼W¸ê¤U§«ôÀ³¸Ó¥i¥H¦A°e¤F¡A¤£¹L§Ú·Q¤j®a¤ñ¸ûÃö¤ßªºÀ³¸Ó¬O±ÂÅv§a¡A§Æ±æ¥i¥H»°§Ö¦³¦n®ø®§¶Ç¥X¤F! |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2019/9/27 ¤U¤È 01:48:52²Ä 1356 ½g¦^À³
|
¤µ¤Ñ´N·í²Ä¤G°¦¸}¤F¦n¶Ü¡H °ò¥»°¾¥¿¦V ¤j¤áÄw½X¬Û¹ïªºÃ©w ·dªºªÑ²¼¨S¦³¤Hn£¸¼Ë ¥[ªo¤F¦Ñ·à ·à¤Í¥[ªo Ó¤HÆ[ÂI |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/26 ¤W¤È 09:05:06²Ä 1355 ½g¦^À³
|
¼ÒÀÀ¤G. ¥¼¨Ó¿zÀËHER®a±Ú, IHC +2/+3 ***¥h°£IHC+1,¹w«á®ÄªG¦ôOS¦b<=5.8¤ë***** °²³]IHC+1 ,¦û30%HER®a±Ú, «hHER®a±Ú, IHC +2/+3 ¦ûÁx¹DÀù¤ñ²v=70%*70%(1-30%)=¥H50%pºâ. ¥H¤¤°ê61¦ìÁ{§É¨äOS--/¦ô²Ä25%OS±N¥i¯à¼W¥[¨ì16~19Ӥ몺¾÷·|¬Û·í¤j. OS 12¤ë36%(¤¤°ê61¦ìÁ{§É¸ê®Æ) OS 6¤ë45% (12-6) ¤ë/(45%-36%)=0.67¤ë/1% 12(36%OS )¤ë+0.67*11=19¤ë(²Ä25%OS) ¥H¤W¥i©MINCYTE ªºFGFR2 MOS15.8¤ë Ävª§ ----------------------------------------- ·sÃĦb¤G½uÁx¹DÀùMOS 15.8-6.8=9 ,¼W¥[9Ӥ몺¦s¬¡ ¥Ø«e°ê»Ú·sÃĨC¼W¤@¤ë¦s¬¡,¥iÈ10,000¬ü¤¸. 9*10,000=90,000 ¬ü¤¸ªºq»ù. MPFS=9.2¤ë, ¨C¤ëÃÄ»ù¬ù 10,000 ¬ü¤¸ ---------------------------------------- HER®a±Ú70% -¦©20%IHC+1-¦©°£FGFR2 10%= 40%ªºÁx¹DÀù¥«³õ ¥«³õ»ùȬù¬ù9~14»õ¬ü¤¸¥«³õ , ¬OFGFR2 10% ,(1.8»õ¬ü¤¸~2.4»õ)*130% ¬ü¤¸ªº¥«³õªº4~5¿¥H¤W. .[2000¤H~3000¤H(¬ü¡B¼Ú¡B¤é)*4}*130%(¤¤°ê/Áú°ê/¨ä¥L¨È¬w)]*90,000¬ü¤¸= ¬ù9~14»õ¬ü¤¸¥«³õ ---------------------------------- ¥H¤Wµ¥«ÝASLAN001 ¥þ²y127¤HÁ{§É¸ê®Æ¨ÓÅçµý |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/21 ¤W¤È 09:45:37²Ä 1354 ½g¦^À³
|
1. ¼Ð¹v·sÃĦb¤G½uÁx¹DÀùMOS 12¤ë-6.8¤ë(¤ÆÀøÃÄMOS)=5.2 ,¼W¥[5.2Ӥ몺¦s¬¡ ¥Ø«e°ê»Ú·sÃĨC¼W¤@¤ë¦s¬¡,¥iÈ10,000¬ü¤¸. 5.2*10,000=52,000 ¬ü¤¸ªºq»ù. 2. ¼Ð¹v·sÃÄ:MPFS 5.59¤ë, q»ù52,000/5.59=8813¬ü¤¸/¤ë 3.[2000¤H~3000¤H(¬ü¡B¼Ú¡B¤é)*6}*130%(¤¤°ê/Áú°ê/¨ä¥L¨È¬w)]*52,000¬ü¤¸= ¬ù8~12»õ¬ü¤¸¥«³õ ***§Ü·½¦ûÁx¹DÀù¤ñ²v :FGFR2 10%, HER®a±Ú70% HER®a±Ú70% ¦©°£FGFR2 10% ¥«³õ»ùȬù¬ù8~12»õ¬ü¤¸¥«³õ , ¬OFGFR2 10% ,(1.8»õ¬ü¤¸~2.4»õ)*130% ¬ü¤¸ªº¥«³õªº4¿¥H¤W. 4.±q Arqule ¤G½uÁx¹DÀù±ÂÅv(1b Á{§É§¹¦¨«á)¨óij, ¨È·à±d ASLAN 001 (2´ÁÁ{§É§¹¦¨«á)ªº»ùÈ»P¼ç¤O =(«eª÷1000¸U¬ü¤¸ ¨½µ{ª÷ 3.26»õ¬ü¤¸)*4¿¥H¤W. -------------------- ±q Arqule ¤G½uÁx¹DÀù±ÂÅv¨óij§Ú¬Ý¨ì¨È·à±d ASLAN 001 ªº»ùÈ»P¼ç¤O 1 ³oÁûÃľA¥Î¨x¤ºÁxºÞÀù FGFR ¬ðÅÜ ( 40% -50% X 10% -20% = 4% -10% ) ¦û Áx¹DÀù10% ¥H¤U 2 «eª÷1000¸U¬ü¤¸ ¨½µ{ª÷ 3.26»õ¬ü¤¸ «eª÷/ ¨½µ{ª÷ 1/32.6 ¦³ÂI°¾§C ªí¥Ü ±ÂÅv¶i¨Óªº¤½¥q±Ä¨ú¤ñ¸û«O¦u ºA«× , «eª÷/ ¨½µ{ª÷ ¤ñ²v¶V°ªªí¥Ü±ÂÅv¶i¨Óªº¤½¥q¹ï³oÁûÃÄ¥¼¨Óµo®i«H¤ß«×¶V°ª -------------------------------------------------------------- -------------------------------- ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/19 ¤U¤È 11:12:18²Ä 1349 ½g¦^À³ ªí¥ÜY¥¼¨ÓASLAN001 ¤G½uÁx¹DÀù¥þ²y¤T´ÁÁ{§É ¿z¿ï 70%¦³HER®a±ÚªÌ, ¨äMOS¥i¯à±µªñ12Ó¤ë( ¤ñ²{¦³¥ô¦ó¤ÆÀøMOS 5.5~6.0¤ë,¦h100%.) MPFS ¦ôp¥i¹F 12/(5.8/2.7)=5.59 Ó¤ë( ¤ñ²{¦³¥ô¦ó¤ÆÀøMPFS 2.7~3¤ë,¦h100%) ORR ¦ôp¥i¹F 11%/70%=15.7%( ¤ñ²{¦³¥ô¦ó¤ÆÀøMPFS 0~8%¤ë,¦h100%) (µ¥ASLAN001 ¤G½uÁx¹DÀù¥þ²y127¤HÁ{§É---ÂX¥R©Ê¬ã¨s¯àµý©ú) ----------------------- ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/6/12 ¤U¤È 04:38:19²Ä 1043 ½g¦^À³ ¦ô ·sÃĦbFGFR2 °ò¦]¤U, ¤G½uÁx¹DÀù ¬ü¡B¼Ú¡B¤é¥«³õ ,2000¤H~3000¤H,¬ù1.8»õ¬ü¤¸~2.4»õ¬ü¤¸ªº¥«³õ. --------- ·sÃĦb¤G½uÁx¹DÀùMOS 15.8-6.8=9 ,¼W¥[9Ӥ몺¦s¬¡ ¥Ø«e°ê»Ú·sÃĨC¼W¤@¤ë¦s¬¡,¥iÈ10,000¬ü¤¸. 9*10,000=90,000 ¬ü¤¸ªºq»ù. MPFS=9.2¤ë, ¨C¤ëÃÄ»ù¬ù 10,000 ¬ü¤¸ 90,000*2000¤H~3000¤H(¬ü¡B¼Ú¡B¤é) 1.8»õ¬ü¤¸~2.4»õ¬ü¤¸ªº¥«³õ The incidence of cholangiocarcinoma with FGFR2 rearrangements is increasing and is currently estimated at 2,000-3,000 patients in the U.S., Europe and Japan. finance.yahoo.com/news/incyte-announces-first-patient-treated-113000907.html |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/20 ¤U¤È 06:55:14²Ä 1353 ½g¦^À³
|
1. aslanpharma.com/¡K/uploads/2019/09/CSCO-2019_ASLAN001-008.pdf JADETREE*: A phase 2A, single arm, multicenter, study of the panHER inhibitor varlitinib plus capecitabine in Chinese patients with advanced or metastatic biliary tract cancer (BTC). Result: As of 16-Jun-19, 61 pts were treated, 2.aslanpharma.com/¡K/ASLAN001-008_CSCO-poster-version-_¡K The enrollment started in December, 2017. As of 3rd September 2018, 46 patient has been screened and 33 patients were enrolled while 3 patients are in screening. Aslan001 ¤¤°ê61¦ìÁ{§É 2017¦~12¤ë¤¤¦¯¶}©l²Ä¤@¦ìªvÀø¡A 2018¦~9¤ë3¤é¡AªvÀø¦@33¦ì¡A ¦¬®×§¹¦¨¥i¯à¦b2018¦~©³?? 2019¦~6¤ë16¤é(cut data date)ªvÀø61¦ì¡C ²Ä34~61¦ì¡]28¦ì) ªvÀø¸g¾ú<9.5(??~9.5)Ó¤ë¡A OS¦@¦³31Өƥ󬰰ò¦¡A©|¦³30¦ì¬¡µÛ¡C(¦s¬¡²v30/61=49%) ¡]¥H¤U¼Æ¾Ú¨ì¦~©³ÁÙ·|ÅܤÆ)- ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- os>12Ó¤ë36%. os> 6Ó¤ë45% PFS ORR(¦³¨Ç±wªÌ©|¦b½w¸Ñ¤¤) |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/9/20 ¤W¤È 09:40:09²Ä 1352 ½g¦^À³
|
Y¬O¤¤°ê¦¬®×¯f±w¬O¸û¬°ÄY«ªº,¨º¦¹¦¸¥þ²y¤G½uÁx¹DÀù¸Ñª¼®Éµ{n¨ì10¤ë¤U¦¯©Î11¤ë´N¦³¸ñ¥i´`,¦¹«e¤«ü¤Þ§Æ±æ¥i¥H¤Þ¥X¸Ñª¼¦¨¥\ªº¦n®ø®§,¤×¨ä¬OORRªº¹LÃö¾÷²v«Ü°ª,PFS´Nn¦h¬Ý¤@¨Ç¾÷¹B¤F(¦]¤¤°ê¦¬®×mPFS¶È2.7Ó¤ë,Y¬O¦h¦¬¨ìHER®a±Ú°ò¦]Åܲ§ªº¯f±w,¦¨¥\¾÷·|´N¯à¦A¼W°ª).... ¥H¤W¨Ñ°Ñ¦Ò,¤Å·í¶i¥XªÑ²¼¨Ì¾Ú.... |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2019/9/20 ¤W¤È 08:49:33²Ä 1351 ½g¦^À³
|
2019-09-20 08:00:18 °OªÌ ·s»D¤¤¤ß ³ø¾É ......¨È·à±dªí¥Ü¡A±´°Qvarlitinib¹ï¤G½uÁx¹DÀùÀø®Ä¤§¥þ²y©Ê¼Ï¯Ã¸ÕÅçTreeTopp(TREatmEnT OPPortunity)¡A¤w©ó2018¦~12¤ë´£«e§¹¦¨¨ü¸ÕªÌ¦¬®×¡Aªì¨BÁ{§É¼Æ¾Ú¹wp±N©ó2019¦~¤U¥b¦~¥XÄl¡C¦]TreeTopp¼Æ¾Ú±N¤ñ¤¤°êÁ{§É¹êÅ礽¥¬±o¦¡A¨È·à±d¤w©ó¤@¤ë®É«Å¥¬¡A¦¹¤¤°ê³æÁuÁ{§É¹êÅç±N´£¦µ²®×¡CYTreeToppµ²ªG¬°¥¿±¡A¨È·à±dÀÀ±NTreeTopp¬ã¨s¼Æ¾Ú¤Î¤¤°êÁ{§É¬ã¨s¼Æ¾Ú¥Î©ó¤¤°ê¡B¬ü°ê©M¨ä¥L¥Dn°Ï°ì¶i¦æ·sÃÄÃÄÃҥӽС]NDA¡^¡C ------------------------------------------------------------------------------------------- ¤W¬q¸`¿ý¬O«ü®³Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer (TreeTopp) clinicaltrials.gov/ct2/show/NCT0309387ªº¤G´ÁÁ{§É¼Æ¾Ú»P¤¤°êÁ{§É¬ã¨s¼Æ¾Ú¶i¦æ·sÃÄÃÄÃÒ¥Ó½Ð???(¦W²Å¨ä¹ê¬ð¯}©ÊªvÀø´£«e¥Ó½Ð¤W¥«!) |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/9/20 ¤W¤È 12:47:01²Ä 1350 ½g¦^À³
|
4 ³o¦¸¦¬®× ªº½T¬O±¡ªp¸ûÄY«ªº¯f±w ECOG PS 2/3 23¤H ¦û 37.7¢H ECOG PS 0/1 38¤H¦û62.3¢H (¥þ²y²y¼Ï¯Ã¥þ³¡¦¬ ECOG PS 0/1 ªº¯f±w) 5 The ORR for evaluable patients with advanced BTC receiving VC was 10.8% and the DCR was 70.2%. This is higher than observed with mFOLFOX in the ABC-06 study (ORR = 5% and DCR = 33%.) (±µ¨üVC¤ñ±µ¨üABC-06¬ã¨s¤¤ªº mFOLFOX ¤ÆÀøÃÄ ¦b «ÈÆ[¤Ï¬M²v»P¯e¯f±±¨î²v°ª¡]BC-06¬ã¨sORR 5¢H¡ADCR = 33¢H) ¥H¤W¸É¥R ¶È¨Ñ°Ñ¦Ò ÀR«Ý¥þ²y¼Ï¯Ã¼Æ¾Úªº¤½§i |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/19 ¤U¤È 11:12:18²Ä 1349 ½g¦^À³
|
ªí¥ÜY¥¼¨ÓASLAN001 ¤G½uÁx¹DÀù¥þ²y¤T´ÁÁ{§É ¿z¿ï 70%¦³HER®a±ÚªÌ, ¨äMOS¥i¯à±µªñ12Ó¤ë( ¤ñ²{¦³¥ô¦ó¤ÆÀøMOS 5.5~6.0¤ë,¦h100%.) MPFS ¦ôp¥i¹F 12/(5.8/2.7)=5.59 Ó¤ë( ¤ñ²{¦³¥ô¦ó¤ÆÀøMPFS 2.7~3¤ë,¦h100%) ORR ¦ôp¥i¹F 11%/70%=15.7%( ¤ñ²{¦³¥ô¦ó¤ÆÀøMPFS 0~8%¤ë,¦h100%) (µ¥ASLAN001 ¤G½uÁx¹DÀù¥þ²y127¤HÁ{§É---ÂX¥R©Ê¬ã¨s¯àµý©ú) ---------------------------------------------------- ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/19 ¤U¤È 08:08:52²Ä 1346 ½g¦^À³ The ORR for evaluable patients with advanced BTC receiving VC was 10.8% and the DCR was 70.2%. ¥»¦¸ªºDCR 70.2% è¦nµ¥©ó¤½¥qªº¬ã¨sHER®a±Úªº¤ñ²v 70%. (YASLAN001 ¤G½uÁx¹DÀù¥þ²y127¤HÁ{§É---ÂX¥R©Ê¬ã¨s¯àµý©ú,±aHER®a±Ú§Ü·½ªÌªvÀø«á=CR+PR+SD.) ¥»¦¸OS12Ӥ릳35%, ªí¥ÜY¥¼¨ÓASLAN001 ¤G½uÁx¹DÀù¥þ²y¤T´ÁÁ{§É ¿z¿ï ¦³HER®a±ÚªÌ,¨äMOS¥i¯à±µªñ12Ó¤ë , ¤ñ²{¦³¥ô¦ó¤ÆÀøMOS 5.5~6.0¤ë,¦h100%. ¤T´ÁÁ{§É¥Dn«ü¼ÐOS,¹LÃö¾÷²v´N«D±`°ª. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/9/19 ¤U¤È 11:03:33²Ä 1348 ½g¦^À³
|
JADETREE : A phase 2A, single arm, multicenter, study of the panHER inhibitor varlitinib plus capecitabine in Chinese patients with advanced or metastatic biliary tract cancer (BTC) ¥H¤U( ) ÄÝ Ó¤H¤À¨É ¶È¨Ñ°Ñ¦Ò 1 ¥»¦¸¬ã¨s¹ï¶H¯f¯g´c¤Æµ{«×¸û°ª¡A¥[¤J¥»¬ã¨s«e¶È10%¹ï©ó¥Hgemcitabine¬°¥D¤§¤@½uªvÀø ¦³©Ò¤ÏÀ³ (¤ÏÀ³²v¤ñ§Ú¹w´Á°ª ³ºµM¦³2¤H¸~½F§¹¥þ®ø¥¢, Áx¹DÀù¤G½u¤@¯ë¤ÏÀ³²v«Ü§C 3 % ¥ª¥k ) 2 Varlitinib¦X¨ÖcapecitabineªºªvÀø¡A¥i¯à¬°¤G½uÁx¹DÀù¯f±w´£¨Ñ¥þ·sªºªvÀø¿ï¶µ 3 ¦@¦¬®×62¦ì¸g¾ú¹Lgemcitabine¤ÆÀø¤§¤¤°ê¯f±w¡A¥iµû¦ô±wªÌªº«ÈÆ[¤ÏÀ³²v¬°11%¡]¥]¬A2¦ì¯f±w§¹¥þ½w¸Ñ¡^¡AµL´c¤Æ ¦s¬¡´Áªº¤¤¦ì¼Æ¬°2.7Ó¤ë¡A¾ãÅé¦s¬¡´Á«h¬°5.8Ó¤ë¡C6Ó¤ë«á¦³45%¯f±w¦s¬¡¡A12Ó¤ë«á¬°35%¡C¾ãÅé¦s¬¡¼Æ¾Ú¥Ø«e¥H31Өƥ󬰰ò¦¡A¥B«ùÄò¦¨¼ô¤¤¡C³o¸sÃøªv«¬¯f±w¹ïvarlitinib¦X¨Öcapecitabineªº@¨ü©Ê¤Q¤À¨}¦n¡C ( ¦]ÄÝ2A ´Á ¾ãÅé¦s¬¡¼Æ¾Ú¥Ø«e¥H31Өƥ󬰰ò¦ ( ¦@¦¬®×62¦ì ) ¥B«ùÄò¦¨¼ô¤¤ , ORR PFS OS ÁÙ·|ÅܤÆ, ¤£ª¾¹D¬O§_»P¥þ²y¤T´Á ¤@¼Ë µo¥Í¨Æ¥ó 70 % ( ¬ù43¤H) |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/19 ¤U¤È 10:52:55²Ä 1347 ½g¦^À³
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/10 ¤U¤È 11:44:12²Ä 136 ½g¦^À³ ±q Arqule ¤G½uÁx¹DÀù±ÂÅv(¤¤°êÃļt)¨óij§Ú¬Ý¨ì¨È·à±d ASLAN 001 ªº»ùÈ»P¼ç¤O 1 ³oÁûÃľA¥Î¨x¤ºÁxºÞÀù FGFR ¬ðÅÜ ( 40% -50% X 10% -20% = 4% -10% ) ¦û Áx¹DÀù10% ¥H¤U 2 «eª÷1000¸U¬ü¤¸ ¨½µ{ª÷ 3.26»õ¬ü¤¸ «eª÷/ ¨½µ{ª÷ 1/32.6 ¦³ÂI°¾§C ªí¥Ü ±ÂÅv¶i¨Óªº¤½¥q±Ä¨ú¤ñ¸û«O¦u ºA«× , «eª÷/ ¨½µ{ª÷ ¤ñ²v¶V°ªªí¥Ü±ÂÅv¶i¨Óªº¤½¥q¹ï³oÁûÃÄ¥¼¨Óµo®i«H¤ß«×¶V°ª 3 ¨È·à±d ASLAN 001 ¾A¥ÎÁx¹DÀù¤H¤f¦û¤ñ70% 4 derazantinib 2021 ¦~¤~·|§¹¦¨Á{§É¸ÕÅç ASLAN 001 2018 ¦~©³§¹¦¨Á{§É¸ÕÅç 5 §Ú¬Ý¨ì¨È·à±dªº»ùÈ»P¼ç¤O 6 ADR»ù®æ¤W¤W¤U¤U¬O·n®Ìªº¼v¤l,±ÂÅv¥X¥h½æÓ¦n»ù¿ú,¯à©µÄò¥¼¨Ó¤Q¦~¬ãµo¸g¶O¤£¯Ê¤~¬O¥»½è 7 ¨È ·à±d¤£¦ý¬O²Ä¤@®a¦b¬ü°ê±¾µPªº¥xÆW¥Í§Þ¤½¥q, ¤]¦³«Ü¤j¼ç¤O¦A³Ð°ê¤º±ÂÅvª÷·s°ªªº¥xÆW¥Í§Þ¤½¥q seekingalpha.com/news/3346036-arqule-licenses-derazantinib-basilea-pharma-327m-shares-9-percent-premarket files.shareholder.com/downloads/ARQL/0x0x952609/7FD86678-3664-476F-A556-8B92F36E9C80/Derazantinib_ARQ_087_FGFR_Inhibitor_-_August_2017.pdf ¥H¤W¨Ñ°Ñ¦Ò,¤Å¥H¦¹¬°ªÑ²¼¶i¥X¨Ì¾Ú~~~ ·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/6/12 ¤U¤È 06:29:14²Ä 1045 ½g¦^À³ ¨CºØÀù¯g¤£¦P´Á§O»Ýn¤£¦PªºÃĪ«¥Hº¡¨¬¤£¦P¥ÎÃıø¥ó, Áx¹DÀù¬ü°ê¬ù12000¤H ¼Ú¬w13000¤H ¤é¥»20000¤H Á`¼Æ45000¤H ( 2017 12 ªk»¡Â²³ø17¶) ¤¤°ê170000¤H ³o¤TÓ¦a°Ï»P°ê®a ¦³ FGFR2°ò¦]¤U¤G½uÁx¹DÀù ¬ü¡B¼Ú¡B¤é¬ù2000¤H~3000¤H( ¨Ì¤Ñ©R¤j´£¨Ñ¸ê°T) 2000-3000/45000 ±À¦ô¦³FGFR2°ò¦]¤ñ²v¬ù4.4% -- 6.6% ( Ó¤H²Ê¦ô ¦³¥i¯à¤£«Ü¥¿½T) ¨S¦³FGFR2°ò¦]ªº¯f±w¦û¤j¦h¼Æ¥u¯à¨Ï¥Î¤ÆÀøÃÄ, ¨È·à±d¤G½uÁx¹DÀù ¨Ì¾Ú106¦~«×¦~³ø43¶´£¨ì: ÅX°ÊÁx¹DÀùªº¯S©w¶Ç»¼¸ô®|©|¥¼³QÃÒ¹ê, ¤£¹L¤é¥»»P¤¤°ê¼Æ¾ÚÅã¥Ü¬ù70%Áx¹DÀù¯f±w¸~½F¦³HER®a±Ú¹L«×ªí²{ªº±¡§Î(HER1 HER2 HER3 HER4 ) varlitinib ¬OªxHER§í¨î¾¯,¯à«ÊÂêÂ꦳ªºHER¨ü¾¹ ,Ãö³¬¦hºØ¸~½F¥Íªø¸ô®|, ¾A¥Î¤H¤f¼Æ»·¤j©óIncyte Pemigatinib ¤µ¤Ñ¤À¨Éªº¸ê°T ¶È¨Ñ°Ñ¦Ò ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/6/12 ¤W¤È 10:26:18²Ä 1041 ½g¦^À³ Cholangiocarcinoma is a cancer that arises from the cells within the bile ducts. It is often diagnosed late (stages III and IV) and the prognosis is poor. It is most common in those over 70 years old and is more common in men than women. FGFR2 fusion genes are drivers of the disease ¡V occurring almost exclusively in patients with intrahepatic cholangiocarcinoma (iCCA), a subset of the disease. The incidence of cholangiocarcinoma with FGFR2 rearrangements is increasing and is currently estimated at 2,000-3,000 patients in the U.S., Europe and Japan. finance.yahoo.com/news/incyte-announces-first-patient-treated-113000907.html |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/19 ¤U¤È 08:08:52²Ä 1346 ½g¦^À³
|
The ORR for evaluable patients with advanced BTC receiving VC was 10.8% and the DCR was 70.2%. ¥»¦¸ªºDCR 70.2% è¦nµ¥©ó¤½¥qªº¬ã¨sHER®a±Úªº¤ñ²v 70%. (YASLAN001 ¤G½uÁx¹DÀù¥þ²y127¤HÁ{§É---ÂX¥R©Ê¬ã¨s¯àµý©ú,±aHER®a±Ú§Ü·½ªÌªvÀø«á=CR+PR+SD.) ¥»¦¸OS12Ӥ릳35%, ªí¥ÜY¥¼¨ÓASLAN001 ¤G½uÁx¹DÀù¥þ²y¤T´ÁÁ{§É ¿z¿ï ¦³HER®a±ÚªÌ,¨äMOS¥i¯à±µªñ12Ó¤ë , ¤ñ²{¦³¥ô¦ó¤ÆÀøMOS 5.5~6.0¤ë,¦h100%. ¤T´ÁÁ{§É¥Dn«ü¼ÐOS,¹LÃö¾÷²v´N«D±`°ª. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/19 ¤U¤È 05:31:07²Ä 1345 ½g¦^À³
|
aslanpharma.com/app/uploads/2019/09/CSCO-2019_ASLAN001-008.pdf JADETREE*: A phase 2A, single arm, multicenter, study of the panHER inhibitor varlitinib plus capecitabine in Chinese patients with advanced or metastatic biliary tract cancer (BTC). Result: As of 16-Jun-19, 61 pts were treated, 31 (50.8%) intrahepatic, 19 (31.3%) gallbladder, 9 (14.8%) extrahepatic, and 2 (3.3%) ampulla of Vater. Gender M/F is 33(54.1%)/28 (45.9%); median (range) age was 56 (22-77); ECOG PS was 0/1 in 23 (37.7%)/38 (62.3%) pts. The ORR for evaluable patients with advanced BTC receiving VC was 10.8% and the DCR was 70.2%. This is higher than observed with mFOLFOX in the ABC-06 study (ORR = 5% and DCR = 33%.) VC in 2L led to a similar ORR versus JadeTree historical data for gem/cis in 1L (10.8% vs. 10.3%). Median PFS in JadeTree was 2.7 months and median OS was 5.8 months. 12-month OS for JadeTree was 36%, versus 26% for ABC-06. All causes Grade 3 or more events in 2 or more pts include blood bilirubin increase (19.7%), GGT increase (6.6%), Anemia (4.9%), and 2 pts (3.3%) each for abdominal pain, ascites, AST increase, conjugated bilirubin increase, disease progression, hyponatremia, Jaundice, malaise and UGI bleeding. Conclusion JadeTree provides the first ¡§real world¡¨ data in Chinese patients with 2nd Line BTC and shows that Varlitinib plus Capecitabine is efficacious and well tolerated compared to previously reported studies. *: JADETREE: Joint Assessment of Drug Efficacy of Pan-Her inhibition using Varlitinib in second line BTC in China Background: BTC is a rare and aggressive malignancy arising from the biliary epithelium, characterized by poor prognosis and poor response to current treatments. The 5-year overall survival rate is 5% to 10% for advanced BTC (ref). Human epidermal growth factor receptor (HER) family receptors are expressed at high levels in BTC and may be driving tumor proliferation and survival. In fact, overexpression of epidermal growth factor receptor (EGFR/HER1), HER2, HER3, and HER4 range from 23-57%, 4-13%, 12-23%, and 59-60% of BTCs, respectively. Varlitinib (VAR) is a well-tolerated, nanomolar small molecular tyrosine kinase inhibitor of EGFR, HER2, and HER4 with potent anti-tumor effect in preclinical BTC models. The recently published ABC-06 study from the UK in 2nd line (2L) Caucasian BTC patients showed promising efficacy using mFOLFOX regiment, however, the toxic profile from doublet chemotherapy may be highly selective for a fitter 2L western population and might not represent the real-world situation for patients with aggressive BTC in China. Here we present a phase 2A, single arm, multicenter, study using VAR plus capecitabine (VC) in unselected Chinese patients with 2L BTC. Method: Patients with advanced or metastatic BTC having failed on prior 1st line gemcitabine containing regimens were given VAR (300 mg twice daily in a 21-day cycle) plus capecitabine (1,000mg/m2 twice daily for 2 weeks followed by a 7-day rest period). Patients with no evidence of biliary duct obstruction (unless controlled by local treatment or endoscopic or percutaneous decompression), ECOG PS 0-1 and adequate organ function were eligible. The primary endpoint was to assess the objective response rate (ORR) as defined by RECIST v1.1 criteria. Secondary endpoints include duration of response, progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and the safety and tolerability of VC. Clinical trial information: NCT03231176. ************************************************** ABC-06 ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4003 ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. Background: Level A evidence supports use of CisGem as first-line chemotherapy for ABC; no robust evidence is available for second-line chemotherapy. Methods: Pts diagnosed with ABC with disease progression after prior CisGem were randomised (1:1) to either ASC+mFOLFOX or ASC. Randomisation was stratified by serum albumin levels ( < 35 vs ≥35 g/L), platinum sensitivity (determined from first-line CisGem) and disease extent (locally advanced vs metastatic). Pts with ECOG PS0-1, adequate haematological, renal and liver function, and adequate biliary drainage were eligible. Primary end-point was overall survival (OS) (multivariable Cox regression adjusted for stratification factors); sample size: 162 pts delivering 148 events were required (80% power; 5% two-sided alpha) for a hypothesised hazard ratio (HR) of 0.63. Assumed median survival for ASC was 4 months. Results: 162 pts (81 in each arm) were randomised (27 March ¡¥14 - 04 Jan ¡¥18); median age 65 yrs (range 26-84); sex: 80 (49%) male, 82 (51%) female; primary site: intrahepatic 72 (44%), extrahepatic 45 (28%), gallbladder 34 (21%) and ampullary 11 (7%). Baseline characteristics were balanced between arms except platinum sensitivity (ASC+mFOLFOX 27 pts (33%); ASC 34 pts (42%)). After 150 OS events, the adjusted HR was 0.69 (95% CI 0.50-0.97; p = 0.031; ASC+mFOLFOX vs ASC). Median OS (months (m)), 6m and 12m OS-rate (%) were 6.2m, 50.6% and 25.9% for the ASC+mFOLFOX and 5.3m, 35.5%, 11.4% for the ASC arm, respectively. Grade 3/4 toxicities were reported in 48 (59%) and 32 (39%) pts in the ASC+mFOLFOX and ASC arm, respectively; these were balanced between arms except for fatigue and neutropenia (more frequent in ASC+mFOLFOX arm); data cleaning is ongoing. No chemotherapy-related deaths were reported. Conclusion: Survival with ASC was greater than assumed; ASC+mFOLFOX improved OS after progression to CisGem with a clinically meaningful increase in 6m and 12m OS rate. ASC+mFOLFOX should become standard of care in second-line for ABC. Clinical trial information: NCT01926236. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/19 ¤U¤È 03:45:29²Ä 1344 ½g¦^À³
|
¶¡:2019/7/31 ¤U¤È 02:03:40²Ä 1147 ½g¦^À³ ¥xÁÞ¤j ¼ÒÀÀ5²Õ ORR¹LÃö,P<5%¤§ª¬ªp , (1)°²³] ORR , ¹ï·Ó²Õ 4¤H(4/63=6.3%)¡A¹êÅç²Õ14¤H (14/64=21.9%) (2)°²³] ORR , ¹ï·Ó²Õ 3¤H(3/63=4.8%)¡A¹êÅç²Õ12¤H (12/64=18.8%) (3)°²³] ORR , ¹ï·Ó²Õ 2¤H(2/63=3.2%)¡A¹êÅç²Õ10¤H (10/64=15.6%) (4)°²³] ORR , ¹ï·Ó²Õ 1¤H(1/63=1.6%)¡A¹êÅç²Õ8¤H (8/64=12.5%) (5)°²³] ORR , ¹ï·Ó²Õ 0¤H(0/63=0%)¡A¹êÅç²Õ6¤H (6/64=9.4%) ¦]¹ï·Ó²Õ³æ¤ÆÀø ORR <=1.6%ªº¾÷²v«D±`°ª.(¬Ý¹L¼ÆӨƫá¤ÀªRӮסA¦bµL§Ü·½¿zÀˤU,ORR ¬Û¹ï§C) ORR ,¥þ³¡(127¤H)Y¦³9¤H ,¸Ñª¼¦¨¥\²v¬Û·í°ª. µù: )¹ï·Ó²Õ<5¤H¡A¥H¥d¤è¤À°t¥|¤è®æ¤§®Õ¥¿¤½¦¡pºâ. ***************************************************** ¤µ¤Ñ¤½§G ASLAN001¤¤°ê¤G½uÁx¹DÀù Á{§É¸ê®Æ, ORR=11% 7/62 (CR 2/62+PR 5/62) ----------------------------- ASLAN001¥þ²y¤G½uÁx¹DÀù Á{§É ----Y¦P¤¤°ê7¤H/64=10.9%, ¦Ñ¤Ñ«O¦ö ¹ï·Ó²Õ¬°0¤H. ©Î ¹êÅç²Õ¦A¼W1¤H , P<0.05 ¾÷·|¤j.. ------------------------------------ |
|
|
·|û¡GÀ³µL©Ò¦í10144738 µoªí®É¶¡:2019/9/19 ¤U¤È 03:17:55²Ä 1343 ½g¦^À³
|
1.¨Æ¹êµo¥Í¤é:108/09/19 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: 2019¦~©ó¤¤°ê·HªùÁ|¦æ¤§¤¤°êÁ{§É¸~½F¾Ç·|¦~·|¤W¡A¥Ñ®ý¦¿¤j¾Ç¸~½F¤º¬ì°Æ¥D¥ôÂå®v ¤èºû¨Î³Õ¤h¶i¦æ¤fÀY³ø§i¥»¤½¥qvarlinitib©ó¤G½uÁx¹DÀù¤§¬ÛÃö¦¨ªG¡C - Áx¹DÀù¡]BTC¡^¯f±w±µ¨ü¤G½uvarlitinib¦X¨ÖcapecitabineªºªvÀø¸ÕÅç¡A¤ÏÀ³²v ¡]response rate¡^¹F¨ì11%¥B¨ä¤¤¨â¨Ò§¹¥þ½w¸Ñ¡]complete response¡^¡AµL´c¤Æ¦s¬¡´Á ªº¤¤¦ì¼Æ¡]median PFS¡^¬°2.7Ó¤ë¡A¾ãÅé¦s¬¡´Á¡]OS¡^¬°5.8Ó¤ë - ¬ã¨s¹ï¶H¯f¯g´c¤Æµ{«×¸û°ª¡A¥[¤J¥»¬ã¨s«e¶È10%¹ï©ó¥Hgemcitabine¬°¥D¤§¤@½uªvÀø ¦³©Ò¤ÏÀ³ - Varlitinib¦X¨ÖcapecitabineªºªvÀø¡A¥i¯à¬°¤G½uÁx¹DÀù¯f±w´£¨Ñ¥þ·sªºªvÀø¿ï¶µ ³o¶µ¤G´ÁÁ{§É¸ÕÅç¦bì¥ý¤½¥¬ªººI¤î¤é«e§Y¤w§¹¦¨©Û¶Ò¡A¦@¦¬®×62¦ì¸g¾ú¹Lgemcitabine ¤ÆÀø¤§¤¤°ê¯f±w¡A¥iµû¦ô±wªÌªº«ÈÆ[¤ÏÀ³²v¬°11%¡]¥]¬A2¦ì¯f±w§¹¥þ½w¸Ñ¡^¡AµL´c¤Æ ¦s¬¡´Áªº¤¤¦ì¼Æ¬°2.7Ó¤ë¡A¾ãÅé¦s¬¡´Á«h¬°5.8Ó¤ë¡C6Ó¤ë«á¦³45%¯f±w¦s¬¡¡A12Ó¤ë «á¬°35%¡C¾ãÅé¦s¬¡¼Æ¾Ú¥Ø«e¥H31Өƥ󬰰ò¦¡A¥B«ùÄò¦¨¼ô¤¤¡C³o¸sÃøªv«¬¯f±w¹ï varlitinib¦X¨Öcapecitabineªº@¨ü©Ê¤Q¤À¨}¦n¡C ¬ã¨sºKn½Ð¨£¨È·à±d-KY¤½¥qºô¯¸¡]www.aslanpharma.com¡^¡A ¼ÐÃD¬°¡uJADETREE*: A phase 2A, single arm, multicenter, study of the panHER inhibitor varlitinib plus capecitabine in Chinese patients with advanced or metastatic biliary tract cancer (BTC)¡v¡C 6.¦]À³±¹¬I:µL 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1) ·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI¡A §ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C (2) ¸Ô²Ó¤º®e½Ð¸Ô¤½¥q©xºôµo¥¬¤§·s»D½Z¡C |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/9/19 ¤U¤È 01:41:53²Ä 1342 ½g¦^À³
|
ªÑ»ù³Ìªñ¦³ÂI¤p¤Ï¼u¡A¤£ª¾³Ìªñ·|¤£·|¦³¦n®ø®§¶Ç¥X©O? Åý§ÚÌÄ~Äòµ¥¤U¥h§a! |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2019/9/14 ¤U¤È 02:13:15²Ä 1341 ½g¦^À³
|
¬Q±ßADR¬O¬Ý¦n¥¿¦V Ãz¶qªº¶R½L¡H ¦Ñ·à¥[ªo¡I ·à¤Í¥[ªo¡I |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/9/11 ¤W¤È 10:45:09²Ä 1340 ½g¦^À³
|
ESMOµoªí½×¤å³o¬O¦n®ø®§,§Æ±æ¤G½uÁx¹DÀùºÉ§Ö¸Ñª¼¦¨¥\,±a°Ê«áÄò§ó¦h¤j¼t¨Ó½Í±ÂÅv¦X§@,®É¶¡¬O¤£µ¥¤Hªº~~¦Ñ·à¥[ªo |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/9/11 ¤W¤È 08:04:16²Ä 1339 ½g¦^À³
|
¨È·à±dVARLITINIB ¾À³ø±N©ó2019¼Ú¬w¸~½FÂå¾Ç·|¨È¬w¦~·|¶i¦æµoªí 2019 ¦~9¤ë10¤é¡A·s¥[©Y¡V»EµJ©óÁ{§É¶¥¬q¸~½F¤Î§K¬Ì¾Ç¤§Á{§É¶¥¬q¥Íª«»sÃĤ½¥q¨È·à±d-KY(NASDAQ:ASLN, TPEx:6497)¤µ¤é«Å¥¬±N©ó2019 ¼Ú¬w¸~½FÂå¾Ç·|(ESMO)¨È¬w¦~·|µoªí¤@½g¦³Ãö¥DnÔ¿ïÃĪ«varlitinibªº¾À³ø¡C¥»¦¸¦~·|±N©ó11¤ë22¤é¦Ü24¤é¦b·s¥[©YÁ|¦æ¡C¾À³ø¼Æ¾Ú±N¤ÀªR¥ý«e¥Htrastuzumab ªvÀøªºHER2 ¶§©ÊÂಾ©Ê¨ÅÀù±wªÌ¤¤¨CÓ¸~½F¦ì¸m¤W¸~½FÅé¿n¤§ÅܤơA¥H¦¹¤ñ¸ûvarlitinib¦X¨Öcapecitabine©Mlapatinib¦X¨ÖcapecitabineªºªvÀø¤ÏÀ³¡C¦¹½g¾À³ø(Abstract #681) ¼ÐÃD¬°¡uThe challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumor location¡¦¡v¡C11¤ë19 ¤é¼Ú¬w¤¤³¡®L¥O®É¶¡17:05«á¥iÂI¦¹¬d¬Ý¥þ¤åwww.esmo.org/Conferences/ESMO-Asia-Congress-2019¡C ³oÓ¸ò¤§«e¤½§iªº¤£¤@¼Ë¡A³o¬O¨È¬w¦~·|¡A¤W¦¸¤½§iªº¬O¼Ú¬w¦~·|¡A¦b¦è¯Z¤úÁ|¦æªº¡A³o¦¸¬O¨È¬w¦~·|¡A¦b·s¥[©YÁ|¦æªº¡C ½Ð¤j®a°Ñ¦ÒÅo! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/10 ¤U¤È 12:40:51²Ä 1338 ½g¦^À³
|
¥xÁÞ¤j, ·PÁÂ! INCYTE FGFR2 , SDªº mPFS ¤w¤ñ¤ÆÀøSDªºmPFS ¦h4Ó¦h¤ë,¦h100% ¼F®`! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/10 ¤U¤È 12:22:26²Ä 1337 ½g¦^À³
|
¥xÁÞ, §¹¥þ¤F¸Ñ. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/9/10 ¤W¤È 11:43:06²Ä 1336 ½g¦^À³
|
¤Ñ©R¤j §Y±N¦b¤¤°êµoªíªº¬ð¯}©Ê¬ã¨s½×¤å¬O¨S¦³¿z¿ï¯f±w¡A³o»P·à¤lÁx¹DÀù¬O¤£¦Pªº©Û¶Ò¹ï¶H¤£¯àÃþ¤ñ¡AVarlitimib¤]¤£¬OnINCYTE¤G½uÁx¹DÀù¥uÂê©w¤Ö¼Æ±Ú¸s¬Û¤¬Ävª§¡A·à¤l¤G½uÁx¹DÀù¾A¥Î±Ú¸s±µªñ¦Ê¤À¤§70¥ª¥k¡Aªp¥B¾A¥Îfight 202ªº¯f±w¦³«Ü¤j¾÷²v¾A¥ÎVarlitimib¡A¥H¤W³o¨âÓÆ[©À¦Ü¬°«n¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2019/9/10 ¤W¤È 08:16:35²Ä 1335 ½g¦^À³
|
²H©w¥HÀR¨î°Ê! 2016-04-02 06:00 ¡e°OªÌ³¯¥Ã¦N¡þ¥x¥_³ø¾É¡f¦b¬ü°ê¸~½FÂå¾Ç¦~·|¡]ASCO¡^³qª¾¡AÁܽЯE¹©¤»¤ë¨ì¦~·|¤W±NOBI-822¸Ñª¼µ²ªG½×¤å¶i¦æ¤fÀY³ø§i¤U¡A¨ü¦¹®ø®§¿EÀy¡A¯E¹©¬QªÑ»ù¸õªÅº¦°±¨ì²×³õ¡C ¥«³õ¦³¤H¸ÑŪ¡A¹L¥h³\¦hÀòÁܤfÀY³ø§i½×¤å¡A³Ì²×¤]¨S¦¨¥\¦a±N·sÃıÀ¤W¥«¡A³o¤£ºâ¬Æ»ò¦n®ø®§¡F¦ý¤]¦³¤H»{¬°¡AASCO¨C¦~¥u·|ÁܽФּƽפå§@ªÌ¤W¥x¤fÀY³ø§i¡A¥YÅã¨ä¯S®í©Ê¡A¦Ü¤ÖÃÒ©ú¯E¹©³o¸s¤H¤£¬O¶BÄF¶°¹Î¡C ¯E¹©ªí¥Ü¡AOBI-822¦b¥xÆW¬OÁ{§É¤G¡B¤T´Á¸ÕÅç¦P®É¶i¦æ¡A¦Ó¦¹Á{§É¦b¬ü°ê¤]¦¬¤C¤QÓ¯f±w¡A©Ò¥H¦b¬ü°êºâÁ{§É¤G´Á¸ÕÅç¡A¦]Á{§É¤G´Á¥u¶·ÃÒ©ú¦w¥þ©Ê¤Î¬O§_¦³Àø®Ä¡A¨S¦³©Ò¿×¥¢±Ñ¤£¥¢±Ñªº°ÝÃD¡C........... |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2019/9/9 ¤U¤È 03:48:04²Ä 1334 ½g¦^À³
|
º©ªøªº¬Oµ¥«Ý ¸Õ·Q¡G¦pªG¨S¦³¦nªº®i±æ ·|¤J¿ï¤fÀYµoªí¡H ¤½¥q¬O¦³¦b¶i®iªº §Æ±æ¬O¦nªº±¦V ²{ª÷¦b2©u´N·|¥ÎºÜ °ª¼h¦n¹³¦Ñ¯«¦b¦b §ë¸ê¤HÃú¸Ì¬Ýªá °ß¦³µ¥«Ý19¤é¼Æ¾Úµoªí ¥un¥¿¦V´N............... Á`Âk ¥[ªo¦Ñ·à ¥[ªo·à¤Í ¡]Ó¤HÆ[ÂI¡^ |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/9/9 ¤U¤È 02:51:46²Ä 1333 ½g¦^À³
|
To ©t¨àÃĤj, ³Ìªñ³o¤@¨âÓ§«ô§Ú¨S¦³¸òµo¨¥¤HÁpµ¸¡A¤£¹L¥L¤§«e¦³³zº|¹L¡A¥L¥i¯à°µ¨ì9¤ë©³¦Ó¤w¡A¨ì®ÉÔ¤½¥qÀ³¸Ó·|´«¨ä¥Lªº¤H¿ï¾á¥ôµo¨¥¤H§a¡AÁöµM§Ú¤]«Ü·Qª¾¹D³Ìªñ¤½¥q¦³¨S¦³°£¤FADR¼W¸ê¤§¥~ªº¨ä¥L¶Ò¸ê¶i«×¡A¤£¹L§Ú·QÁÙ¬O¥u¯àµ¥¤½¥q¤½§i§a¡A³Ìªñ¦pªG§ä¤£¨ì¥L¡A¥i¯à¥L¶}©l¥ð°²¤F§a! Thanks, |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/9 ¤W¤È 11:27:13²Ä 1332 ½g¦^À³
|
www.ncbi.nlm.nih.gov/pmc/articles/PMC5344285/#!po=2.38095 ¤G缐Áx¹DÀù¤ÆÀø¤§Á{§É¸ê®Æ¤§¤@ Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients Âù¤ÆÀøDCR 51.7%, ,MPFS(26%) 4Ӥ륪¥k(¥Øµø¹Ï1) ³æ¤ÆÀøDCR¡C46.1%,MPFS(23%) ,4.5Ӥ륪¥k(¥Øµø¹Ï1) *************************** INCYTE FGFR2 ,DCR (19¡Ï11)/47=63.8% , MPFS(²Ä15¦ì)¦b10Ӥ륪¥k,¤´¥¼PD¤§±wªÌ¤W. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/9 ¤W¤È 10:49:38²Ä 1331 ½g¦^À³
|
¸É¥R1. ***INCYTE, FGFR¤G½uÁx¹DÀù ªº¤G´ÁÁ{§É¤¤ 47¦ì±aFGFR2*§Ü·½ DCR= (PR19+SD11)/47=63.8% , PD 18 ¦ì ¥¼PD19¦ì ¦³10¦ì¤¤³~Â÷¶}/µL§P©w¸ê®Æ ¸É¥R2. ***INCYTE, FGFR¤G½uÁx¹DÀù ªº¤G´ÁÁ{§É¤¤ 47¦ì±aFGFR2*§Ü·½ ¥X²{, (3)19¦ìPR , ¨ä¤¤¨ì2018,07,26 cut data date, a. ¤´¦³13¦ì¥¼PD,«ùÄò¥ÎÃĤ¤. b. ¤wPD3¦ì(11¤ë/9¤ë/7¤ë) c.¤¤³~Â÷¶}3¦ì(7¤ë/5¤ë/4¤ë) (4)11¦ìSD , ¨ä¤¤¨ì2018,07,26 cut data date, a. ¤´¦³6¦ì¥¼PD,«ùÄò¥ÎÃĤ¤. b. ¤wPD 0¦ì c.¤¤³~Â÷¶}5¦ì(7¤ë/5¤ë/2¤ë ¦U1¦ì+ 1¤ë2¦ì) ************************************************ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/7 ¤U¤È 07:08:49²Ä 1329 ½g¦^À³ ***INCYTE, FGFR¤G½uÁx¹DÀù ªº¤G´ÁÁ{§É¤¤ 47¦ì±aFGFR2*§Ü·½ ¥X²{, (1)19¦ìPR ¤¤, ¦³2 ¦ì¦b²Ä7Ó¤ë¤~¦¨¬°PR, ¥t¥~5¦ì¬O²Ä5Ó¤ë¤~¦¨¬°PR. ¦³13¦ì¥¼PD(3¦ì15~16Ó¤ë, 2¦ì13/14Ó¤ë,4 ¦ì11/12Ó¤ë, 4¦ì9/10/11Ó¤ë) ,¦s¬¡¥ÎÃĤ¤. (2)11¦ìSD ¤¤, MPFS 9Ó¤ë, ²Ä6~11 ¦ì (2¦ì13Ó¤ë,1¦ì11Ó¤ë,3¦ì,9/10Ó¤ë)¬Ò¥¼PD¦s¬¡¥ÎÃĤ¤. 2018 ESMO¸ê®Æ. ESMO 2018: Incyte Posters ---October 22, 2018 investor.incyte.com/events-and-presentations/presentations?field_nir_tags_target_id=All&promote=All&field_nir_asset_type_target_id%5B26%5D=26&items_per_page=10&page=1 ¹Ï4. |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/9/9 ¤W¤È 10:25:08²Ä 1330 ½g¦^À³
|
½Ð°Ý¤j®a³Ìªñ¦³¸ò¦Ñ·à¤½¥qÁpµ¸¶Ü?µo¨¥Åé¨t¦n¹³³£§ä¤£¨ì¤H,¦³·s®ø®§¥i¤À¨É¶Ü ?? |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/7 ¤U¤È 07:08:49²Ä 1329 ½g¦^À³
|
***INCYTE, FGFR¤G½uÁx¹DÀù ªº¤G´ÁÁ{§É¤¤ 47¦ì±aFGFR2*§Ü·½ ¥X²{, (1)19¦ìPR ¤¤, ¦³2 ¦ì¦b²Ä7Ó¤ë¤~¦¨¬°PR, ¥t¥~5¦ì¬O²Ä5Ó¤ë¤~¦¨¬°PR. ¦³13¦ì¥¼PD(3¦ì15~16Ó¤ë, 2¦ì13/14Ó¤ë,4 ¦ì11/12Ó¤ë, 4¦ì9/10/11Ó¤ë) ,¦s¬¡¥ÎÃĤ¤. (2)11¦ìSD ¤¤, MPFS 9Ó¤ë, ²Ä6~11 ¦ì (2¦ì13Ó¤ë,1¦ì11Ó¤ë,3¦ì,9/10Ó¤ë)¬Ò¥¼PD¦s¬¡¥ÎÃĤ¤. 2018 ESMO¸ê®Æ. |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2019/9/7 ¤W¤È 06:06:17²Ä 1328 ½g¦^À³
|
¤w¥[½X1¦¸,Y9/19ªº¬ð¯}©Ê¬ã¨s¼Æ¾Ú¥¿¦V,±b±¤j·§¤]´NÂॿ,¦¹®É±N³Ì«á¥[½X, µ¥ASLAN004²§¦ì©Ê¥Ö½§ª¢P2Á{§É...... |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/9/6 ¤W¤È 10:40:47²Ä 1327 ½g¦^À³
|
¤Ñ©R¤j ¼Æ¾Úµoªí¤~ª¾¹D¡A@¤ßµ¥«Ý |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/9/5 ¤U¤È 11:08:57²Ä 1326 ½g¦^À³
|
¥xÁÞ¤j, 2019,09,19 µoªíªº¡u¬ð¯}©Ê¬ã¨s¡v,¬ã¨s¼Æ¾Ú. ORR PFS OS ·|¬O¦h¤Ö¤~·|¶i¤J¡u¬ð¯}©Ê¬ã¨s¡v ? 2018/09/17 ,¤½¥q¤½§iªº¼Æ¾Ú ORR=1/14=7.14% DCR=(1+6)/14=50% ¦b14¦W¤w±µ¨ü6¶g±½´yªº¨ü¸ÕªÌ¤¤¡A®Ú¾Ú¸ÕÅç¾÷ºcµû¦ô¦³1¦W¨ü¸ÕªÌ¥X²{³¡¤À¤ÏÀ³¡A6¦W¨ü¸ÕªÌ¹F¯e¯féw ***INCYTE, FGFR¤G½uÁx¹DÀù ªº¤G´ÁÁ{§É¤¤ ¥X²{,19¦ìPR ¤¤, ¦³2 ¦ì¦b²Ä7Ó¤ë¤~¦¨¬°PR, ¥t¥~5¦ì¬O²Ä5Ó¤ë¤~¦¨¬°PR. **** ¼Ð¹vªvÀø¤¤ªºÅܼƬO§Ü·½ªºIHC°ª§C,Y¥u¦³IHC+1/+2 ³q±`,ªvÀø«áªì´Á¥u·|¸¨¦b¯e¯féw. ±a§Ü·½IHC+3 ±wªÌ,¦³¸û°ªªº¾÷·|¹FORR(partial response (PR)+ CR ). *********************************************** ¥»¤½¥q±N©ó2019¦~9¤ë19¤é¦b¤¤°ê·HªùÁ|¦æ¤§¤¤°êÁ{§É¸~½F¾Ç·|(CSCO)¦~·|¤fÀYµoªí Àò¦~·|¤J¿ï¬°¡u¬ð¯}©Ê¬ã¨s¡v(late-breaking abstract)¤§varlitinib©ó¤¤°ê±ß´Á©Î Âಾ©ÊÁx¹DÀù¤G´ÁÁ{§É¸ÕÅçµ²ªG¡C ¦¹½gºKn¼ÐÃD¬°¡uJADETREE*: A phase 2A, single arm, multicenter, study of the panHER inhibitor varlitinib plus capecitabine in Chinese patients with advanced or metastatic biliary tract cancer (BTC)¡v¡A¨Ã±N¥Ñ®ý¦¿¤j¾Ç¸~½F¤º¬ì ¤èºû¨Î³Õ¤h¶i¦æ¤fÀY³ø§i¡A¤è³Õ¤h©ó®ý¦¿¤j¾ÇÂå¾Ç°|ªþÄݲĤ@Âå°|¾á¥ô°Æ¥D¥ôÂå®v¡C ¥»½gºKnµoªí®É¶¡¬°2019¦~9¤ë19¤é¬P´Á¥|¤¤°ê¼Ð·Ç®É¶¡¤U¤È¤TÂI¤T¤Q¤À¦Ü¤TÂI¥|¤Q¤À¡C ------------------------------------------------------------------------------------- ***************************************************************** ·s»D½Z2018/09/17 ¨È·à±d-KY§ó·sVARLITINIB¤¤°êÁx¹DÀùÁ{§É¸ÕÅç®Éµ{ ¥»¤½¥qºÞ²z¹Î¶¤±N©ó¬ü°êªF³¡®É¶¡(2018¦~)9¤ë17¤é¬P´Á¤@¤W¤È8:30 /·s¥[©Y®É¶¡¤U¤È8:30¥l¶}¹q¸Ü·|ij¡A¨Ã©óºô¸ô¦P¨Bª½¼½¡C 2018¦~9¤ë17¤é¡A·s¥[©Y ¡V ±Mª`©ó¶}µo¨È¬w²±¦æ»P¼Ú¬ü©t¨à¯e¯fÀù¯g¡B¦ì©óÁ{§É¶¥¬q¤§¥Íª«»sÃĤ½¥q¨È·à±d -KY (6497. TT, NASDAQ: ASLN) ¤µ¤é«Å¥¬±N§ó·svarlitinib¤¤°êÁx¹DÀùÁ{§É¸ÕÅ窺®Éµ{³W¹º¡A¦¹¶µ¶i¦æ¤¤ªº¶}©ñ©Ê¸ÕÅ笰varlitinib¦X¨Öcapecitabine©ó±ß´Á©ÎÂಾ©ÊÁx¹DÀùªº³æÁu¸ÕÅç¡Aì¹wp©Û¦¬ 68 ¦ì¨ü¸ÕªÌ¡A¨ü¸Õ¹ï¶H¬°¦Ü¤Ö±µ¨ü¹L¤@½u¤ÆÀø¦ý¤´´c¤ÆªºÁx¹DÀù¯f±w¡C ¦b¹ï¨ü¸ÕªÌ¶i¦æÀ˵ø¤Î»P¥Dn¬ã¨s¤Hû°Q½×«á¡A¦U¤è¦P·NÀ³¦V·í¦a¥DºÞ¾÷Ãö´£¥XÁ{§É¸ÕÅç³]p×¥¿®×(protocol amendment)¡Aקï¨ü¸ÕªÌªº¯Ç¤J±ø¥ó¡A¥H½T«O¦¹¶µ¬ã¨s¯à·Ç½Tµû¦ôvarlitinibªºÀø®Ä¡C¼f¬d»P¹ê»Ú°õ¦æ³o¶µ¦ÛÄ@©Ê×¥¿®×©Ò»Ýnªº®É¶¡¹wp¬ù¬°¥|Ó¤ë¡C¦b¦¹´Á¶¡¡A¨È·à±d-KY±NÄ~Äò©Û¦¬¯f±w¡A¨Ã©ó2019¦~ªì§ó·s¶i¤@¨Bªº¸ÕÅç¶i«×¡C ¨È·à±d-KYªº¤G½uÁx¹DÀù¥þ²y©Ê¼Ï¯Ã¸ÕÅçTREETOPP¤´±N«öpµe©ó2019¦~ªì§¹¦¨¨ü¸ÕªÌ¦¬®×¡CTREETOPP¬O¤@¶µÀH¾÷¡AÂùª¼¡A¦w¼¢¾¯¹ï·Óªº¤G½uÁx¹DÀùÁ{§É¸ÕÅç¡A¦®¦b¤ñ¸ûvarlitinib»P¦w¼¢¾¯¤À§O¦X¨Öcapecitabine¨Ï¥ÎªºÀø®Ä ¡CY¬ã¨sµ²ªG¬°¥¿±¡ATREETOPP¤§¸ÕÅç¼Æ¾Ú±N¥Î©óvarlitinib¥þ²yªºÃÄÃҥӽСC ¦¹¶µ¤¤°ê¤G½u¸ÕÅ窺¨ü¸ÕªÌ¹ï©ó¤@½uªvÀøªº¤ÏÀ³©úÅã¸û¥þ²y©Ê¬ã¨s¤¤ªº¼Æ¾Ú¤£²z·Q¡C¦b«e27¦W¨ü¸ÕªÌ¤¤¡A²Ä¤@½uªvÀøªº¤ÏÀ³²v¬ù¬°7%¡AµL´c¤Æ¦s¬¡´Á(PFS)¬°2.7Ó¤ë¡C¬Û¤ñ¤§¤U¡AÁx¹DÀù²{¦³¤@½u¼Ð·ÇÀøªk©Ò®Ú¾ÚªºABC-02 1¸ÕÅç¦b¨Ö¥Îcisplatin¤ÎgemcitabineªºªvÀø¤ÏÀ³²v¬°26%¡AµL´c¤Æ¦s¬¡´Á(PFS)¬°8Ó¤ë¡A¸Ó¸ÕÅ笰¤ñ¸ûcisplatin¨Ö¥Îgemcitabine(Áx¹DÀù²{¦³¤@½u¼Ð·ÇÀøªk)»P³æ¿W¨Ï¥Îgemcitabine©ó±ß´ÁÁx¹DÀù¤§Àø®Ä¡C ¦b14¦W¤w±µ¨ü6¶g±½´yªº¨ü¸ÕªÌ¤¤¡A®Ú¾Ú¸ÕÅç¾÷ºcµû¦ô¦³1¦W¨ü¸ÕªÌ¥X²{³¡¤À¤ÏÀ³¡A6¦W¨ü¸ÕªÌ¹F¯e¯féw¡C¥H¤W14¦W¨ü¸ÕªÌ¦b¤@½uªvÀø¤¤¡A¦³2¦W¨ü¸ÕªÌ¥X²{³¡¤À¤ÏÀ³¡A4¦W¨ü¸ÕªÌ¹F¯e¯féw¡C ¨È·à±d-KYÀç¹Bªø Mark McHale ³Õ¤hªí¥Ü¡G¡u§Ú̹椦¨û¹L¥h´¿¶}µogefitinib»Pafatinib³oÃþ¹ï¬ü°ê»P¤¤°ê¯f±wªºªvÀø®ÄªG¨ã¦³®t²§©ÊªºÃĪ«¡A®Ú¾Ú³o¼Ëªº¸gÅç¡A§Ṳ́@ª½±K¤ÁÃöª`³o¶µ¤¤°êªº¬ã¨s¡C»P¹L¥hªº¬ã¨s¬Û¤ñ¡A³o¶µ¬ã¨s±N§ó¦³§U©ó§ÚÌ¿ëÃѯf±w±Ú¸s¶¡ªº®t²§©Ê¡AÅý§Ú̯à±Ä¨ú±¹¬I¥H½T«O¦¹¸ÕÅç¯à°÷·Ç½Tµû¦ôvarlitinibªºÀø®Ä¡C³æÁu¸ÕÅ祻¨´N¦s¦bµÛ³o¼Ë·ÀI¡A¦ý§ÚÌ»{¬°¨ä¥L¶i¦æ¤¤ªº¦w¼¢¾¯¹ï·Ó¸ÕÅ礣·|¨ü¨ì¥ô¦óªº¼vÅT¡C¨È·à±d¥Ø«e¥¿»P¦h¦ìª¾¦Wªº¤¤°êÁx¹DÀù±M®a±K¤Á¦X§@¡A¥H¥[²`¤F¸ÑªvÀø®ÄªG¦³©Ò®t²§ªºì¦]¡C¡v |
|
|
·|û¡GÀ³µL©Ò¦í10144738 µoªí®É¶¡:2019/8/30 ¤W¤È 07:04:46²Ä 1325 ½g¦^À³
|
ÀR«Ý ¥[ªo |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/8/30 ¤W¤È 06:36:53²Ä 1324 ½g¦^À³
|
¥þ²y¾P°âªñ¦Ê»õ¬ü¤¸ªº贺Àù¥¡C ¨ÅÀù¡BGÀù¤@½u¥ÎÃÄ¡A³Ì¦³Àø®Äªº§ÜìHER2+,IHC+3 Incyte ¤@½uÁx¹DÀùFGEG2¤w¦¬¯f±w¡C ¨È·à¥[ªo¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/8/30 ¤W¤È 12:19:26²Ä 1323 ½g¦^À³
|
¤Ñ©R¤j ±q^¤å·s»D¨Ó¬Ý Dr Carl Firth, Chief Executive Officer of ASLAN Pharmaceuticals, said: ¡§Our study of varlitinib is the largest clinical trial conducted to date on biliary tract cancer patients in China and we are pleased to see the data we have generated welcomed as an important insight into the treatment of BTC by a prestigious academic group like CSCO.¡¨ קïGoogle ½Ķ ASLAN»sÃĤ½¥q CEO Carl Firth³Õ¤h»¡¡G§Ú̹ïvarlitinibªº¬ã¨s¬O¨´¤µ¬°¤î¦b¤¤°ê¶i¦æªº³Ì¤jªºÁx¹DÀù±wªÌÁ{§É¸ÕÅç¡A§ÚÌ«Ü°ª¿³¬Ý¨ì§ÚÌ©Ò²£¥Íªº¼Æ¾Ú¨ü¨ì¹³¤¤°êÁ{§É¸~½F¾Ç·|( CSCO )³o¼ËªºµÛ¦W¾Ç³N¹ÎÅéÅwªï¨Ã¹ïÁx¹DÀùªvÀø¦³²`¨è¬}¹î Ó¤H¤À¨É: 1 ¤¤°ê¥«³õ«Ü¤j , ¨È·à±d¦b¤¤°ê¶i¦æ¬ã¨s¬O«Ü¦ÛµMªº 2 ¤J¿ï¬°¬ð¯}©Ê¬ã¨s (late-breaking abstract)¤§varlitinib©ó¤¤°ê±ß´Á©ÎÂಾ©ÊÁx¹DÀù¤G´ÁÁ{§É¸ÕÅçµ²ªG¡C ¬Ý°_¨Ó¤J¿ï¬°¬ð¯}©Ê¬ã¨s ²q´ú¼Æ¾ÚÀ³¸Ó¨ã¦³¬ð¯}©Ê»P¼ç¤O 3 Ó¤H»{¬°¬O±q·s©Û¶Òªº¯f±w , ³o¶µ¸ÕÅ禮¦b±´°Qvarlitinib¦X¨Öcapecitabine¥Î©ó¤¤°ê¤G½u¥¼¸g¿z¿ï¤§Áx¹DÀù¯f±w ¤§Àø®Ä 4 ¬Ý°_¨Ó¤£¤Ó¹³¬OHER®a±Ú§Üì¨Æ«áÂX¥R©Ê¬ã¨s ( ¥þ²y¼Ï¯Ã¸ÕÅç·|¤½§iHER®a±ÚÀø®Ä) 5 ¤¤°ê¤G½u¥¼¿z¿ï¯f±w°²³]¼Æ¾Ú¨Î, ¥þ²y¼Ï¯Ã¸ÕÅ禳¿z¿ï¯f±w²z½×¤W¼Æ¾Ú¥u·|§ó¦n 6 ¹ï¦³¼ç¤Oªº¤½¥q¨Ó»¡( ASLAN001 ASLAN003 ASLAN004 ) ¦³¤@¤Ñ¨È·à±d¨CªÑ²bȶW»PEPS ¹L XX ¤¸ ¤@ÂI¤]¤£·P¨ì·N¥~ ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/8/29 ¤U¤È 11:12:44²Ä 1322 ½g¦^À³
|
¥xÁÞ¤j, ¤¤°êCSCO ¥i¦³HER®a±Ú§Üì¨Æ«áÂX¥R©Ê¬ã¨s? |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/8/29 ¤W¤È 10:29:08²Ä 1321 ½g¦^À³
|
¬ü°ê¥Í§Þ¤j¼t¦w¶i¡]Amgen¡^©ó¥»(2019)¦~8¤ë26¤é«Å¥¬¡A±N¥H134»õ¬ü¤¸²{ª÷¦¬Áʥͧޤ½¥qCelgeneªºªvÀø¤û¥ÖÅ~ÃÄOtezla¡A¦¹Á|¤£¦ý±j¤Æ¦w¶iªº¤û¥ÖÅ~»P§Üµoª¢ÃĪº²£«~²Õ¦X¡A¤]§U©ó¥²ªv§´¬I¶QÄ_¡]Bristol-Myers Squibb¡^§¹¦¨¦¬ÁÊCelgeneªº¥æ©ö¡C ¥²ªv§´¬I¶QÄ_©ó¤µ(2019)¦~1¤ë«Å¥¬¥H740»õ¬ü¤¸¦¬ÁÊCelgene¡A¦ý¬ü°êÁp¨¹¶T©ö©eû·|½èºÃ¦¹¦¬ÁÊ®×®£¤£§Q§Üµoª¢ÃĪº¥«³õÄvª§¡C¥²ªv§´¬I¶QÄ_¤ÎCelgene¨M©w¥X°âOtezla¡A¬ß¯à¸Ñ¨MºÊºÞ¾÷ºc¤ÏÃbÂ_ªºÃöª`¡C ¤µ(2019)¦~1¤ë¥÷ªº¥²ªv§´¬I¶QÄ_ªí¥Ü¡A¦¬ÁÊÄvª§¹ï¤âCelgene«á¡A¸Ó¤½¥q±N¦¨¬°¥«È1,230»õ¬ü¤¸ªº¥þ²yÀù¯gÃĪ«¥«³õªº»â¾ÉªÌ¡C Á`³¡¦ì©ó¯Ã¬ù¥«ªº¥²ªv§´¬I¶QÄ_P¤O©ó¬ãµo§K¬Ì§ÜÀùÃÄ¡A¦¹ÃĪ«¥iÄÀ©ñ¤HÅé¹ï¸~½Fªº§K¬Ì¨t²Î¡CÁ`³¡¦ì©ó¯Ã¿A¦è¦{SummitªºCelgene«h¬°ªvÀø¦hµo©Ê°©Åè¸~½F¯e¯fÃÄ«~ªº¥Dn¨ÑÀ³°Ó¡C¨â®a¦X¨Ö«á¡A·í®É¹wp¦~¦¬¤J¬ù380»õ¬ü¤¸¡C Otezla¥h¦~¬°Celgene±a¨Ó16»õ¬ü¤¸ªºÀ禬¡C¸ÓÃĥΩóªvÀø¤û¥ÖÅ~¡A¤û¥ÖÅ~¬O¤@ºØ¥Ö½§¯f¡A¨ä¤¤§K¬Ì¨t²Îªº¹L«×¤ÏÀ³¾ÉP¨Åé¤W§Î¦¨µoÄoªº¥Ö¯l¡C¥²ªv§´¬I¶QÄ_¥Ø«e¤£¾P°â¤û¥ÖÅ~ÃÄ¡A¦ý¦³¶µ¸ÕÅçÃĪ«¥¿¶i¤JÁ{§É«á´Á¶¥¬q¡C ¦n©_¥h§ä¤FRoger¥S¤À¨Éªº·s»D¡Aµo²{¤F¨âÓ«ÂI¡C 1. ¨S·Q¨ì¤@ÁûªvÀø¤û¥ÖÅ~ªºÃÄ¡A¥i¥H½æ¨ì100¦h»õ¬üª÷¡A¨º004¥¼¨Ó¦pªG¦¨¥\¡A°Ó¾÷¬O«D±`¥i¥H´Á«Ýªº¡C 2. BMS³o¶¡¤½¥qªá¤F700¦h»õ¬üª÷¥h¦¬ÁÊ¥t¥~¤@¶¡¤½¥q¡A¦Ó¨È·à±d¸òBMS¤]¦³¤@Áû002¬O¦X§@Ãö«Yªº¡A002¦b2016¦~¤w¸g°^Äm1000¸U¬üª÷ªºÃ±¬ùª÷¡A¥¼¨ÓÁÙ¦³¾P°â¤À¼í¡A¦U¶¥¬qªºÅv§Qª÷¦¬¤Jµ¥µ¥¡A¤£ª¾¹D002¥Ø«eªº¶i«×¦p¦ó©O¡H³o¦U¦n¹³¨S¦³¬Ý¨ì§ó·s»¡¡A¤£¹LBMSÄ@·Nªá¿ú¶R¦^¡AÀ³¸Ó¤]¬O¬Ý¦n¥¦ªº¥¼¨Ó§a! ¤@ÂI¤ß±o¤À¨É! Thanks, |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2019/8/28 ¤U¤È 12:25:21²Ä 1320 ½g¦^À³
|
©êºp,§ó¥¿¬O¬K©M¥S! ¤û¥ÖÅ~(°®Å~/»È®h¯f);²§¦ì©Ê¥Ö½§ª¢(²§¦ì©ÊÀã¯l) «¥¶R¨È·à¬Ý¤¤¦a¬OASLAN004²§¦ì©Ê¥Ö½§ª¢! 2019.8.26·s»D:¬ü°ê¥Í§Þ¤j¼t¦w¶i¡]Amgen¡^©ó¥»(2019)¦~8¤ë26¤é«Å¥¬¡A±N¥H134»õ¬ü¤¸²{ª÷¦¬Áʥͧޤ½¥qCelgeneªºªvÀø¤û¥ÖÅ~ÃÄOtezla...... |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2019/8/28 ¤U¤È 12:18:11²Ä 1319 ½g¦^À³
|
¬K¬î¥S,¤£¦n·N«ä! ³Òª©¥D±N³o½g[·|û¡GROGER588910148151 µoªí®É¶¡:2019/8/28 ¤W¤È 11:06:42²Ä 1316 ½g¦^À³]§R°£,ÁÂÁÂ~ |
|
|
·|û¡G¬K©M´º©ú10141799 µoªí®É¶¡:2019/8/28 ¤U¤È 12:04:18²Ä 1318 ½g¦^À³
|
ROGER5889¤j¡A ¦]¬°§Ú¦³®É·|¦]¬°Ó¤H¦]¯À¡A¦bµo¤å«á·|n¨Dª©¥D§R¤å §Æ±æ±z¥H«á·QÂà¸ü©Î¸`¿ý§Úµoªº³¡¤À¤º®e®É½Ð¥ý´M¨D§Úªº¦P·N¦AÂà ¦³¨Ç®ÉÔ§Ú·|§R¤å¡A¨Ã¥B¤£§Æ±æµo¤å¤º®e¥X²{¦b¨ä¥L¤½¶}³õ©Ò µL¥ô¦ó§iª¾ÀH·NÂà§Úªº¤å¬O·|³y¦¨§Úªº§xÂZªº ³oÂIÁٽбz²z¸Ñ¡AÁÂÁ¡C |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/8/28 ¤W¤È 11:50:38²Ä 1317 ½g¦^À³
|
¨ä¹ê¨È·à±d³Ìªñªº°ÝÃD³£¤£¬O¬ãµo°ÝÃD¡A¬Q¤Ñªº¤½§i´N¥Nªí¤½¥qªºÃĬO«Ü¦³«e´ºªº¡A¥u¬O¤½¥q¸êª÷±±ºÞ¯à¤O¯uªº¦³«Ý¥[±j¡AY¬O¦p¤§«e¸gÀÙ¤é³ø¨º½g±M³X¡A¨È·à±d¥xÆW¥DºÞ¥h¦~¦~©³´N¤w¸g¦³¸ò¸³¨Æ·|³ø§iªÑ»ù²bȪº¨Æ±¡¡A¦ý¬O¤½¥q°ª¼h°ê¥~¥DºÞ¨Ã¨S¦³¹w®Æ¨ì¥þÃB¥æ³ÎªÑ©Ò±a¨Óªº½ÄÀ»¦³¦h¤j¡A§_«h°t¦X¬Q¤Ñªº¤½§i¡AªÑ»ù«Ü¥i¯à¦b¸Ñª¼«e¡A´N¦³¾÷·|¤W¬Ý30¤F¡AÓ¤Hı±o¥Ø«e³Ì«nªº¨Æ±¡¡A´N¬O»°§ÖÅý²{ª÷¬y¦^¨ì¦w¥þ¤ô¦ì¡A¬Ý¬On¥Î±ÂÅvªº¤è¦¡©Î¬O§ä¨ä¥LÃļt¦X§@¬Æ¦Ü´M¨D¥xÆW¬F©²¬Ý¬O¥Î°òª÷ªº¤JªÑµ¥¤è¦¡¡AÅý²bÈ»°§Ö¦^¤É¨ì5¤¸¥H¤W¡A³oÂI§Úı±o¬O¤ñ¸û«n¥B¥²¶·¥ß°¨¥h¶i¦æªº¨Æ¶µ¡An¤£µM¤½¥q¬ãµo¶i«×³£«Ü¶¶§Q¥B¤½§iªº¼Æ¾Ú³£«Ü¤£¿ù¡AY¬O¦]¬°¸êª÷ªºÃö«Y¡A¦Ó¤ÞÅT«áÄò¤½¥qªºµo®i´N«Ü¥i±¤¤F¡A¤@ÂIÂI¤p¤ß±o¤À¨É! ÁÂÁÂ! |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/8/28 ¤W¤È 11:35:59²Ä 1316 ½g¦^À³
|
To:¸¤H¤j ¤W¶g1000±iªº¤j¤á«ùªÑ¬O¼W¥[¬ù640±i,¥B¤W¶gµØ«n-¤½¸ÛÁÙ¤j½æ¤F¦Ü¤Ö500±i¥H¤W,·Pı¤j©@¤ñ¸û³ßÅw¦b¥þÃB¥æ³Î¤Î¤À½Lªº¾÷¨î¤U¶R¶i,«¢«¢... ¥H¤W¨Ñ°Ñ¦Ò |
|
|
·|û¡GÀ³µL©Ò¦í10144738 µoªí®É¶¡:2019/8/27 ¤U¤È 05:56:44²Ä 1315 ½g¦^À³
|
1.¨Æ¹êµo¥Í¤é:108/08/27 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¥»¤½¥q±N©ó2019¦~9¤ë19¤é¦b¤¤°ê·HªùÁ|¦æ¤§¤¤°êÁ{§É¸~½F¾Ç·|(CSCO)¦~·|¤fÀYµoªí Àò¦~·|¤J¿ï¬°¡u¬ð¯}©Ê¬ã¨s¡v(late-breaking abstract)¤§varlitinib©ó¤¤°ê±ß´Á©Î Âಾ©ÊÁx¹DÀù¤G´ÁÁ{§É¸ÕÅçµ²ªG¡C ¦¹½gºKn¼ÐÃD¬°¡uJADETREE*: A phase 2A, single arm, multicenter, study of the panHER inhibitor varlitinib plus capecitabine in Chinese patients with advanced or metastatic biliary tract cancer (BTC)¡v¡A¨Ã±N¥Ñ®ý¦¿¤j¾Ç¸~½F¤º¬ì ¤èºû¨Î³Õ¤h¶i¦æ¤fÀY³ø§i¡A¤è³Õ¤h©ó®ý¦¿¤j¾ÇÂå¾Ç°|ªþÄݲĤ@Âå°|¾á¥ô°Æ¥D¥ôÂå®v¡C ¥»½gºKnµoªí®É¶¡¬°2019¦~9¤ë19¤é¬P´Á¥|¤¤°ê¼Ð·Ç®É¶¡¤U¤È¤TÂI¤T¤Q¤À¦Ü¤TÂI¥|¤Q¤À¡C 6.¦]À³±¹¬I:µL 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1) ·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI¡A §ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C (2)¸Ô²Ó¤º®e½Ð¸Ô¤½¥q©xºôµo¥¬¤§·s»D½Z¡C ¥[ªo¥[ªo¥[ªo |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/8/26 ¤W¤È 08:38:20²Ä 1314 ½g¦^À³
|
¦U¦ì·à¤Í¦n, ±q¨È·à±d¤W§«ôªºÄw½X¨ÓÆ[¹î¡AªÑªF¤H¼Æ´î¤Ö¤F§Ö300¤H¡A±q±µªñ5400¤H´î¤Ö¨ì±µªñ5100¤H¡A¥§¡¨C¤H«ù¦³ªº±i¼Æ¤W¤É1.7±i¨ì¨CӪѪF¥§¡«ù¦³31.4±iªÑ²¼¡A¦Ó400±i¥H¤Wªº¤j¤á¤]¼W¥[¤F¡A«ùªÑ¤ñ¨Ò¤W¤É¨ì77.7%¡A¥i¥H¸Ñ¿W¬O¤W§«ô´²¤áºÆ¨g¥X²æªÑ²¼¡A¦ÓÄw½X¦³¦V¤j¤á¾aÃlªº±¡§Î¡A¤£¹L«áÄòªÑ»ùn¤îáAÁÙ¬On¬Ý¤½¥qªºªí²{¡A¬Ý¬O§_¦³±ÂÅv®×©Î¬O¨ä¥Lªº¼W¸ê¤è¦¡¡A«e¤Ñ¦³¤@½g·s»D´£¨ì¡A¥Í§Þ·~ªÌ«P¬F©²¨ó§U¤Þ¸ê¡A¤£ª¾¹D¨È·à±d¦³µL¥i¯à´M¨D¥xÆW¬F©²ªº¤ä´©¡A¨ó§U¤½¥q¶Ò¸ê©O? ³oÂI©Î³\¥i¥H¦Ò¼{¡A²¦³º¥Ø«e°õ¬Fªº¬F©²¬O¹ªÀy¥Í§Þ²£·~ªº¡A¥H¤W¤@ÂI¤ß±o¡C Thanks, |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/8/25 ¤U¤È 11:53:25²Ä 1313 ½g¦^À³
|
ªÑ²¼¦³´£«e¤ÏÀ³ªº¯S©Ê¡A·à¤l³Q¦C¤J¥þÃB¥æ³ÎªÑ«e¤@¦~¦h´N¶}©l¤ÏÀ³¥H«á¥i¯àªº§QªÅ¡A ¦P¼Ëªº¹D²z¤Ï«ä¡A·à¤l¥Ø«eªÑ»ùÀ³¸Ó¦³¤ÏÀ³ ¨ì¤À½L¥æ©öªº§QªÅ¡A¥¼¨Ó¦³¥ô¦óÁ{§É¼Æ¾Ú©Î±ÂÅv¡A¼W¸êµ¥¥ô¦óµïµ·°¨¸ñªº¸ê°T¡A·à¤lªº»ùÈ´N·|¤ÏÂਫ¦V¥¿±¹D¸ô¡A¤£¬Oµ¥¨ì²bȦ^¨ì¤¤¸¤~¶}©l¤ÏÀ³¨äÀ³¸Ó¦³ªº»ùÈ¡A ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/8/24 ¤W¤È 09:05:23²Ä 1312 ½g¦^À³
|
§ÚÓ¤H¤]¬Oı±o¤½¥q°ª¼hÀ³¸Ó¦³¦b¶i¦æªº±ÂÅv½Í§P¡A§_«h¥H¤½¥q²{¦bªºÀç¹B¤ä¥X¡A±q¤½§iªº¤C¤ë°]³ø¡A¤@Ó¤ënªá7000¦h¸U¡A¥H¤½¥q²{¦bªº²{ª÷¡A¥|»õ¦h¨Ó¬Ý¡A¥i¥H¥Î¨ì¤µ¦~µ²§ô¡A¦ý¬O¥HADR¼W¸êµo¦æªº®É¶¡±À¦ô¡A³Ì§Ö¤]n©ú¦~²Ä¤@©u¤~¥i¯à¦b¬ü°ê¼W¸êµo¦æ¡A¸êª÷¤~·|¨ì¦ì¡A©Ò¥H¨ì¦~©³«e¡A¤@©w·|¦³±ÂÅv®×µo¥Íªº¡A¤j®a´NÄ~Äò¬Û«H¤½¥qªº§V¤O§a¡A¨º»ò¦hÃij£ÁÙ¨S±À¥X¡C§Æ±æ»°§Ö±ÂÅv®×µo¥Í¨Ó¨ë¿EªÑ»ùÅo¡I |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2019/8/24 ¤W¤È 07:05:19²Ä 1311 ½g¦^À³
|
¥Ø«eADR1.7¬ü¤¸ªÑ»ù¤£¦n ¦pªGµo¦æADR½w¤£ÀÙ«æ¤]¶Ò¤£¨ì¦n»ù®æ §ïµ½¤£¤F²bÈ°ÝÃD ªÑ»ù10¤¸¥u¬O¦h¼W¥[ªÑ¥» ²{¶¥¬q¥u¯àµ¥«Ý¤½¥q°µ¦n¸Ñª¼¼Æ¾Ú Âà¥X¦A±ÂÅv¤ñ¸û¹ê¦b ¡]§Æ±æÂà¥X±ÂÅv¥ýµo¥Í¡A´Á«Ý¡^ Ó¤HÆ[ÂI µ¥«Ý¬OÃø¼õªº ¦U¦ì·à¤Í ¥[ªo¥[ªo¦b¥[ªo |
|
|
·|û¡G¤p©ú10146339 µoªí®É¶¡:2019/8/23 ¤W¤È 10:57:02²Ä 1310 ½g¦^À³
|
Ó¤H«D±`ÃÙ¦P¸¤H¤jªº»¡ªk¡A ¦]¬°ADR¯uªº¬O½w¤£ÀÙ«æ¡C ¤E¤ë©³¤~°e¥ó¡AÁÙnµ¥ÃÒ´Á§½¨S¦³·N¨£¤~¯à¶¶§Q¥Ó³ø¥Í®Ä¡A ÁÙn¿ì²z©Ó¾P¡A³o¼Ë¤l¯à°÷¨Ó±o¤Î¦b11¤ë¤¤¦¯¤½¥¬3Q©u³ø«e§¹¦¨¶Ü¡H ´Nºâ¯uªº¦p¦¹¤õ³t¡A¯à¦b11¤ë¤¤¦¯«e§¹¦¨©Ó¾P¦n¤F¡A¤]n¬Ý¬Ý·|p®v¹ï¦¹´Á«á¨Æ¶µ¡]9/30¥H«á¤~µo¥Íªº¨Æ¶µ¡^ªººA«×¡C ªG¯u¦p¦¹¡A¨º3Q©u³ø¤£´N¦³·¥¤jªº¥i¯à¡A·|±¼¨ì3¤¸¥H¤U¡H5¤¸¥H¤U¬O¥þÃB¥æ³Î¡A3¤¸¥H¤U¡A¥i¬On¦A¤À½L¥æ©öªº¡I ¨º¹ïªÑ»ù¤£¬O¤S¤@«À»¡H Ó¤H·Qªk¡AÂԨѰѦҡC |
|
|
·|û¡GÀ³µL©Ò¦í10144738 µoªí®É¶¡:2019/8/23 ¤W¤È 09:21:24²Ä 1309 ½g¦^À³
|
¥[ªo ¥[ªo ¥[ªo |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/8/23 ¤W¤È 09:08:46²Ä 1308 ½g¦^À³
|
To ¦U¦ì·à¤Í, ¬Ý¤j®a«Ü¼ö¤ß¤À¨É¨È·à±d¦UºØÃĪº¥¼¨Óªº²L¤O¡A·Pı¬O«Ü¤£¿ù¡A¤£¹L¥Ø«eÁÙ¬On¦^¨ì²{¹ê±¡AªÑ»ùª½ª½¸¨¡A¤½¥qµo¤F¤@½g¸É¥R»¡©ú¡A»¡¦]¬°¨ü©óªk¶Q¥¼¯à©ó2019/09/27«e¦A¦¸°eADR¼W¸ê¥Ó½Ð¡A¤½¥qÁÙ¬OºÉ¤O»PÃÒ´Á§½·¾³q¡A§Æ±æ¥i¥H¦b2019/09/27«e¦A¦¸¥Ó½Ð°e¥ó¡A°ÝÃD¬O³oÓ¥u¬O°e¥ó¦Ó¤w¡A´NºâÅý§A°e¤F¡A¼f¬d³q¹LADR¼W¸ê¤]ÁÙ»Ýn¤@¬q®É¶¡¡AÃø¹D¤½¥q°ª¼h¹ï©ó¶Ò¸ê¥u¯à´Á±æADR¼W¸ê¶Ü?¤£¯à³z¹L±ÂÅv©Î¬O¨p¶Ò¥ý¤Þ¶i¤@µ§¸êª÷¸Ñ¨M¿U¬Ü¤§«æ¶Ü? ³o¼Ën¤½¥qªºªÑªFµ¥¨ì¤°»ò®ÉÔ©O? ÁÙ¬O§Æ±æ¤½¥q¯à°µ¤@¨Ç¨Æ±¡¡A¦Ó¤£¬O¥Îµ¥«Ýªº¤è¦¡¡A¥Ø«eªÑ»ùµuµu¤£¨ì¤@Ó¤ë¤w¸g±q20¶^¨ì§Ö¶^¯}²¼±»ù¤F¡Aª¾¹D·sÃĤ½¥q¤£¥i¯à¹ê¬I®wÂêѡA¦ý¬O§Úı±o¤½¥q°ª¼hÁÙ¬O»Ýn°µÂI¬Æ»ò¨Æ±¡Ã¦íªÑ»ù¡A²¦³º¤§«eADR¼W¸ê¬O¤½¥q°ª¼h±Â·N°h¦^ªº¡A¤§«e¥xÆW³oÃ䪺¥DºÞ¤]¦³´£¿ôªÑ»ù²bȪº¨Æ±¡¡A³o¨Ç¥~°êÄy¥DºÞ¦]¹ï¥xÆW³oÃäªk³W¤£¼ô±x¡A©Ò¥H¨S¦³«Ü¦b·N¡Aµ²ªG¦b¸Ñª¼¤§«eµo¥Í¶^¯}²bÈ5¤¸¡AÅܦ¨¥þÃB¥æ³ÎªÑ¡A³oÂI§Úı±o¯uªº«Ü¤£À³¸Ó¡AÅý¥xÆW³oÃ䪺§ë¸ê¤H²`¨ü·l¥¢¡A¤]¨S¦³¬Ý¨ì¤½¥q°ª¼h¥X¨Ó¹ï³o¶¡¨Æ±¡»¡©ú¡A°²³]¦]¬°¥~°ê§ë¸ê¤H·Qnµ¥¨ì¸Ñª¼µ²ªG¥X¨Ó¤§«á¤~¨M©wn¤£n§ë¸ê¡A¨ºÀ³¸Ó»°§Ö´M§ä¨ä¥LªººÞ¹D¡Aºû«ù²bȤ~¬O¡AÅܦ¨³o¼Ëªº§½±¡A§Ú·Q¥xÆW³oÃ䪺§ë¸ê¤H«Ü¦h¤HÀ³¸Ó¤£¯à±µ¨ü§a¡AªÑ»ù¤£¬O¦]¬°¸Ñª¼¥¢±Ñª½ª½¸¨¡A¦Ó¬O¦]¬°¼W¸ê¨S¨ì¦ì¦Ó¶^¤£°±¡A¥H«e³Å«i°õ¦æªø¡AÁÙ·|©ê«èªÑ»ù¤Ó©e©}¡A³Ìªñ¤]³£¨S¬Ý¥L¥X¨Ó»¡¸Ü¤F¡A¥u§Æ±æ¤½¥q°ª¼h¯à»°ºò°µ¤@¨Ç¨Æ±¡¡AæíªÑ»ù¡A¦pªG¯uªº¦³¨ä¥LºÞ¹D¦b¶i¦æ¶Ò¸ê¡A¤]¥i¥H¸ò§ë¸ê¤j²³»¡©ú¤@¤U¶i«×¡AÅý§ë¸ê¤H¦w¤ß¡A§Æ±æ¨È·à±d¯àÄ~Äò¥[ªo¤F¡C Thanks, |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/8/23 ¤W¤È 07:00:31²Ä 1307 ½g¦^À³
|
¬ü°êÓ¤H«OÀI²[»\²v«Ü°ª¡A¹³¤¤¸Îªº·R´þ¯f须ªø´Á¤ä¥I¡A¨C¦~11¸U¬ü¤¸¡A«OÀI(°ê®a/¨p¤H)¤½¥q¡A·|¥I95%.Ó¤H¥I5%. ¥h¤¤¸Î¥h¦~©Î«e¦~°Q½×区¡A¦³¸Ô²Ó¸ê®Æ¡C 欧¬w¹³¥xÆW¦³°·«OÅé¨t¡AÓ¤Ht¾á«Ü¤Ö¡C Á`¤§ÃÄ»ù¤W没¤°»ò¤j°ÝÃD |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/8/23 ¤W¤È 12:27:04²Ä 1306 ½g¦^À³
|
§ó¥¿ The 2017 price for Rydapt was $133.84 for each 25mg capsules. The recommended dose for a patient with acute myeloid leukemia (AML) is 4 capsules The annual costs for AML is $195,405 per year |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/8/23 ¤W¤È 12:20:16²Ä 1305 ½g¦^À³
|
¥t¥~¤@Áû«æ©Ê°©Åè©Ê¥Õ¦å¯fÃĪ«Rydapt¡A¤@¦~ÃÄ»ù19.5¸U¬ü¤¸¡C 2017 price for Rydapt was $133.84 for each 25mg capsules. The recommended dose for a patient with acute myeloid The annual costs for AML is $195,405 per year |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/8/22 ¤U¤È 11:48:54²Ä 1304 ½g¦^À³
|
«æ©Ê°©Åè©Ê¥Õ¦å¯fFLT3¼Ð¹vÃĪ«gilteritinib¡A¦b¬ü°ê¹s°â»ù30¤Ñ2.25¸U¬ü¤¸¡A¤@¦~27¸U¬ü¤¸¡A©t¨àÃÄ»ù¯uªº¬O¤Ñ»ù¡A®z¶Õ±Ú¸s¦p¦ó¥I¾á±o°_ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/8/22 ¤U¤È 09:17:05²Ä 1303 ½g¦^À³
|
¨È·à±d ASLAN003 ¬°¤@¤fªA±j®Äªº¤G²B¨Å²M»Ä²æ²B酶(DHODH)§í¨î¾¯¡A¥i±æ¦¨¬°«æ©Ê°©Åè©Ê¥Õ¦å¯fªvÀø»â°ì¤¤¤§¦P¯Åº¨£Àøªk, ¤w¨ú±o¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)±Â¤©¤§ AML©t¨àÃĸê®æ»{©w¡C 20¦~¨Ó«æ©Ê°©Åè©Ê¥Õ¦å¯f¶È¦³3Áû¼Ð¹vn³QFDA®Öã ³£¬OÂê©w±Ú¸s¸û¤pªº¨È«¬ ,¤´¦³«Ü¤jÂåÀø»Ý¨D¥¼³Qº¡¨¬ www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html ¬ü°ê«æ©Ê°©ÀH©Ê¥Õ¦å¯f²Îp About 21,450 new cases of acute myeloid leukemia (AML). Most will be in adults. About 10,920 deaths from AML. Almost all will be in adults. «æ©Ê°©ÀH©Ê¥Õ¦å¯f¥þ²y¥«³õ www.marketwatch.com/press-release/the-global-market-for-acute-myeloid-leukemia-2019-to-2024---market-to-exhibit-a-cagr-of-14---researchandmarketscom-2019-03-19 |
|
|
·|û¡GÀ³µL©Ò¦í10144738 µoªí®É¶¡:2019/8/22 ¤U¤È 04:03:43²Ä 1302 ½g¦^À³
|
¥[ªo |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/8/22 ¤U¤È 03:19:50²Ä 1301 ½g¦^À³
|
To ©t¨àÃĸò¤Ñ©R¤j, ¬Ý¨ì¬O¬üªL¶Rªº¡A¤ß¸ÌÁÙ¬O¦³ÂI¤£½ñ¹ê¡A¤£½T©w³o¦¸¬üªL¬O¯uªº¶R¨Óªø´Á§ë¸êªº¡AÁÙ¬O±q¥xÆW³oÃä¶R¶iÂà´«¨ì¨ìADR¥hÁÈ®t»ù©O? ³o¨Ç¥~¸ê¨ä¹êÁÙ·|¦Y¨§»Gªº¡A¤§«e¬üªL¤j³£¬O°µµu½u¡A©Î¬O³z¹LADRÂà´«¨ÓÁÈ»ù®t¡A¥i¯àÁÙ¬OnÆ[¹îÓ´X¤Ñ¡A¥Ø«e´X¤ÑADRÂà´«¼Æ¶q³£¨S¦³´î¤Ö¡AÁÙ¨S¦³¬Ý¨ì¦³¥xÆWÂà´«¨ì¬ü°ê¥h½æªº¡Aı±o¦AÆ[¹îÓ´X¤Ñ·|¤ñ¸û©ú®Ô¡C¤@ÂIÂI¤p¤ß±o! Thanks, |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/8/22 ¤U¤È 03:12:31²Ä 1300 ½g¦^À³
|
www.tpex.org.tw/web/stock/3insti/daily_trade/3itrade_hedge.php?l=zh-tw ¤µ¤Ñ¥~¸ê¶R¶W400±i. ¬üªL ¨é°Ó¤ÀÂIӪѶi¥X ¬üªL ¨é°Ó¤ÀÂI¥þ³¡ÓªÑ¾Þ§@ÁZ®Ä/Àò§Q¤ÀªR ¤é´Á ¶R¶i±i¼Æ ¶R¶i§¡»ù ½æ¥X±i¼Æ ½æ¥X§¡»ù ¦¬½L»ù ¶R½æ¶W ¦¨¥æ¶q ¦¨¥æ¦û¤ñ ¤j¶q¥æ©ö´£¥Ü 2019/08/21 228 11.42 0 0.00 12.00 228 3,208 7.11 % ¤j¶R/¹dÃB¥æ©ö 2019/08/20 324 12.00 0 0.00 12.00 324 385 84.16 % ¤j¶R/¹dÃB¥æ©ö 2019/08/19 175 13.30 0 0.00 13.30 175 197 88.83 % ¤j¶R/¹dÃB¥æ©ö histock.tw/stock/brokertrace.aspx?bno=1440&no=6497 ¬üªL«e¤T¤Ñ¤w¶R727±i ¤µ¤Ñ¦p¥i¤´¬O¬üªL727+400? ¨È·àCEO ¥X¦Û¬üªLÃÒ¨é Carl Firth °õ¦æªø Carl Firth³Õ¤h¬°¨È·à±d¤½¥qªº³Ð¿ì¤Hº[°õ¦æªø¡C Carl Firth³Õ¤h¦b³Ð¿ì¨È·à±d«e´¿¥ô¾©ó¬ü»È¬üªLÃÒ¨é (Bank of America Merrill Lynch) ¾á¥ô¨È¬wÂåÀø¥Í§Þ²£·~Á`ºÊ¡At³dÂåÀø¥Í§Þ¤½¥q¦UÃþ«¬¤§¶Ò¸ê¬¡°Ê¤Î¨ÖÁÊ¥æ©ö®×¥ó¤§¿Ô¸ßÅU°Ý¡C aslanpharma.com/zh/our-team/ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/8/22 ¤U¤È 03:09:58²Ä 1299 ½g¦^À³
|
www.tpex.org.tw/web/stock/3insti/qfii_trading/forgtr.php?l=zh-tw ¦Ñ·à¥~¸ê¶R½æª¬ªp |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/8/22 ¤U¤È 01:25:33²Ä 1298 ½g¦^À³
|
To À³µL©Ò¦í, ³sÄò¶^°±ªºªÑ²¼¡A¥»¨Ó´N¤£¤j¥i¯à¤@¤Ñ´N¤î¶^¤F¡A¥Ø«eÄw½X¤]ÁÙ¨S¦³§¹¥þ¨I¾ý¡A¬Q¤Ñ¶Rªº¤j¤á°Ê¦V¤]ÁÙ¤£©ú®Ô¡A¥[¤W¤§«e¥D¤O¥Ã©÷¤½¸Û³o¨â¤Ñ½æ¤F¤£¤Ö¡A¤£½T©w¤µ¤Ñ¦³¨S¦³Äò½æ¡A¥i¯àÁÙn¦A´X¤Ñ¡AÄw½X§¹¥þéw«á¡A¦³«H¤ßªº¦A¥[½X·|¤ñ¸û¦n¡A¦pªG¬Q¤Ñ¶Rªº¤j¤á¤µ¤Ñ³£¨S½æ¡A¨ºµu½u´N¥H¾÷·|¤îäF¡A§Æ±æ¤£n¬O¹j¤é¨R³o¼Ë¡C Thanks, |
|
|
·|û¡GÀ³µL©Ò¦í10144738 µoªí®É¶¡:2019/8/22 ¤U¤È 01:04:36²Ä 1297 ½g¦^À³
|
ÅQ¥D¯Å XX»õ¬üª÷»ùÈ Á{§É¤j¦¨¥\ ±ÂÅv¤jÃzµo Äw¸ê±À©ì©Ô ¤p¨Æ¤@¼Î ¤U¶^³£¬O²´·ú¦³·~»Ù ü¡I ¤p½ä¤ÏÂà Äò½ß ¥[ªo¥[ªo¥[ªo |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/8/22 ¤U¤È 01:03:01²Ä 1296 ½g¦^À³
|
To ¥xÁÞ¤j, ÁÂÁ§Aªº¸Ñ»¡¡A¨ü±Ð¤F! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/8/22 ¤U¤È 12:55:06²Ä 1295 ½g¦^À³
|
¸¤H¤j §Ú«Ü¤£³ßÅw¦Y¿}³á¡A¹êÅç³]p¸Ñª¼®É¾÷¥ÎOR PFS- part 1 [ Time Frame: The later of 3 months after last subject in or when 70% of the subjects (84 subjects) have experienced a PFS event ¡AORR»PPFS¤@¼Ë¡A³o¬O¸Ñª¼®É¶¡±ø¥ó¡A¤£¬O180¤Ñ |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/8/22 ¤U¤È 12:34:55²Ä 1294 ½g¦^À³
|
To ¥x¿} ¤Ñ©R¤j, ¤§«e001¦¬®×¬O¦b¤µ¦~¤@¤ëµ²§ô¡AµM«á180¤Ñ«á·|¦³µ²ªG¡A©Ò¥H¤§«e´X¦ì¤j¤j±À½×¥i¯àQ2µ²§ô´N¥i¥H¸Ñª¼¤F¡A¤£¹L¬O¤£¬O¦³©Ò¿×ªºData Lock®É´Á©O? ¹êÅç¼Æ¾Ú¦³³¬Âê¤TÓ¤ë¡A©Ò¥H¦A¦h¥[90¤Ñ¡AÅܦ¨µ²ªGnQ4¤~¥X¨Ó¡A¤¤¶¡®tªº90¤Ñ¬O§_´N¬O©Ò¿×±o¸ê®Æ³¬Âê´Á©O? Thanks, |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/8/22 ¤U¤È 12:22:36²Ä 1293 ½g¦^À³
|
¸ÕÅ礽§i¤~ª¾¹D¡Aì«h¤W¬O¶V±ß¸Ñª¼¶V°¾¦V¥¿±. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/8/22 ¤U¤È 12:07:42²Ä 1292 ½g¦^À³
|
¤Ñ©R¤j ³o¬O¦]¬°©µÔ¸Ñª¼©Ò§@ªº±À´ú¡A¨Æ¹ê¤WÂùª¼ ¸ÕÅ礽§i¤~ª¾¹D¡Aì«h¤W¬O¶V±ß¸Ñª¼¶V°¾¦V¥¿±¡A¦]¬°¹ï·Ó²Õ¬O¤wª¾¹Dªº¤ÆÀøÃÄ¡A¦s¬¡´Á¤j®a³£ª¾¹D¡C |
|
|
·|û¡G¤p©ú10146339 µoªí®É¶¡:2019/8/22 ¤W¤È 10:28:54²Ä 1291 ½g¦^À³
|
ADR¥Ø«e¬°¤î¡AÂà¦^°ê¤ºªÑ²¼¤w¦³3¤d¦h±i¡A³o3¤d¦h±iªºÃB«×ÁÙ¯à¨Ï¥Î¶Ü¡H½Ö¥i¥H¨Ï¥Î¡H¤°»ò¸ê®æªºªÑªF¥i¥Hn¨DÂনADR°Ú¡H ©|½ÐªO¤W¥ý¶i¤£§[½ç±Ð¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/8/22 ¤W¤È 10:16:26²Ä 1290 ½g¦^À³
|
¥xÁÞ¤j, ¬Y¨Ç¦¸±Ú¸s¦s¬¡´Á (mPFS mOS ) ¯S§Oªø , ¤ñ¹ï·Ó²Õªø«Ü¦h , §Ú¤@ª½¦b«ä¦Ò³o¤@Ó°ÝÃD , ³o¹ï¨È·à±d¥þ²y¼Ï¯Ã¸ÕÅç¨Ó»¡µ¥©ó¬O¥[¤WÂù«OÀI. ³o¬On¥Ó½Ð¬ü°êÃĵýªº¸Ñª¼,µ{§Ç¥²¸g±M®a·|ij. |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/8/22 ¤W¤È 09:58:32²Ä 1289 ½g¦^À³
|
To ©t¨àÃĤj, ·Pı¥Ã©÷¤½¸Û¥LÀ³¸Ó¬O³QÀ~¨ì¤F¡A³sÄòÂê¤F¤T®Ú¶^°±¡A¬Q¤Ñ²Ä¥|®Ú¥´¶}«á¡AnÆ[¹î¤µ¤ÑªºÄw½X¡A¬Q¤Ñ¶R¶iªº¤j¤á°Ê¦V¤]¬OÆZ«nªº¡A¤£ª¾¹D·|¤£·|ª£µu½u¡A¤]ȱoÆ[¹î¡A¥Ø«eªÑ»ùÁÙ¨S§¹¥þ¤îáAÁÙnÆ[¹î´X¤Ñ¡AÀ³¸Ó¤]·|¦³¤£¤Ö¦³«H¤ßªº§ë¸ê¤H³{§C¶R¶iªº¡C¸Ü»¡¬Q¤ÑADR²×©ó¤î¶^¤F¡A§Æ±æ¤µ¤Ñ¥xÆW³oÃä¤]¯àµy·L®¶§@¤@¤U! Thanks, |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/8/22 ¤W¤È 09:14:58²Ä 1288 ½g¦^À³
|
ÁÂÁÂ¥»ª©¨â¤j¥x¬W¤Ñ©R¤j¤Î¥xÁÞ¤jªº¤À¨É: §Ú¤]ı±o¦Ñ·à¹wp¦b²Ä¥|©u¸Ñª¼ªº½×ÂI,À³¬O±N«e´Á¦¬ªº¯f±w°µ¤F°ò¦]¤ÀªR,µM«á±À¦ô«á´Á©Ò¦¬ªº¯f±wªº°ò¦]ª¬ªp,¥i¯à·|¦b¦ó®É¶i¤JPD,©Ò¥H±o¨ì²Ä¥|©uªº¹w´Á(§Ú¬Oı±o·|¦b10¤ë©³¨ì11¤ë¤¤),¬Ý¨Ó³Ó²v¶V¨Ó¶V°ª... To:¸¤H¤j µØ«n¥Ã©÷-¤½¸Û¤ÀÂI,³o¤ÀÂI©ó20-22¶R¶i,¥Ø«eÂର½æ¥X,±zªº¬Ýªk¬O ? ¥H¤W¶È¨Ñ°Ñ¦Ò... |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/8/21 ¤U¤È 10:28:23²Ä 1287 ½g¦^À³
|
ÁÂÁ¤ѩR¤j»{¯uªº¤À¨É §Ú¬Ý¹LIncyte ¤G½uÁx¹DÀù¦s¬¡¦±½u ¦³°ò¦]¼Ð§âªº²Õ§O¬ù²¤PD¤ñ²v 2Ó¤ë ---10% 3Ó¤ë -- 20% 5-6Ó¤ë -- 30% 9Ó¤ë-- 40% 10Ó¤ë 50 % 12Ó¤ë 60 % 14Ó¤ë 70% 15Ó¤ë 75% 16Ó¤ë 80% 19-20Ó¤ë 90% 24Ó¤ë 100% µL°ò¦]¼Ð§âªº²Õ§OPD¤ñ²v 2Ó¤ë 45% 3Ó¤ë 50% 4Ó¤ë 60% 5-6Ó¤ë 65% 7-8Ó¤ë 80% 9-10Ó¤ë 100% Ó¤H±À¦ô¨È·à±d¤G½uÁx¹DÀù ¹ï·Ó²Õ2018¦~²Ä¤T©u¼Æ¾Ú¤w¦¨¼ô, °²³]¹êÅç²Õ»P¹ï·Ó²ÕmPFS ¤@ ¼Ë ( mPFS ³£¬O2-3Ó¤ë ) 2018¦~©³´NÀ³¸Ñª¼¤½§i¼Æ¾Ú, ¬°¦ó¤½¥q¤½§i2019¦~²Ä¥|©u¤~¸Ñª¼¤½§i¼Æ¾Ú, ®t¶Z¹F¤@¦~, ¦³«Ü¤j¥i¯à¬O¨È·à±dªxHER®a±Ú ¬Y¨Ç¦¸±Ú¸s¦s¬¡´Á (mPFS mOS ) ¯S§Oªø , ¤ñ¹ï·Ó²Õªø«Ü¦h , §Ú¤@ª½¦b«ä¦Ò³o¤@Ó°ÝÃD , ³o¹ï¨È·à±d¥þ²y¼Ï¯Ã¸ÕÅç¨Ó»¡µ¥©ó¬O¥[¤WÂù«OÀI ¨È·à±d¤G½uÁx¹DÀù´N¾ã²Õ¨Ó»¡ mPFS ¦³ 4-5Ӥ륪¥k ´N¦³¹LÃö¹F¼Ðªº¾÷·|, ¦¸±Ú¸smPFS¤£ª¾¹D·|¤£·|ÅýÂå¬É¾_Åå ? ¥H¤W¤À¨É ¥i¯à¬OÓ¤H°¾¨£ ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/8/21 ¤U¤È 08:18:14²Ä 1286 ½g¦^À³
|
¥xÁÞ¤j, ¨Ì¦pIncyte ¤G½uÁx¹DÀù¼Æ¾Ú¨Ó¬Ý,(³Ì«á¤@¦ì¨ü¸ÕªÌ¦Ü¤Ö8Ó¤ë) 47¤H¦³FGFR2°ò¦]ªÌ, Median PFS was 9.2 months , ¨ü25¤H(¨ä¤¤8Ӥ뤺¤¤³~Â÷¶}4¤H,¤]´N¸ê®ÆºI¤î,²Ä9Ó¤ë®É,¦³21¤H¥¼PD), PD22¤H PFS K-M¹Ï ²Ä8Ó¤ë¦s¬¡23¤H ²Ä9Ó¤ë¦s¬¡17¤H(¥t4¤H¦]¸ê®ÆºI¤î,¦s¬¡¤ë¥u¯àºâ8Ó¤ë) ----------- ¨È·à¦b°µHER®a±Ú§¹¾ãªºPFS/OSÂX¥R¬ã¨s¸ê®Æ¦¬¶°. ©Ò¥HQ4¸Ñª¼¥i¥H²z¸Ñ. (Incyte: 2018,07/26--- data cut date , 2018,10,22 --¤½§Gµ²ªG.) ¨È·àHER°ò¦]®a±Ú§Æ±æ¦pIncyte ¦³°ò¦]ªÌ,¯à±µªñMedian PFS was 9.2 months ,MOS 15.8 months ¨ºHER°ò¦]®a±Ú¦û70%Áx¹DÀù¥«³õ³W¼Ò¬OFGFR2¤ñ²v 8~10%, ªº9~10¿. ---------- ¦pIncyte ¤G½uÁx¹DÀù ¦³FGFR2 §Ü·½47¤H,ORR°ª¹F40%. Interim Results of fight-202, A Phase 2, Open-Label, Multicenter Study of INCB054828 in Patients With Previously Treated Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma (CCA) With/Without Fibroblast Growth Factor (FGF)/FGF Receptor (FGFR) Genetic Alterations Median PFS was 9.2 months in cohort A (Figure 5) ¡V¡V Median PFS in cohorts B and C were 2.1 and 1.7 months, respectively ¡´¡´ Median OS was 15.8 months in cohort A ¡V¡V Median OS in cohorts B and C were 6.8 and 4.0 months, respectively Figure 5. Kaplan-Meier Estimates of PFS (Assessed by Independent Reviewer) ESMO 2018: Incyte Posters ---October 22, 2018 investor.incyte.com/events-and-presentations/presentations?field_nir_tags_target_id=All&promote=All&field_nir_asset_type_target_id%5B26%5D=26&items_per_page=10&page=1 |
|
|
·|û¡G¦N¦Ì10148522 µoªí®É¶¡:2019/8/21 ¤U¤È 05:29:38²Ä 1285 ½g¦^À³
|
¡iªL§»¤å±MÄæ¡j¨È·à±d¥þÃB¥æ³Î µ¹¤F¥xÆW¤°»ò±Ò¥Ü¡H ¥Í§Þ·sÃĪѨȷà±d-KY¡]6497¡^¤½¥q¡A19¤é¦]¬°¤W¥b¦~¨CªÑ²bȧC©ó5¤¸¡A³Q¥´¤J¥þÃB¥æ³ÎªÑ¡AªÑ»ù¦]¦¹³sÄò¤T¤Ñ¶^°±¡A¨È·à±d¦b¬üªÑ±¾µPªºADR¡]¬ü°ê¦s°U¾ÌÃÒ¡^¤]¸òµÛ¤j¶^¨â¦¨¥H¤W¡C ¨È·à±d¬O²Ä¤@®a¨Ó¥x±¾µPªº¥~°ê·sÃĤ½¥q¡A¦¹¦¸ªÑ»ù³sµf«®À¤w¤Þµo¸ê¥»¥«³õÃö¤Á¡A¹ï©ó¥Í§Þ·sÃIJ£·~¤]¬O¤@¦¸¤£¤pªº¥´À»¡C ¨È·à±dÁ`³¡¦ì©ó·s¥[©Y¡A¸gÀç¹Î¶¤¤j³¡¤À¬O¦Ñ¥~¡A°õ¦æªø³Å«i¡]Carl Firth¡^´¿¥ô¬ü»È¬üªLÃÒ¨é¨È¬wÂåÀø²£·~§ë¸êÁ`ºÊ¡A¤]¾á¥ô¹Lªü´µ¯S±¶§Q±d¡]AstraZeneca¡^¨È¤Ó°Ï¨Æ·~µo®iÁ`ºÊ¡A¨ä¥L¸gÀç¹Î¶¤¤]¦³¤£¤Ö³£«Ý¹L°ê»Ú¤jÃļt¡AªÑªF¤¤¤]¤£¥F°ê¤º¥~«n§ë¸ê¾÷ºc¡C ¨â¦~«e¡A¨È·à±d¨S¦³¿ï¾Ü·s¥[©Y©Î¬ü°ê¡A¤Ï¦Ó¨M©w¨Ó¥xÆWÂd¶R¥«³õ±¾µP¡A·í®Éªº½T¤Þ°_¥DºÞ¾÷Ãö°ª«×«µø¡A¤]Åý¥xÆW¥Í§ÞªÑ§ë¸ê¤H¬Û·í®¶¾Ä¡C ¤£¹L¡A¨È·à±d±¾µP®É¾÷¤£¤Ó¦n¡A·í®É¸ê¥»¥«³õ¹ï·sÃIJ£·~ªº§ë¸êµû»ù¤w¶}©l¼@¯P¤UסA¨È·à±d¤]±q±¾µP»ù68.92¤¸¤@¸ô¤U®À¡A³Ì§C¶^¨ì21¤éªº10.8¤¸¡C ¶Ò¸ê¤£¶¶ ºØ±Ñ¦] ÁöµM¨È·à±d¥h¦~¦¨¥\¨ì¬ü°ê¨º´µ¹F§J±¾µP¡A»P¥x·LÅ馨¬°¤Ö¼Æ¦b¥xªÑ»P¬üªÑ³£±¾µPªº¥Í§Þ·sÃĪѡA¦ý¬O¡A쥻¤µ¦~6¤ë¹wp§¹¦¨¬ü°ê¦s°U¾ÌÃÒ¡]ADR¡^²{¼W®×¡A³Ì«á«o«Å¥¬¶Ò¸ê¥¢±Ñ¡A´N¦¨¬°¦¹¦¸©ì²Ö²bȶ^¦Ü3.56¤¸¡B¨Ã²_¬°¥þÃB¥æªÑªº³Ì«á¤@®Ú½_¯ó¡C ®Ú¾Ú¨È·à±d¤½¥q¥N²zµo¨¥¤H«¸¥ç´Ðªí¥Ü¡A¦¹¦¸¬ü°êADR²{¼W®×¥¢±Ñ¡A¥D¦]¬O¤½¥q¥D¤O²£«~¤G½uÁx¹DÀùªº¥þ²y©Ê¼Ï¯Ã¸ÕÅç¡A¹wp¦b¤µ¦~²Ä4©u«e´N¥i¥H§¹¦¨¡A¥Ñ©ó¦A¥b¦~´N¥i¥Hª¾¹Dµ²ªG¡A«Ü±µªñ6¤ëªº²{¼W®É¶¡¡A¦³¤£¤Ö§ë¸ê¤H¤Ï¬M¡A§Æ±æ¦~©³¸Ñª¼µ²ªG¥X¨Ó«á¦A°Ñ»P¼W¸ê¡A¤]¦]¦¹¼W¸ê®×µLªk¦b´Á¤º§¹¦¨¡A¥u¯à«Å¥¬¥¢±Ñ¡C ¨ä¹ê¡A¨È·à±d¤µ¦~²Ä1©u¨CªÑ²bÈ´N¤w¹F5.06¤¸¡A¥u®t¤@ÂIÂI´N§C©ó5¤¸¡A®Ú¾Ú¤½¥q¤º³¡«ü¥X¡A°w¹ï¤½¥qY¦C¤J¥þÃB¥æ³ÎªÑ«á¡A¹ïªÑ»ù¤@©w·|²£¥Í«À»¡A¥h¦~©³¤º³¡¥DºÞ´N¤w¸ò¦Ñ¥~°ª¼h¥DºÞ°µ¤F¥R¤À³ø§i¡A¦ý¥Ñ©ó¬ü°ê¤Î·s¥[©Y³£¨S¦³Ãþ¦ü¨î«×¡A¦Ñ¥~¥DºÞ¨Ã¨S¦³¯S§O«µø¡A¤~Åý½ÄÀ»ÂX¤j¡A¬Û·í¥i±¤¡C ¦Ü©ó¦b·sÃĶ}µo¤ÎÁ{§É¶i«×¤W¡A¨È·à±d¦b¤µ¦~1¤ë¤¤¡A¤@½uGÀùªº¤G´ÁÁ{§É¹êÅç¼Æ¾Ú¨S¦³¹F¨ìÅãµÛ®ÄªG¡A¦]¦¹¥u¯àÅfµM«Å¥¬¥¢±Ñ¡A³o¹ï¨È·à±dû¤u¤h®ð¬O¤£¤pªº¥´À»¡C¤£¹L¡A¨ì¤F2¤ë©³¡A¨È·à±d«h«Å¥¬¦¨¥\±ÂÅvªº¦n®ø®§¡A±NºX¤U·sÃÄ¿W®a±ÂÅvµ¹«nÁúBioGenetics¤½¥q¶i¦æ°Ó«~¤Æ¡A¨È·à±d¥i¥H¨ú±o200¸U¬ü¤¸Ã±¬ùª÷©M³Ì°ª1,100¸U¬ü¤¸ªº¾P°â»P¬ãµo¨½µ{ª÷¡C ¥Ø«e¤½¥q¹ï¤U¥b¦~ªº²£«~¶i«×¬O¡A9¤ë©³±N©ó¼Ú¬w¸~½FÂå¾Ç·|µoªí·s¼Æ¾Ú¡A¤U¥b¦~®i¶}¤¤««×²§¦ì©Ê¥Ö½§ª¢±wªÌªº¸ÕÅç¡AÁÙ¦³¦~©³«eÁx¹DÀùÁ{§Éµ²ªGªº¤½¥¬¡C ¤½¥q½L¾ã ¦A¥Xµo ¹ï©ó·sÃĶ}µo¿N¿ú³t«×¤Ó§Ö¡A¨È·à±d¸gÀç¹Î¶¤¤]°µ¤F§V¤O¡A¤µ¦~ªì«Å¥¬µ¦²¤©Ê«¾ã¤½¥q¬[ºc¡A°£¤FÁY½s¤T¦¨¤H¤O¥~¡A¤]±N¸ê·½¶°¤¤©óÁx¹DÀù¡B«æ©Ê°©Åè©Ê¥Õ¦å¯f¤Î²§¦ì©Ê¥Ö½§ª¢µ¥¤T¶µ¥DnÁ{§É¶µ¥Ø¡A¹w´ÁÂÇÀç¹B¦¨¥»¬å¥b¡A½T«O«áÄòÀç¹BÄò¯è¤O¡C¦¹¥~¡A쥻¨Ý¸³¨Æªø¤Î°õ¦æªøªº³Å«i¡A¸³¨Æªø¾°È¤]¥æµ¹¥t¤@¦ì¸³¨ÆAndrew Howden¡A³Å«i¥u±M¤ß°µ°õ¦æªø¡C ¦¹¥~¡AY±q¨È·à±d¦b¨È¬wªº¸gÀ給²¤¨Ó¬Ý¡A¤]¤£¯à»¡¦³¤°»ò¤j°ÝÃD¡C¨Ò¦p¤½¥q³Ìªì´N¬OÂê©wµo®i¨È¬w¥«³õ¬°¥D¡A¹³¤½¥q¥D¤O²£«~ÁxºÞÀù¦b¨È¬w«Ü²±¦æ¡A¦ý¦b¼Ú¬ü¯f±w«Ü¤Ö¡B¬O¨S¦³Ãļt·Q§ë¤Jªº¡u©t¨à¡v¯e¯f¡C ¦¹¥~¡A¨È·à±d¦b¬P¡B¥x¡BÁú¡B¤¤µ¥°ê®aªºµ¦²¤¡A¤]¥R¤À¹B¥Î¦U°êªº¤ñ¸ûÀu¶Õ¡A¨Ò¦pÁ`³¡³]¦b·s¥[©Y¡A¥þ^¤åÀô¹Ò¹ï¼Ú¬üû¤u³Ì¤Íµ½¡A¤S¦³¦nÂå°|¤Î°·¥þªk³Wµ¥±ø¥ó¡A¦Ü©ó¥xÆWÁ{§É¹êÅç°µ±o³Ì¦n¡A¥[¤W¥xÆW¥Í§Þ¸ê¥»¥«³õµo®i®É¶¡ÁöµM¤£ªø¡A¦ý§ë¸ê¤H¹ï¥Í§ÞªÑ´±¶R´±°l¡A³Ì¾A¦XªÑ²¼¤W¥«¡C ¦Ü©ó«nÁú¬O¤j¥ø·~·í¹D¡A¦]¦¹¨È·à±dµ¦²¤¤W¥H±ÂÅvµ¹¤j¶°¹Î¬°¥D¡A¨Ò¦p¥|¦~«e±ÂÅvµ¹²{¥N¶°¹Î¤Î¤µ¦~±ÂÅvµ¹BioGenetics¤½¥q¡A¥Hµ²·ù¤j°]¹Î°µ¦b¦a¸gÀç¡A¨Ã¦ø¾÷¥´¶i¥]¬A¤¤°êµ¥¦a¨È¬w¥«³õ¡A¤]ºâ¬O«Ü¦X²z©ú½Tªºµ¦²¤¡C ·sÃÄ«e´ºÀ£¤O´ú¸Õ Á`µ²¨Ó¬Ý¡A¨È·à±dªº¬ãµoºâ¬O²Å¦Xì¥ý¶i«×¡A¦ý¥Ñ©ó¬O¥~°Ó¤½¥q¡A±M·~¸g²z¤H¤S³£¬O°ªÁ~ªº¦Ñ¥~¡A¿N¿ú³t«×¤ñ¥xÆW¥ø·~§Ö¡A¦Ó³ÌP©Rªº«h¬O¸êª÷¶Ò¶°¤£¶¶§Q¡A³Ì«á¾ÉP²bÈÁY¤ô¡AªÑ»ù¸òµÛ¤j¶^¡C ±q³o¨ÇÂk¯Ç¦]¯À¨Ó¬Ý¡A³o®a¥xÆW¿W¤@µL¤Gªº¥~°Ó·sÃĤ½¥q¨È·à±d¡A¥¼¨ÓÁÙ¦³¤@¬q¨¯Wªº¸ôn¨«¡A¥þÃB¥æ³ÎªÑªº³±¼v¦Ü¤Ön«ùÄò¨ì¦~©³¡A¦]¬°³Ì§Önµ¥¨ì¦~©³«eÁx¹DÀùªº¦¨ÁZ´¦¾å¡A¤~¥i¯à¦³¦A¦¸¶Ò¸êªº¾÷·|¡C ¦Ü©ó¹ï¤w³Æ¨ü¥´À»ªº¥xÆW¥Í§Þ·sÃĪѧë¸ê¤H¨Ó»¡¡A³o¤S¬O¤@¦¸ÄY®æªºÀ£¤O´ú¸Õ¡A¦b¾ú¸g³\¦h§QªÅ¥´À»«á¡A§ë¸ê¤HÅãµM»Ýn¥ø·~ú¥X§ó¦h§ó¦nªº¦¨ÁZ³æ¡A¤~¯à¯u¦a¬Û«H·sÃĬO¤@Óȱo«H¿à»P§ë¸êªº²£·~¡C |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2019/8/21 ¤U¤È 05:01:21²Ä 1284 ½g¦^À³
|
¤µ¤Ñ¸gÀÙ¤é³ø¦³¤@½g¨È·à±d³ø¾ÉÁÙ¤¤ªÖ ºô¸ôgoogle¤@¤U´N¥i¥H¬Ý¨ì |
|
|
·|û¡G¥ß§»10147985 µoªí®É¶¡:2019/8/21 ¤U¤È 02:42:09²Ä 1283 ½g¦^À³
|
¸¤H¤j¡G ³o´X¤Ñ¬Ý°_¨ÓÀ³¸Ó¬O¤jªÑªF·QÅý¯S©w¤H¤h¤JªÑªº·Pı¡A¤£µMªº¸Ü¤£¥i¯àÀ£§CªÑ»ù¡A¦]¬°¤µ¤Ñ³Ì§C10.85¡Aµ¥©ó¬O·íªì¤jªÑªFªº¦¨¥»»ù10¤¸¡A¥H¤U¬O¥»¤H±À¤å¡C |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/8/21 ¤U¤È 01:38:01²Ä 1282 ½g¦^À³
|
³Ì«á¦¬¥½L¡A½L¤¤ÁÙ¦³Â½¬õ¹L¡A¤£ª¾¹D²Ä¤@½L¬Oþ¤@Ó¤j¤á¶Rªº©O? ±ßÂI¦A¨Ó¬Ý¤@¤UÄw½X¡AÄ~Äò¥[ªo¤F! |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2019/8/21 ¤W¤È 09:44:09²Ä 1281 ½g¦^À³
|
¦Ü¤ÖÅý·Q¨«ªº¥i¥H¨« ¦º½Þ¤£©Èºu¤ô¿S §Ú¨ÌµM¤£Â÷¤£±ó ÁöµMÁÙ¦³¤@¬q¸ôn¨« ¥[ªo¤F ·PÁ ¦U¦ì«e½ú¥ý¶iªº¤£§[¤À¨É ·P®¦ |
|
|
·|û¡G§ë¸ê¬ö«ß10145266 µoªí®É¶¡:2019/8/21 ¤W¤È 09:13:15²Ä 1280 ½g¦^À³
|
Ãz¶q¤F Â÷²Ä¤@°¦¸}¤£»·¤F |
|
|
·|û¡G³¯Ë¢¦w10144680 µoªí®É¶¡:2019/8/21 ¤W¤È 09:11:50²Ä 1279 ½g¦^À³
|
¤Ó´Î¤F¡I¥[ªo |
|
|
·|û¡GÀ³µL©Ò¦í10144738 µoªí®É¶¡:2019/8/21 ¤W¤È 09:06:20²Ä 1278 ½g¦^À³
|
¥[ªo |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/8/21 ¤W¤È 09:03:13²Ä 1277 ½g¦^À³
|
²Ä¤@½L1948±i. ¤j³æ¦¨¥æ. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/8/21 ¤W¤È 04:25:17²Ä 1276 ½g¦^À³
|
¨È·à±dªº¹ï·Ó²Õ¬O³æÃÄ¡AORR³q±`·|¤ñÂù¤ÆÀø§C¤£¤Ö¡C ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/7/31 ¤U¤È 02:03:40²Ä 1147 ½g¦^À³ ¥xÁÞ¤j ¼ÒÀÀ5²Õ ORR¹LÃö,P<5%¤§ª¬ªp , (1)°²³] ORR , ¹ï·Ó²Õ 4¤H(4/63=6.3%)¡A¹êÅç²Õ14¤H (14/64=21.9%) (2)°²³] ORR , ¹ï·Ó²Õ 3¤H(3/63=4.8%)¡A¹êÅç²Õ12¤H (12/64=18.8%) (3)°²³] ORR , ¹ï·Ó²Õ 2¤H(2/63=3.2%)¡A¹êÅç²Õ10¤H (10/64=15.6%) (4)°²³] ORR , ¹ï·Ó²Õ 1¤H(1/63=1.6%)¡A¹êÅç²Õ8¤H (8/64=12.5%) (5)°²³] ORR , ¹ï·Ó²Õ 0¤H(0/63=0%)¡A¹êÅç²Õ6¤H (6/64=9.4%) ¦]¹ï·Ó²Õ³æ¤ÆÀø ORR <=1.6%ªº¾÷²v«D±`°ª.(¬Ý¹L¼ÆӨƫá¤ÀªRӮסA¦bµL§Ü·½¿zÀˤU,ORR ¬Û¹ï§C) ORR ,¥þ³¡(127¤H)Y¦³9¤H ,¸Ñª¼¦¨¥\²v¬Û·í°ª. µù: )¹ï·Ó²Õ<5¤H¡A¥H¥d¤è¤À°t¥|¤è®æ¤§®Õ¥¿¤½¦¡pºâ.¤@ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/8/20 ¤U¤È 11:53:41²Ä 1275 ½g¦^À³
|
¤G½uÁx¹DÀùCape+CisÁp¦X¤ÆÀøÀø®Ä www.ncbi.nlm.nih.gov/m/pubmed/28848173/ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/8/20 ¤U¤È 11:24:36²Ä 1274 ½g¦^À³
|
¥xÁÞ¤j, n¬Ý§Ü·½HER®a±Ú¦û¹êÅç²Õªº¤ñ²v¤ÎIHC+2/+3ªº¤ñ²v. Ó¤H²q ¨È·à±d¦b«÷ORR ¾÷·|°ª, ¥unORR PR , 6 ¤H, PFS/OS ªø¤@ÂI. ---------- ¦pIncyte ¤G½uÁx¹DÀù ¦³FGFR2 §Ü·½47¤H,ORR°ª¹F40%. Interim Results of fight-202, A Phase 2, Open-Label, Multicenter Study of INCB054828 in Patients With Previously Treated Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma (CCA) With/Without Fibroblast Growth Factor (FGF)/FGF Receptor (FGFR) Genetic Alterations Median PFS was 9.2 months in cohort A (Figure 5) ¡V¡V Median PFS in cohorts B and C were 2.1 and 1.7 months, respectively ¡´¡´ Median OS was 15.8 months in cohort A ¡V¡V Median OS in cohorts B and C were 6.8 and 4.0 months, respectively Figure 5. Kaplan-Meier Estimates of PFS (Assessed by Independent Reviewer) ESMO 2018: Incyte Posters ---October 22, 2018 investor.incyte.com/events-and-presentations/presentations?field_nir_tags_target_id=All&promote=All&field_nir_asset_type_target_id%5B26%5D=26&items_per_page=10&page=1 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/8/20 ¤U¤È 11:03:58²Ä 1273 ½g¦^À³
|
¤Ñ©R¤j ¨È·à±d¤G½uÁx¹DÀùÀø®Ä¦³¥i¯à¶W¹L¥Ø«e¤@½uÁx¹DÀùÀø®Ä ? ¥Ø«e¤@½uÁx¹DÀùÀø®Ä Cisplatin plus Gemcitabine PK Gem Median PFS 8.0 mo / 5.0 mo Median overall survival (OS) 11.7 mo / 8.1 mo 2019 ASCO¤j·|³ø§i¤FPD-1 ¤G½uÁx¹DÀù¬ã¨s ( µ²ªG¤]¬O¥O¤H¥¢±æ ) KEYNOTE-158( Á{§É¤G´Á)¬ã¨sªºµ²ªGÅã¥Ü¡AORR¬°5.8%¡]6/104)¡A¤¤¦ì¼Æ OS 7.4Ó¤ë ©M ¤¤¦ì¼Æ PFS 2 Ó¤ë «Ü¦h¿³ÂdªÑ²¼n¤WÂd¨D¤§¤£¥i±o,¦]¬°Âd¶R¤¤¤ß¹ï¤WÂdn¨D°ª, ¥u¦n¤U¿³Âd¥h§O°êµo®iÄw¸ê, ¨È·à±d¬O²Ä¤@®a¦b¬ü°ê»P¥xÆWÂù±¾µPªº¥xÆW¥Í§Þ¤½¥q¡A¤]¬O²Ä¤@®a¦b¬ü°ê±¾µPªº·s¥[©Y¥Í§Þ¤½¥q,¨È·à±d¦n¤£®e©ö¦b¥x¤WÂd,·|§Q¥Î¥xÆW·s¥[©Y¬°¬ãµo°ò¦a³s±µ¤¤°ê»P¼Ú¬ü¤éÁú, Ó¤H»{¬°°£«D³Q¼Ú¬ü¤jªº¥Í§Þ¤½¥q¨ÖÁʤ~¦³Â÷¶}¥xÆWªº¥i¯à ¥H¤W¬OÓ¤H¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/8/20 ¤U¤È 09:59:52²Ä 1272 ½g¦^À³
|
¤§«e¼ÒÀÀORR ¹ï·Ó组0¤HPR ¹êÅç组6¤HPR ³o¼Ë´N·|¹LÃö¡C »¡¹ê¦bORR¹LÃöªº¾÷·|°ª¡C6¤HPR´N¦³¾÷·|¹LÃö¡A¨ä¦s¬¡¦pIycyteªº¤G´Á¡A·|¶W¹L15Ó¤ë¡APFS¶W¹L9Ó¤ë PFSÅܼƤñ¸û¤j¡AYHER®a±Ú§Ü·½¤ñ²v¤£°ª¡AIHC+2/3¤£û{¦h¡A³£·|¼vÅTÃĪ«ªvÀø®ÄªG¡C |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2019/8/20 ¤U¤È 08:11:38²Ä 1271 ½g¦^À³
|
¦b³oÓª©³o»ò¤[ §Úı±o¤j®a³£¬O¬°·à¤l¦n ©t¨àÃĤj´£ªº¤U¥«¤]¤£¬OÀH«K¶Ã·Q ¦]¬°ªñ¦~¥Í§ÞªÑ¤]¤£¤Ö¤U¥«ªº ¦ý´Nºâ¤U¥«¡A¥un·|¦A¥~¦a¤W¥«¡A¨ä¹ê¤]¤£·|«ç¼Ë ¥un§A¤£½æ¡A¥¦¨ì°ê¥~¤W¥«¡A¤½¥q·|À°§AÂà´«¹L¥h·s¤W¥«¦aªºªÑ²¼ ¤£¹L¡A»¡¤F³o»ò¦h §Ú¤]¤£»{¬°¨È·à±d·|¨«³o±ø¸ô ¤@¯ë·|³o»ò°µªº¬O¦]¬°¦b¥xÆWÄw¤£¨ì¿ú(¿³Âd©~¦h) ·à¤l°ê»Ú¦W«×°÷¡AÁÙ¦³ÓADR¦b¬ü°ê µP³£ÁÙ¨SÅu´N´²³õ¨«¤H¬O¤£¥i¯àªº ¥Ø«eªÑ»ù¨«¨ì³o³Ì«nªº ¤£¬O¥þ¤£¥þÃB¥æ³Î¡A¤]¤£¬O¶^°±º¦°± ¦Ó¬O¤G½uÁx¹DÀù¹L¤£¹L ¸¤H¤j¤@ª½Ãöª`ªº¤jªÑªF¬°¦ó±¾¤j½æ³æ³oÂIÅý§Ú¦³¨Ç³\¾á¤ß §Æ±æ²{¦b¥u¬O¾¤©ú«eªº¶Â·t §Æ±æ¤jªÑªF¥u¬O¦]¬°¯Ý¦³¦¨¦Ë¦Ó¦Ñ¯«¦b¦b |
|
|
·|û¡G¥ß§»10147985 µoªí®É¶¡:2019/8/20 ¤U¤È 06:12:27²Ä 1270 ½g¦^À³
|
¸¤H¤j¡A§ÚªºÀç·~û¤µ¤Ñ¥~¥X¡A©Ò¥HµLªk¬d¸ß½æ®a¡A¦ý¬O¤µ¤Ñ¬üªL¤S¶R¶W¡A¥i¬O¦³¼W¥[¤@®aµØ«n¥Ã©÷¤½¸Û½æ¥X100±i¡]¥Ø«e³Ñ¤U1235±i¡^¡An¬Ý©ú¤Ñªºª^³ò¤~¤U©w½×¡C |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/8/20 ¤U¤È 04:39:15²Ä 1269 ½g¦^À³
|
To ¤Ñ©R¤j¡A ±z¤§«e´£¨ìªºÓ¤H«Øij¨È·à±d¬O§_¥i¥H¤½§G¥Ø«e¥H²ÖpªºPD¤H¼Æ¡A³oÂI¥i¥H³Ò·Ð±zÄ~ÄòÀ°¦£°lÂܨçó·sª¬ªp¶Ü? ÁÙ¦³¤µ¤Ñ¦³¸òµo¨¥¤H²á¨ì¡A¤U¥«ªº±¡ªp¡A°ò¥»¤W¬O¤£¤j¥i¯àµo¥Í¡A¦pªG¥xÆW³oÃä¤U¥«¡A¨ºADR¤]·|¤@¨Öµ²§ô®ø¥¢¡A³o¹ï¤½¥q¥¼¨Ón¼W¸ê¬O³z¹LADR¼W¸êµo¦æ¬O¤£¤¹³\¥xÆW³oÃä¤U¥«ªº¡A²¦³ºADR¬O®ü¥~¦s°U¾ÌÃÒ¡A°²³]쥻¥i¥HÂà´«ªº¥xªÑ®ø¥¢¤F¡A¨ºADR¤]´N·|¸òµÛ¤]¤U¥«¡A§Ú·Q¤½¥q°£¤F¬Q¤Ñµo¤½§i¡AÀ³¸ÓÁÙ¦³¦A·Q¨ä¥L¹ïµ¦¡A²¦³ºn«ì´_²bȳ̧֪º´N¬O¦³¤@µ§¦¬¤J¡A³o¼Ë¤~¦³¥i¯à¨Ó±o¤Î¦bQ3°]³øµ²ºâ«e«ì´_²bȦb5¶ô¥H¤Wªº¡A§Æ±æ¤½¥q¦AÄ~Äò§V¤O¤F¡C Thanks, |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/8/20 ¤U¤È 03:27:26²Ä 1268 ½g¦^À³
|
www.tpex.org.tw/web/stock/3insti/daily_trade/3itrade_hedge.php?l=zh-tw ¤µ¤é¥~¸ê¶R¶W324±i |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/8/20 ¤U¤È 02:32:37²Ä 1267 ½g¦^À³
|
To ¥ß§», ¥i¥H¦A³Ò·Ð±z³oÃäÀ°¦£¬Ý¤@¤U¡A¤µ¤Ñ½æ³æ¬Oþ¨Ç¨é°Ó±¾ªº©O? ¬O§_ÁÙ¬O¨º¥|®a©O? ³Í°ò¡B¸s¯qª÷¹©©µ¥¡B¤j©M°ê®õÁÙ¦³¼¯®Ú¤j³q¡A³Â·ÐÅo! Thanks, |
|
|
·|û¡G¦N¦Ì10148522 µoªí®É¶¡:2019/8/20 ¤U¤È 02:25:16²Ä 1266 ½g¦^À³
|
¬Û«H¤j®a³£¬O§Æ±æ¦Û¤vªº§ë¸ê¯à¦³¦nªº¦^À³¡A¤~·|¦³Ó§Oªº·Qªk¡C ¬Ý¬Ý¤µ¤Ñªº¶R³æ¡A¦³³æµ§77±i¸ò248±i¡C ¾ß«K©yªºÁÙ¬O¤j¦³¤H¦b~ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/8/20 ¤U¤È 12:50:56²Ä 1265 ½g¦^À³
|
©t¨àÃĤj ¨CÓ¤H³£¥i¥H¦hªÅ½×z¡A¥un¨¥¤§¦³²z¡A§Úª¾¹D§A¬O¬°¤j®a¦n¡A¥u¬O§Aªºµo¨¥·|Åý¤j®a »~¸Ñ¡A¯u¹êªº±¡ªp¬O¤½¥qn¼W¸ê©Î±ÂÅv¡A ¤£·|´î¸ê¡A¤]¨S¦³n¤U¥«ªº³W¹º¡AÁ{§É¶i®i«ö¹w©w®Éµ{¶i¦æ¡C |
|
|
·|û¡G¥ß§»10147985 µoªí®É¶¡:2019/8/20 ¤U¤È 12:50:49²Ä 1264 ½g¦^À³
|
¦U¦ì¤j¤j¡G¤@°_¥[ªo§a¡I |
|
|
·|û¡GÀ³µL©Ò¦í10144738 µoªí®É¶¡:2019/8/20 ¤U¤È 12:49:53²Ä 1263 ½g¦^À³
|
¤£¤U¥«/¤£n³Q§C»ù¦¬ÁÊ/¤£n§C»ù¨p¶Ò(«Ü¦³¥i¯à)... ¶^¦¨³o¼Ë(¤j¯f),n¦n¤]¤£®e©ö ¼Æ¾ÚÁÙ¨S¥X¨Ó±ÂÅv®e©ö¶Ü¡H¥i¯à¤]n¨ì©ú¦~¡A¤é¤lÃø¼õ ¥[ªo |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/8/20 ¤W¤È 11:34:37²Ä 1262 ½g¦^À³
|
¨ä¹êµ¥¤F¨º»ò¤[ªº¤G½uÁx¹DÀùªº¸Ñª¼,Y¯u¨Sµ¥¨ì¦b¥xÆW¤W¥«Âdªº¨È·à±d¨Ó°µ¸Ñª¼µ²ªG,¤ß¸Ì¯uªº·|«Ü¹Ã,©Ò¥H§Æ±æ¦Ñ·à¯à°O¨ú±Ð°V,§Ö§ÖÅý¤½¥qªºªv²z¨B¤J¥¿y,¤£µM§ë¸ê¤H¨C¤Ñ¬Ý¶^°±¹ê¦b¬O¤ßÅåÁx¸õ°Ú~~~~ ¥H¤W¨Ñ°Ñ¦Ò.... |
|
|
·|û¡GÀ³µL©Ò¦í10144738 µoªí®É¶¡:2019/8/20 ¤W¤È 11:00:06²Ä 1261 ½g¦^À³
|
¹ï©ó (((¨S¦³¨}¤ß))) ¤§»¡ À³¹Dºp ¥[ªo |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/8/20 ¤W¤È 10:55:17²Ä 1260 ½g¦^À³
|
è観¥´¹q¸Ü»P «¸µo¨¥¤H¥æ½Í. ½T»{²Ä¥|©u¸Ñª¼ªº®Éµ{¬O¸g±M®a·|ij¨M©w. ¥¼¨Ó±M®a·|ijY½T»{¸Ñª¼¤é´Á,¤½¥q·|§Y®É¤½§G. Ó¤H«Øij¨È·à±d¬O§_¥i¥H¤½§G¥Ø«e¥H²ÖpªºPD¤H¼Æ, ¨Ì·ÓÁ{§É¸Ñª¼ ²Ä¤@±ø¥ó ³Ì«á¦¬®×¤H«á3Ó¤ë ©Î ²Ä¤G±ø¥ó,PD ¤H¼Æ¹F127¤Hªº70%=89¤H Primary Outcome Measures ƒÊ : 1.Incidence of Adverse events (AE) - safety lead-in [ Time Frame: Through 28-days post last study medication administration ] Safety-lead-in: Incidence of AEs, categorized in accordance to CTCAE 4.03 and changes from baseline in safety parameters (including vital signs, ECG parameters, clinical laboratory tests) 2.Objective response rate (ORR) - part 1 [ Time Frame: the later of 3 months after last subject in or when 70% of the subjects (84 subjects) have experienced a PFS event in Part 1 ] Part 1: ORR defined as the proportion of subjects with a best objective response (BOR) of complete response (CR) or partial response (PR), as assessed by an Independent Central Review(ICR) defined by the RECIST v1.1 criteria 3.Progression-free survival (PFS) - part 1 [ Time Frame: The later of 3 months after last subject in or when 70% of the subjects (84 subjects) have experienced a PFS event in Part 1 ] Part 1: Progression-free survival (PFS), defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined in accordance with the RECIST v1.1 criteria and will be derived programmatically based on data from the ICR of radiological data. clinicaltrials.gov/ct2/show/NCT03093870?term=aslan001&rank=9 «¸µo¨¥·|¦V¤½¥q°ª¼h¤ÏÀ³. |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/8/20 ¤W¤È 10:52:48²Ä 1259 ½g¦^À³
|
To:¥xÁÞ¤j ªø¤[¥H¨Ó,§Ú©Ò´£¥Xªº·Qªk¸ò¬Ýªk³£¬O¦hªÅ¨Ã³¯,Åý¤j®a°Q½×,±z¦pªGı±o§Ú´£¥Xªº½×ÂI¤£¦n,±z¤]¥i¥H¦Û³Ð¤@ª©¨Ó°Q½×°Ú,¦Ñ·àºÞ²z¶¥¼hºÞ²z¤½¥qªv²z¨ì¥þÃB¥æ³Î,¤£¨ü§åµû,Ãø¹DÁÙnÆg¬ü¥¦¶Ü?§ÚÁÙ¬Oı±o¸Ñª¼¦¨¥\«Ü¦³§Æ±æ,µM´£¥X®`©È¦Ñ·à¦Û¦æ¤U¥«,¥u¬O¤£§Æ±æ¤j®aµ¥«Ý¨º»ò¤[ªº¤G½uÁx¹DÀùªº¸Ñª¼,³Q¤°·h¹B¨«,¦p¦¹¦Ó¤w... ¥»ª©³Ì§Æ±æªº¬O¤j®a¦h¦h°Q½×¦hªÅªº·Qªk,¤×¨ä¬OASLN001ªº¸Ñª¼¹LÃö»P§_,Åwªï¤j®a´£¥X·Qªk³á~~~ ¥H¤W¨Ñ°Ñ¦Ò |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/8/20 ¤W¤È 10:52:41²Ä 1258 ½g¦^À³
|
¨ä¹ê±q6¤ëÀ禬¥X¨Ó¨S¦³¦¬¤J¡A¦³ÂIsenseªº§ë¸ê¤HÀ³¸Ó´Nª¾¹D·|¶^¯}²bȤF¡A©Ò¥HªÑ»ù±q7¤ë¶}©l¤@ª½¶^¶^¤£¥ð¡A¦ý¬O³o®ÉÔ¨ä¹ê½æ¥Xªº¨é°ÓÀ³¸Ó¤w¸g½æ±o®t¤£¦h¤F¡A´Nºâ¤@¯ë§ë¸ê¤H¤£ª¾¹D±µ¤U¨Ó·|Åܦ¨¥þÃB¥æ³ÎªÑ¡A¥L̤â¤Wªº«ùªÑÀ³¸Ó¤]¤£·|¨º»ò¦h¡A¤£¹L³o´X¤Ñªº½æÀ£¡AÂê¦íªº½æ³æ¼Æ¶q¦h±o«Ü¤£´M±`¡A´²¤á¤â¤¤ªº³fþ¥i¯à¨º»ò¦h¡A¨ä¥L¥´¤J¥þÃB¥æ³ÎªºªÑ²¼¤]¨S¹³¨È·à±d³o¼Ë¡A¥[¤W¥ß§»¬Q¤Ñ¥h½ÐÀç·~û¥h¬dªº½æ³æ¡A¤j³£¬O³Í°ò¡B¸s¯qª÷¹©©µ¥¡B¤j©M°ê®õ©M¼¯®Ú¤j³q³o¨Ç¤jªÑªF¡A¤£À´¬°¦ó¥L̲{¦bn³o¼Ë°µ»s³y®£·W¡A¨ä¹ê´²¤áªº½æ³æ¨Ã¨S¦³¨º»ò¦h¡A¤½¥qªº¬ãµo¦¨ªG¤]¨S¦³¥¢±Ñ¡A¸Ñª¼³£ÁÙ¨S¤½¥¬¡A¤£À´³o¨Ç¤jªÑªFªº¤ßºA¬°Ô£n±¾¤j¶q½æ³æ»s³y®£·W¡A¹ï¥L̤]¨S¦n³B§a¡A¥Ø«e¬Ý¨Ó¦X²zÃhºÃ´N¬O§âªÑ»ùÀ£§C¡AÅý¥xªÑ¸òADRªº»ù®t°÷¤j¡A¦]¬°ADR¼W¸ê»ù®æ¬O¬Ý¥xªÑªº¡A©Ò¥H°²³]ADR»ù®æ²{¦b¬O2.6¡A¦Ó¥xÆW³oÃä¬O¤µ¤ÑªÑ»ù12´«ºâADR¬O1.9¡A³o¼Ë¨âÃä»ù®t´N¤w¸g¦³0.7¤F¡A¦Ó¥B¥Ø«e¥xÆW³oÃä½æÀ£ÁÙ¨Sµ²§ôÁÙ¥i¯à§ó§C¡A¥Ø«e¨âÃä»ù®t¤w¸g¹F¨ì36%¥H¤W¡A³o¼Ë¨º¨Ç¤jªÑªF¥h»{ªÑ´N¥i²{ÁÈ36%¥H¤W¡A·íµM³o¬O¥HADRªÑ»ù¤§«á¨SÅܤƤӦh¬°«e´£¡A©Ò¥H¤§«áADR¼W¸ê¬O°Ñ¦Ò¥xªÑ»ù®æ¥h´«ºâªº¡A³o¼Ë»ù®t´N«D±`¥iÆ[¡A¹ï¤jªÑªF¦Ó¨¥¬O¤@µ§¤£¤ÖÀò§Q¡A³o¬O§ÚÓ¤H±À´úªº¡A§_«h¨S¥²n²{¦b¨Ó»s³y®£·W¡AÀ£¦í¥xÆW³oÃ䪺ªÑ»ù¡A¤@ÂI¤ß±o¤À¨É! |
|
|
·|û¡G³¯Ë¢¦w10144680 µoªí®É¶¡:2019/8/20 ¤W¤È 10:31:59²Ä 1257 ½g¦^À³
|
§Ú¤ä«ù¥xÁÞ¤jªº»¡ªk¡A¤£nÀ~¤j®a¡C襴¥h¤½¥q¸ß°Ý¬Û«H¤½¥q¤£·|ÀH«K¤U¥«¡C¤j®a³£¬O©¾¹ê¤ä«ùªÌ¡A¤~·|Á«·l³s³s¡A§Ú¤]§ë¸êÃÄ£¹ÃÄ¡Aµ²§½¤@¼ËºG¦r§Î®e |
|
|
·|û¡G¤ý¥ý¥Í10140379 µoªí®É¶¡:2019/8/20 ¤W¤È 10:29:18²Ä 1256 ½g¦^À³
|
¹ê¦b¬Ý¤£¥X ©t¨àÃĤj ¨º¸Ì¦b»s³y®£¯î ¥u¬O¦b¦^µª«e±ªO¤Í»¡ªº¸Ñª¼«e¤U¥«ªº°ÝÃD¦Ó¥H ¥t¥~²Ä¥|©u¸Ñª¼·|¤£·|¦¨¥\¡A½T¹ê¤]¬Oªñ´Á¦ÜÃö«nªº¨Æ±¡ ¨S¹L¦A¦Y´XÓ¶^°±ªO¡H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/8/20 ¤W¤È 10:12:40²Ä 1255 ½g¦^À³
|
©t¨àÃĤj §A¦n¹³¦b»s³y®£·W , ¦Û¤v·íª©¥D°µ¤@¨Ç¨S¨}¤ßªº¨Æ,¦b¤M¤f¤WÅxÆQ, ²{¦bªºªk³W¹ï§ë¸ê¤H«OÅ@¦³ÄY®æ³W©w , ¤£«H¤j®a¥i¥H¥´¹q¸Ü¥h°Ý , «Øij¤£n§â¨S¦³ªº¨ÆÁ¿¦¨¯uªº, ¬Æ»ò®É¶¡¨Ó¤£¤Î ..... ¤p¤ßªk«ß°ÝÃD |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/8/20 ¤W¤È 09:48:15²Ä 1254 ½g¦^À³
|
èè¤Wºô¬d¤F¤@¤U,®Éµ{¤WÀ³¸Ó¤£·|¦b¤G½uÁx¹DÀù¸Ñª¼«e´N¯à¦Û¦æ¤U¥«,®Éµ{¨Ó¤£¤Î....©Ò¥H²Ä¥|©uªº¸Ñª¼¦ÜÃö¥Í¦º.... ¥H¤W¨Ñ°Ñ¦Ò.. |
|
|
·|û¡G¤ý¸I¥J10148138 µoªí®É¶¡:2019/8/20 ¤W¤È 08:44:36²Ä 1253 ½g¦^À³
|
¦pªG·Ó§A³o¼ËÁ¿ÁÙ¯u¬O®£©ÆÕÙ §Ú³oÀɤW¥«¤]¦³¶R ¬O©âÅÒ©â¨ìªº »{½ß±þ¥X ¬Ý¨ì¶^¨ì³o»ù¦ìÁÙ¯u¬O¶^¯}²´Ãè¤F ¦Y¹L«Ü¦hKY¨t¦CªºªÑ ©Ò¥H²{¦b¥un¬Oky¶}ÀYªº§Ú³£«Ü·P«_ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/8/20 ¤W¤È 08:18:42²Ä 1252 ½g¦^À³
|
¨ä¹êµo®i¤¤ªº·sÃĥͧޤ½¥q¨S¤H¦A´î¸êªº,Y¬On´î¸ê¨º¤~¬O¯uªºn¾á¤ß,²{¦b¬Ý¨ÓY¬Oì©l¤jªÑªF¬Ý¦n001ªº¸Ñª¼,ªÑ»ù§CÀÉ°Ñ»P¼W¸êè¦n¥¿ÅªÑ»ù°ª¦ì®ÉªºªÑ¥÷,¦p11(ªñ´Á)+50(«e´Á)=30.5¤¸,³o¼Ë¥L̤~¦³¾÷·|¸Ñ®M°Ú~~ ¸Ü»¡¦^¨Ó,§Ú̧ë¸ê¤j²³Ì,«ç»ò·|¹J¨ì³oºØ¶ÆºCªº¥~°êÄê±M®a,©ú©ú²Ä¤@©u¸ê¥»ÃB´N¤w±¼¨ì6.6»õ¤F,ÁÙ¤£¶i¦æ¶Ò¸ê???(³Ì©È´N¬O¥ý«e©Ò´£,¦Û¦æ´£¥X¤U¥«,±aµÛ¸Ñª¼¦¨¥\ªº001¨ì¨ä¥L¦a¤è¤W¥«°Ú!!!) ©Ò¥H¥u¯à¦Û¥ß¦Û±j,¥ý¥´¥hÂd¶R¤¤¤ß°Ý°Ý¹³³o¼Ëªº±¡§Î,§ë¸ê¤HªºÅv¯q¦ó¦b?? ¥H¤W¨Ñ°Ñ¦Ò... |
|
|
·|û¡GÀ³µL©Ò¦í10144738 µoªí®É¶¡:2019/8/19 ¤U¤È 06:52:48²Ä 1251 ½g¦^À³
|
1.¨Æ¹êµo¥Í¤é:108/08/19 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¨ÌÃÒ¨é°ÓÀç·~³B©Ò¶R½æ¦³»ùÃÒ¨é·~°È³W«h²Ä¤Q¤G±ø²Ä¤@¶µ²Ä¤@´Ú¡A³Ìªñ´Á°]°È³ø§iÅã¥Ü ²bȤw§C©ó°]°È³ø§i©Ò¦C¥ÜªÑ¥»¤G¤À¤§¤@ªÌ¡C 6.¦]À³±¹¬I: ³z¹L¶Ò¸ê©Î±ÂÅvÂà¥X¼W¥[Àç·~¦¬¤J¤§¤è¦¡§ïµ½¥»¤½¥q²bÈ¡A¥H´Á«ì´_¬°´¶³q¥æ³Î¤§ ¶R½æ¡C¥»¤½¥qì¹wp©ó¤E¤ë´£¥X¶Ò¸êpµe¡A±©¨ü©óÃÒ´Á§½¤Î¥~°ê¤H¶Ò¶°»Pµo¦æ¦³»ù ÃÒ¨é¬ÛÃö·Ç«h¡A¥»¤½¥q¥¼¯à©ó108¦~9¤ë27¤é«e´£¥æ¶Ò¸ê¥Ó½Ð¡C¥»¤½¥q±NP¤O©ó¨ú±oÃÒ´Á §½¤Î¬ÛÃö¥DºÞ¾÷Ãö®Öã¦A«×´£¥æ¶Ò¸êpµe¡C 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: Åܧó¥æ©ö¤è¦¡¬°¥þÃB¥æ³Î«Y¨Ì¬ÛÃöªk¥O³W©w°õ¦æ¡A´N¥»¤½¥q¤§»{ª¾¡A»P¤½¥qÁ{§É¸ÕÅç ¬ãµo¬¡°Ê¤Î2019¦~²Ä¥|©u¤§TreeTopp¸Ñª¼µ²ªG¨ÃµL¥ô¦óÃöÁp¡C ¨Ì¥»¤½¥q©ó2019¦~8¤ë13¤é¤§·s»D½Z©Ò¤½¥¬¡A¥»¤½¥q¹w´Á©ó2019¦~¤U¥b¦~¹F¦¨¥H¤U ¨½µ{¸O¡G ©ó¤E¤ë©³©ó¼Ú¬w¸~½FÂå¾Ç·|(ESMO) 2019¦~¦~·|µoªívarlitinib¦X¨ÖmFOLFIRI©ó±ß´Á ¹êÅé½F¤§¤@´ÁÁ{§É¸ÕÅç·s¼Æ¾Ú¡C ©ó2019¦~¤U¥b¦~®i¶}ASLAN004©ó¤¤««×²§¦ì©Ê¥Ö½§ª¢±wªÌ¤§¦h¾¯¶q»¼¼W¸ÕÅç¡C ©ó2019¦~²Ä¥|©u¨ú±ovarlitinib¤G½uÁx¹DÀù¥þ²y©Ê¼Ï¯Ã¸ÕÅç(TREETOPP)ªì¨BÁ{§É¸ÕÅç ¼Æ¾Ú¡C ¦¹¥~¡A¤½¥q©ó¤U¦¸¼W¸ê¤§«e¡A¨ÃµL¥ô¦ó´î¸êpµe¡A¯S¦¹»¡©ú¡C |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/8/19 ¤U¤È 05:10:56²Ä 1250 ½g¦^À³
|
¬üªL³o®a¥~¸ê³q±`¬O°µµu½uªº¡A¤£¹L°²³]¦pªG¤@ª½³£¬O¶^°±Âꦺ¡A¤£ª¾¬°¦ó¥L²{¦bn¶R¤J¡A¤§«e¬üªL³£¬O°µµu½u¡A¶RÓ¤@¤Ñ¡A¥i¯à¨â¤T¤Ñ«á´N¥þ¥X¤F¡A¤£¹L¨º¨Ç¤j¤áªº½æ³æ¦pªG¤£°h¡A§ë¸ê¤H«ÜÃø¦³«H¤ß¡A°£«D¦³Ô£·s®ø®§¤½§i! |
|
|
·|û¡G¦N¦Ì10148522 µoªí®É¶¡:2019/8/19 ¤U¤È 04:59:24²Ä 1249 ½g¦^À³
|
è¬Ý¤F¤@¤U¡A¤µ¤Ñ175±i¬O¥~¸ê¶Rªº~ |
|
|
·|û¡G¤p¦t10145840 µoªí®É¶¡:2019/8/19 ¤U¤È 04:54:51²Ä 1248 ½g¦^À³
|
¨ä¹ê´N¬Ý¬Ý«á±¬O¤£¬On´î¸ê¸ü¼W¸ê¡A¦pªG¬O¡A¨º·à¤lÁÙ¦³±Ï ¦pªG¤£¬O¡A¨º´N¯uªºÅܾÀ¯È |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/8/19 ¤U¤È 04:19:46²Ä 1247 ½g¦^À³
|
¨ä¹ê¾á¤ßªº¬O¤½¥q¦Û¤v¥D°Ê·Q¤U¥« ? ³o¦³¤º½u¥æ©öªº¶ûºÃ~~~~ |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/8/19 ¤U¤È 04:03:08²Ä 1246 ½g¦^À³
|
To ¥ß§», ³Í°ò¡B¸s¯qª÷¹©-©µ¥¡B¼¯®Ú¤j³q¡B¤j©M°ê®õ¡A³o¥|®a¨é°Ó¡A¦pªG¤£¬O³Í°ò¤À¦æ¬O³Í°òªº¸Ü¨º´N¬Oì©lªÑªF¡A±q¨È·à±d¤WÂd¤§«á´N¤@¸ô½æªº³Í°ò¡A¦Ó¸s¯qª÷¹©©µ¥¸ò¤j©M°ê®õÀ³¸Ó¤]¬O¬Y¨Ç¤jªÑªF¡A³o¨â®a¤]¬O¤@ª½¦³¦b½æªÑªº¨é°Ó¡A¼¯®Ú¤j³q´N¤ñ¸û©Ç¤F¡A³o®a¬OADR©Ó¿ì¨é°Ó¡A³q±`±q¬ü°êADRÂà´«¨ì¥xÆW¬O³z¹L³o®a¨é°Ó¡A¤£¹L²{¦b¥xÆWªÑ»ù¤ñ¸û§C¡A·|¦³¤H·QÂà¹L¨Ó½æ¶Ü?©Î¬O¤§«eÂà´«¹L¨ÓÁÙ¨S½æ¥Xªº? ¨º³o¼Ë¬Ý¨Ó³o¥|®a³£¬O¤j¤á¡A¤Ï¦Ó´²¤á±¾½æ³æ¤ñ¸û¤Ö¡A³o¼Ë¯uªºÆZ©_©Çªº¡AÃø¹D¬O³o¨Ç¤j¤á¶°©ó¥Î¿ú? ³oÂI´N¤£²M·¡¤F¡A¥H¬°³£¬O´²¤á±¾³æ¡Aµ²ªG³ºµM¬O³o´X®a¨é°Ó¡A쥻³£¦b½æªÑªº¨é°Ó¦A±¾½æ³æ¡A¤£ª¾¥Î·N¬°¦ó? |
|
|
·|û¡G¥ß§»10147985 µoªí®É¶¡:2019/8/19 ¤U¤È 03:41:07²Ä 1245 ½g¦^À³
|
¦U¦ì¤j¤j¡G èè§Ú½ÐÀç·~û¬d¸ß¤@¤U¡A¤µ¤Ñ±¾³æ½æÀ£¬O³Í°ò±¾1544±i¡]³Í°ò±q¥h¦~1¤ë¥÷¶}©l½æªÑ²¼¡A¨ì¬Q¤Ñ¬°¤î¤w¸g½æ¥X7588±i¡^¡A¸s¯qª÷¹©-©µ¥±¾³æ905±i¡]¦ý¬O³o®a¸ò¥»¨S¦³¶R³o»ò¦h±i¡A«ç»ò±¾³æ©O¡H¡^¡AÁÙ¦³¼¯®Ú¤j³q805±i¡A¤j©M°ê®õ600±i¡A¸ß°Ý¤@¤UÀç·~û¡A¦³¥i¯à¬OɧO¤Hªº¨Ó±¾³æ¡A¦Ü©ó¬°¤°»òn¦b³oӮɶ¡ÂI½æ©O¡H ¤U¤È®É¬q¥´¹q¸Ü¥h¤½¥qn§äµo¨¥¤H¡A¦ý¬O¤£¦b¡A¥´¤â¾÷¤]¥¼±µ¡A½Ð°Ý¦U¦ì¤j¤jªº¬Ýªk¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/8/19 ¤U¤È 02:53:32²Ä 1244 ½g¦^À³
|
À³µL©Ò¦í¤j 1232½g¿ûÅK¨k¤j¤À¨É¡A¸³¨Æªø¦³440±i¡A°ÆÁ`¨ó²z¦³100±iªº¡A¦³90±iªº¡A¦³69±iªº¡A¦³48±iªº¡A¦³32±iªº... ¨CÓ¤Hªº§ë¸ê¼Ðªº·Qªk³£¤£¤@¼Ë¡A¤£¬O¨C¦ì°ÆÁ`¨ó²z³£¤@©wn¦³«ùªÑ¡A¥x¿n¹qªº°ÆÁ`¤]¦³4Ó¤H¹s«ùªÑ¡C |
|
|
·|û¡Goldking10148524 µoªí®É¶¡:2019/8/19 ¤U¤È 02:47:25²Ä 1243 ½g¦^À³
|
±q40¦h¨ì²{¦b¤w¸g½ß¤F2/3 ÁÙ¯u¤£ª¾¹D¸Ó«ç»ò¿ì¡A¥u§Æ±æ¤½¥q¥i¥H°µ¨Ç¨Æ¡A¤£nÅý¤½¥q¤U¥«¡AÅý¤pªÑ¥Á¦å¥»µLÂk¡I |
|
|
·|û¡GÀ³µL©Ò¦í10144738 µoªí®É¶¡:2019/8/19 ¤U¤È 02:32:20²Ä 1242 ½g¦^À³
|
©Ó¤W¤å ¤½¥q³Û¸Ü¦³®Ä¶Ü¡H 1.°ÆÁ` ¨ó²z -->¹s«ùªÑ 2.¨º¤@¦¸ªºªk»¡¤£¬O³£»¡²£«~¦³¦h¦n¡A«H¤ßº¡º¡¡H §ë¸êªÌ¤£¶R±bªºì¦]¤§¤@À³¬O°w¹ïºÞ²z°ª¼h¡A¦b¤½§i¬ü°êÄw¸ê¨ú®ø«e¡AÃø¹D³£¤£ª¾¹D¹Lµ{¤£¶¶¡A»Ýn¦hºÞ»ô¤U/«B¤Ñ³Æ®×¡H(¥_·¥¬P¬O²{¼W/¨p¶Ò¤@°_°µ)·í¦~¤¤½T©w¨ú®ø«á«o¤Snµ¥¤E¤ë¡A«Ü®t«lªº°õ¦æ¤O¡C ¤µ¤Ñ²Ä¤@½L4±i¡Aªí¥Üµ´¤j¦h¤H¤£·Q½ä¡AÁÙ¦bÆ[±æ ´Á±æ©ú¤Ñ¯à¦³Âà¾÷ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/8/19 ¤U¤È 02:28:50²Ä 1241 ½g¦^À³
|
¤WÂdªÑ²¼6291¨K¦ë¤§«e³QÅܧó¥æ©ö ÁÙ¦³¤À½L¤è¦¡¥æ©ö 8¤ë19¤é°_«ì´_´¶³q¥æ³Î ¤w³sº¦¨â¤äº¦°±ªO ,¯f³Ð¤U¤¦~¨Ó·s°ª ,±q¤ë½u¬Ý°_¨Ó´£«e°_º¦, ¤£¬Oµ¥¨ì«ì´_´¶³q¥æ³Î¤~º¦ ¤Q¤jªÑªF¸³ºÊ«ùªÑ¦³¤j¶q´î¤Ö¶Ü? ·s¥ô¸³¨ÆªøAndrew James «ùªÑ(440±i) §AªºªÑ²¼¦³¤ñ¥L̦h ? ¤½¥q8/15¤w¤½§i³z¹L¶Ò¸ê©Î±ÂÅvÂà¥X¼W¥[Àç·~¦¬¤J¤§¤è¦¡§ïµ½¥»¤½¥q²bÈ¡A¥H´Á«ì´_¬°´¶³q¥æ³Î¤§¶R½æ ¤½¥q±NP¤O©ó¨ú±oÃÒ´Á§½¤Î¬ÛÃö¥DºÞ¾÷Ãö®Öã¦A«×´£¥æ¶Ò¸êpµe¡C ¬ãµoªº¾AÀ³¯g¦¨¥\¾÷²v¦p¦ó ? ²bÃÒ¥æ©Ò¤ÎÂd¶R¤¤¤ß¤w¬ãÀÀ¤U¥«Âd¾÷¨î¡A¹L¥h¤½¥q²bȬ°t¼Æ¡A¤~·|n¨D²×¤î¤W¥«Âd¡A¥¼¨Ó¹wp±N·s¼W¤U¥«Âd±ø¥ó: 1 ·|p®v»{¬°¦³¤£½T©w«¤j¦]¯À 2 ²bȧC©ó 3 ¤¸ªÌ 3 n¨D§ïµ½Y 3 ¦~¤º¤´µLªk§ïµ½¡A«h·|n¨D¦b¥b¦~«á¤U¥«Âd¡C ¥H¤W¤T±ø¥óѨ¬ 3¦~¥b«á ¤~·|¤U¥« °ÝÃD¬O¤½¥q8/15¤w¤½§i³z¹L¶Ò¸ê©Î±ÂÅvÂà¥X¼W¥[Àç·~¦¬¤J¤§¤è¦¡§ïµ½¥»¤½¥q²bÈ¡A¥H´Á«ì´_¬°´¶³q¥æ³Î¤§¶R½æ , ¥[¤W¥¼¨ÓASLAN001 ASLAN003 ASLAN004 ¤¤¬ü¼Ú¤é ¥|¤j°Ï¶ô¥ô¦ó¤@°Ï±ÂÅv ªÑ²¼²bÈ´N·|¤j´T´£¤É ¤½¥q±NP¤O©ó¨ú±oÃÒ´Á§½¤Î¬ÛÃö¥DºÞ¾÷Ãö®Öã¦A«×´£¥æ¶Ò¸êpµe °O±o·à¤Í¤w´£¹L¤½¥q·|¦A³z¹LADR ¼W¸ê,Ó¤H»{¬°¦³±ÂÅv´N¤£»Ý¦A³z¹LADR ¼W¸ê,ÁÙ¥¼½Í§´¬°´£°ª²bȤ½¥q·|¦A³z¹LADR ¼W¸ê ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò»P«ä¦Ò¤è¦V |
|
|
·|û¡GÀ³µL©Ò¦í10144738 µoªí®É¶¡:2019/8/19 ¤U¤È 01:42:13²Ä 1240 ½g¦^À³
|
ªÑ»ù¹ð¯}·s§C ¦Û¯à¦Û§Ú¦w¼¢ ³o¬O ¨C¤Ñ¤@§Q¦h ¦]¬°-->ªÑ²¼¥«³õ±`»¡ »ù®æ§C ´N¬O ³Ì¤jªº§Q¦h ³o¨â¦~ ¯u¬O §Q¦h¤£Â_¡I¡H ¥X¤£¤F ü¡I ¥[ªo§a¡I t³dªººÞ²z·í§½ ½Ð¥X¨Ó³Û³Û¸Ü |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/8/19 ¤U¤È 01:41:45²Ä 1239 ½g¦^À³
|
¦Ü20190630¬°¤î¦Ñ·à±b¤W²{ª÷ÁÙ¦³4.66»õ,ªñ´ÁYµL¤jµ§¤ä¥X,¼µ¦ÜASLN001¸Ñª¼¬OÁÙ°÷¥Î,¦ý³o¨ÇÄê¥~°ê±M®a¯à§â¤½¥qªv²z·d¨ì³o¼Ë¹ê¦b¬OÄê³z¤F,³Ì©È³o±N¸Ñª¼¹LÃö¾÷²v°ªªº001·|¦b¥xÆW¤U¥«,µM±a¨ì¥t¤@Ó¦a¤è¤W¥«,³o¼Ë¥xÆW§ë¸ê¤H¯uªº´N°I¨ìÃz.... |
|
|
·|û¡G¦N¦Ì10148522 µoªí®É¶¡:2019/8/19 ¤U¤È 12:30:52²Ä 1238 ½g¦^À³
|
¦pªG¥´¥h¤½¥q°Ý¡A·|¦³«ç¼Ëªº¦^À³¡H |
|
|
·|û¡GÀ³µL©Ò¦í10144738 µoªí®É¶¡:2019/8/19 ¤U¤È 12:06:13²Ä 1237 ½g¦^À³
|
¥[ªo¤£¤U¥h¤F ¤£¬Ý¤£ª¾¹D ¤@°ï¨ó²z ¸g²z ¹s«ùªÑ °ÆÁ`¯Å¤]¤Öªº¥i¼¦ Ãø¹D ÅQ¥D¯Å XX»õ¬üª÷»ùÈ-->¤£ª¾¹Dn³{§C¶R? ª©¤W°ª¤â°ª°ª¤â¤@ª½¤@ª½¤£Â_¥Î¤ß«´_Po¤åÀ³ÂX¤j¤O«× ¥ý³ê¿ô¤º³¡¤H§ë¸ê ®¾¦^ÀZ¶Õ |
|
|
·|û¡G¤ý¥ý¥Í10140379 µoªí®É¶¡:2019/8/19 ¤W¤È 11:40:21²Ä 1236 ½g¦^À³
|
¨Æ¹ê¤W¬O«Ü¦³¥i¯à¤U¥«ªº¡AµM«á¿ï¨ä¥Lªº°ê®a¦A¤W¥«¡A¦Ü©ó¤U¥«¹ï»OÆWªºªÑªF ©Ò³y¦¨ªº¼vÅT ¥_·¥¬Pª©³£¤w°Q½×¨ìÄê¤F ·íµMÁÙ¬O¤@©w·|¦³¤H¥X¨ÓÅ@¦æ¡A»¡¤£·|¡KµM«á·|ºë¯«³Û¸Ü¡A¦ý¥¿±`ªÑ»ù¨ì³oÓµ{«×¡A¤S¥´¤J¥þÃB¥æ³ÎªÑ¡A¤U¥«ªº¥i¯à©Ê¬O¤j¤@ÂI °£«D¤½¥q¦³¤@¤°»ò¤@©wn¯d¦b»OÆW¥«³õªº²z¥Ñ¡C¤]¨S·Q¨ìªÑ¤ý¥_·¥¬PªºªÑ»ù²×©óÁÙ¬O¤S¶W¶VªÑ¦Z¨È·à±d¤F¡A ¥u¬O¨S¦³·Q¨ì·|¥H¦p¦¹ªº¤è¦¡¶W¶V¡A¦bªÑ»ù³£§Ö¶^¯}¤Qªº®ÉÔ ¬Û·| ¯¬¤j®a³£ÁÈ¿ú |
|
|
·|û¡G¦N¦Ì10148522 µoªí®É¶¡:2019/8/19 ¤W¤È 11:23:07²Ä 1235 ½g¦^À³
|
¨È·à±d-KY¦b¥xÆW¤U¥«?¯uªº·|¶Ü? |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/8/19 ¤W¤È 10:37:52²Ä 1234 ½g¦^À³
|
³Ì©È³o¨ÇÄê³f¥~°ê±M®anÅý¨È·à±d-KY¦b¥xÆW¤U¥«,µM«á¦b¨ä¥L¦a¤è¤W¥«,¤j®aı±o¦³¥i¯à¶Ü? |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/8/19 ¤W¤È 09:57:03²Ä 1233 ½g¦^À³
|
¨º¨S¬Æ»ò,¥u¬OADRªº¦«ºÞ»È¦æ,§Æ±æ²H°¨¿ü©ÎMerck§Ö¥X¨Ó¼W¸ê§a,µM«á§â³o¨ÇÂi±¤Wªº¹Î¶¤´«±¼§a |
|
|
·|û¡G¿ûÅK¨k¤l10144826 µoªí®É¶¡:2019/8/19 ¤W¤È 09:51:54²Ä 1232 ½g¦^À³
|
¨È·à±d-KY(6497)¸³ºÊ¨Æ¸g²z¤H¤Î¤jªÑªF«ùªÑ©ú²Ó ¸ê®Æ¤é´Á:108/07 ¿ï¥ô¤é´Á:108/06/21 ¾ºÙ¡¶ ©m¦W/ªk¤H¦WºÙ «ùªÑ±i¼Æ¡¶ «ùªÑ¤ñ¨Ò ½è©ã±i¼Æ ½è©ã¤ñ²v ¿W¥ß¸³¨Æ Robert E. Ho 0 0.00% 0 0.00% ¿W¥ß¸³¨Æ ®]¼y¾W 0 0.00% 0 0.00% ¸³¨ÆÝÁ`¸g²z ³Å«i 0 0.00% 0 0.00% ¸³¨Æªø Andrew James 440 0.27% 0 0.00% ¸³¨Æ BV Healthcar(ªÑ)-ªL®¶½÷ 7,542 4.71% 0 0.00% ¸³¨Æ Alnair Inves-§dÂ@ 8,824 5.51% 0 0.00% ¸g²z ©g³· 0 0.00% 0 0.00% ¸g²z ¶À«Ø¾± 0 0.00% 0 0.00% ¸g²z ¼ïÀR©É 0 0.00% 0 0.00% °ÆÁ`/°]·|¥DºÞ Kiran Asarpo 69 0.04% 0 0.00% °ÆÁ` Alain Benjam 100 0.06% 0 0.00% °ÆÁ` Stephen Doyl 0 0.00% 0 0.00% °ÆÁ` Mark McHale 0 0.00% 0 0.00% °ÆÁ` ©PÄ×½¬ 48 0.03% 0 0.00% °ÆÁ` Á§Ӷh 90 0.06% 0 0.00% ¨ó²z ù¿p¤å 24 0.01% 0 0.00% ¨ó²z ³¯ªY©y 6 0.00% 0 0.00% ¨ó²z «¸¥ç´Ð 0 0.00% 0 0.00% ¨ó²z ¿½°¶ÄP 0 0.00% 0 0.00% ¨ó²z Alison Ward 0 0.00% 0 0.00% ¨ó²z Isana Endo 32 0.02% 0 0.00% ¤jªÑªF Kimba Capita(¦³) 3,344 2.09% 0 0.00% ¤jªÑªF Ma Ong Kee 3,191 1.99% 0 0.00% ¤jªÑªF Manbant Inve(¦³) 3,191 1.99% 0 0.00% ¤jªÑªF Guan Yu Chan 4,255 2.66% 0 0.00% ¤jªÑªF Match Point 1,432 0.89% 0 0.00% ¤jªÑªF Maybank Kim(ªÑ) 54 0.03% 0 0.00% ¤jªÑªF Milestone He(¦³) 5,310 3.31% 0 0.00% ¤jªÑªF Naga Capital(¦³) 2,804 1.75% 0 0.00% ¤jªÑªF ¤W®ü¤dÆk³Ð·~(¦³) 1,064 0.66% 0 0.00% ¤jªÑªF ¤¤°ê«H°U°Ó·~ 4,527 2.82% 0 0.00% ¤jªÑªF ¬ü°Ó¼¯®Ú¤j³q 30,000 18.72% 0 0.00% ¡¯¨Ó¦Û¦~³ø©M¤½¶}»¡©ú®Ñªº¤jªÑªF¸ê®Æ¡A¬O«üªÑÅv¦û«e¤Q¦WªºªÑªF¡CY·í¤¤¤jªÑªFè¦n¬O¡G¸³¨Æ¡BºÊ¹î¤H¡B¸g²z¤H¡B«ù¦³ªÑ¥÷¶W¹L¦Ê¤À¤§¤QªÑªF¡A·|¨Ì·Ó¤½¶}¸ê°TÆ[´ú¯¸¤Wªº¨C¤ë§ó·s¸ê®Æ¡C ¡¯«ùªÑ±i¼Æ¡A«ö«ù¦³ªÑ¼Æ¥|±Ë¤¤J¦Ü±i¼Æ¡C ¡¯«ùªÑ±i¼Æ¤Î¤ñ¨Ò¦b¤½¥q¿ì²z²{ª÷¼W¸ê®É¸³ºÊ¨Æ«ùªÑ«Y¥H¼W¸ê»{Áʪº¤ñ¨Ò¥h¦ôºâ¡A¥¼¥²»P¹ê»Ú±i¼Æ¤Î¤ñ¨Ò¬Û²Å¡C ¡¯¸ê®Æ¨Ó·½: ¥xÆW¸gÀÙ·s³ø ³Ì¤U±¤@Ó¤jªÑªF? ¯u?°²? ¨ÓÀY¯u¤j |
|
|
·|û¡G¤ý¸I¥J10148138 µoªí®É¶¡:2019/8/19 ¤W¤È 09:51:33²Ä 1231 ½g¦^À³
|
¬Ý¨ì¨È·à³o¼Ë¯uªº¤ß§N£¸¥b⋯ ¤S£¸°¦·sÃĪѨI¤U¥h¤F ¬Ý¨ì³o¼Ë´N·Q¨ì§Ú§ë¸êªºÃÄxÃÄ ´NºâÀ£¹ï®³¨ìÃÄÃÒ¤F¤S«ç¼Ë ÁÙ¤£¬OºG½ß ¥xÆW·sÃĪѯuªºÁÙ¦³«Üªø£¸¬q®É¶¡n¿i£«⋯⋯ |
|
|
·|û¡G¤p¦t10145840 µoªí®É¶¡:2019/8/19 ¤W¤È 09:42:41²Ä 1230 ½g¦^À³
|
³o¤@ÀɬݨӤSnª±´î¸ê¦b¼W¸ê³o©Û¤F¡A¤£µM¹ê¦b·Q¤£¨ì¤½¥qn«ç»ò±Ï²bÈ¡A«áÄò¹êÅç¤]ÁÙ¬On°µ¡A´î¸ê±Ï²bÈ¥~¡A«áÄò¶Ò´Ú¤]®e©ö¡AÃø©Ç¤jªÑªF¤§«e¤@ª½½æ¡A®Ú¥»¤£¬O¤W±ªº¤£³B²z¡A¤jªÑªF¥ý½æ¤@½æ¡Aµ¥«Í¾î¹M³¥ªº®ÉÔ¦b¶i³õ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2019/8/19 ¤W¤È 09:41:42²Ä 1229 ½g¦^À³
|
¬Ý¤@¤U¸³ºÊ¨Æ¸g²z¤H¤Î¤jªÑªF«ùªÑ©ú²Ó¡AÅܰʤ£¤j¡A¼¯®Ú¤j³q«ù¦³30000±i èè¤@µ§175±i³Q¦³²´¥úªº§ë¸ê¤H¶R¨« |
|
|
·|û¡GºCºC¶]10142302 µoªí®É¶¡:2019/8/19 ¤W¤È 09:33:16²Ä 1228 ½g¦^À³
|
´IÂd200«ü¼Æ¦¨¤ÀªÑ8/26°_§R°£¨È·à±d-KY (108/08/19 08:44:26) ¦³Ãö¥»¤¤¤ßÂd¶R¡u´IÂd200«ü¼Æ¡v¦¨¤ÀªÑ²§°Ê¡C ¤½ §i ¨Æ ¶µ¡G ¤@¡B¦¨¤ÀªÑ§R°£¤§ÅܰʥͮĤé¡G108¦~8¤ë26¤é¡C ¤G¡B¦¨¤ÀªÑ§R°£¡G¨È·à±d-KY(¥N¸¹¡G6497)¡C ¨Ì³W©wn²M,µ¥«Ý¦n¤ß¤H±µ¤â |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2019/8/19 ¤W¤È 09:17:49²Ä 1227 ½g¦^À³
|
ª½±µ¥s³Å«i¥X¨ÓÁ¿¦n¤F,¦]¬°§äµo¨¥¤H¤]¨S¥Î(©Î³\¥L´N¬O¨ü®`ªÌ),³o¨Ç©Ò¿×¥~°ê¥ÕÄê±M®a...ü,Å¥»¡¥xÆW¤º³¡³oÃ䦴N´£¥X·|¦³¥þÃB¥æ³Îªº°ÝÃD,¤WÀY¤£²z~~~ |
|
|
·|û¡GÀ³µL©Ò¦í10144738 µoªí®É¶¡:2019/8/19 ¤W¤È 09:10:05²Ä 1226 ½g¦^À³
|
ADR¤jº¦ ADR¤jº¦... ¬Ý¤£¨ì»ùȪº¥Ñ50 40 30 20...³°Äò½æªº·|«á®¬·|«á®¬.... ÅQ¥D¯Å XX»õ¬üª÷»ùÈ ¨Ó¤@Ó¥O¤HÆf¥Ø/º}«Gªº±ÂÅv ¥þÃB¥æ³Î¥æ©ö¤p¨Æ¤@¼Î °í«ù¤U¥h °í«ù¤U¥h ¥[ªo ¥[ªo ¥[ªo |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2019/8/19 ¤W¤È 08:52:03²Ä 1225 ½g¦^À³
|
¤µ¤Ñ¬Ý¨Ó¥xÆW³oÃ䪺§ë¸ê¤H¤S®£·W¤@°ï¤H±ÆµÛ½æªÑ²¼¡Aı±o¤½¥q¥i¯àn¥X¨Ó»¡©ú¤@¤U¶Ò¸êªº¶i«×¤ñ¸û¦n¡AÅý§ë¸ê¤H¯à¦w¤ß¡A§_«h¬ãµoµ²ªGÁÙ¨S¥X¨Ó¡A«ü¥ÜÅܧó¥æ©ö¤è¦¡¡A¤j®a³£³QÀ~µÛ«æµÛ©ß°â¡A³o¼Ë¤£ª¾¦ó¦~¦ó¤ë¤~¥i¥H¤î¶^¤F! |
|
|
|